Mode of action-based risk assessment of genotoxic carcinogens by Hartwig, Andrea et al.








Mode of action-based risk assessment of genotoxic carcinogens
Hartwig, Andrea ; Arand, Michael ; Epe, Bernd ; Guth, Sabine ; Jahnke, Gunnar ; Lampen, Alfonso ;
Martus, Hans-Jörg ; Monien, Bernhard ; Rietjens, Ivonne M C M ; Schmitz-Spanke, Simone ;
Schriever-Schwemmer, Gerlinde ; Steinberg, Pablo ; Eisenbrand, Gerhard
Abstract: The risk assessment of chemical carcinogens is one major task in toxicology. Even though
exposure has been mitigated effectively during the last decades, low levels of carcinogenic substances in
food and at the workplace are still present and often not completely avoidable. The distinction between
genotoxic and non-genotoxic carcinogens has traditionally been regarded as particularly relevant for risk
assessment, with the assumption of the existence of no-effect concentrations (threshold levels) in case
of the latter group. In contrast, genotoxic carcinogens, their metabolic precursors and DNA reactive
metabolites are considered to represent risk factors at all concentrations since even one or a few DNA le-
sions may in principle result in mutations and, thus, increase tumour risk. Within the current document,
an updated risk evaluation for genotoxic carcinogens is proposed, based on mechanistic knowledge regard-
ing the substance (group) under investigation, and taking into account recent improvements in analytical
techniques used to quantify DNA lesions and mutations as well as ”omics” approaches. Furthermore,
wherever possible and appropriate, special attention is given to the integration of background levels of the
same or comparable DNA lesions. Within part A, fundamental considerations highlight the terms hazard
and risk with respect to DNA reactivity of genotoxic agents, as compared to non-genotoxic agents. Also,
current methodologies used in genetic toxicology as well as in dosimetry of exposure are described. Spe-
cial focus is given on the elucidation of modes of action (MOA) and on the relation between DNA damage
and cancer risk. Part B addresses specific examples of genotoxic carcinogens, including those humans are
exposed to exogenously and endogenously, such as formaldehyde, acetaldehyde and the corresponding al-
cohols as well as some alkylating agents, ethylene oxide, and acrylamide, but also examples resulting from
exogenous sources like aflatoxin B1, allylalkoxybenzenes, 2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline
(MeIQx), benzo[a]pyrene and pyrrolizidine alkaloids. Additionally, special attention is given to some
carcinogenic metal compounds, which are considered indirect genotoxins, by accelerating mutagenicity
via interactions with the cellular response to DNA damage even at low exposure conditions. Part C
finally encompasses conclusions and perspectives, suggesting a refined strategy for the assessment of the
carcinogenic risk associated with an exposure to genotoxic compounds and addressing research needs.
DOI: https://doi.org/10.1007/s00204-020-02733-2






The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Hartwig, Andrea; Arand, Michael; Epe, Bernd; Guth, Sabine; Jahnke, Gunnar; Lampen, Alfonso; Martus,
Hans-Jörg; Monien, Bernhard; Rietjens, Ivonne M C M; Schmitz-Spanke, Simone; Schriever-Schwemmer,
Gerlinde; Steinberg, Pablo; Eisenbrand, Gerhard (2020). Mode of action-based risk assessment of geno-




Archives of Toxicology (2020) 94:1787–1877 
https://doi.org/10.1007/s00204-020-02733-2
REVIEW ARTICLE
Mode of action‑based risk assessment of genotoxic carcinogens
Andrea Hartwig1  · Michael Arand2 · Bernd Epe3 · Sabine Guth4 · Gunnar Jahnke1 · Alfonso Lampen5 · 
Hans‑Jörg Martus6 · Bernhard Monien5 · Ivonne M. C. M. Rietjens7 · Simone Schmitz‑Spanke8 · 
Gerlinde Schriever‑Schwemmer1 · Pablo Steinberg9 · Gerhard Eisenbrand10 
Received: 26 March 2020 / Accepted: 31 March 2020 / Published online: 15 June 2020 
© The Author(s) 2020
Abstract
The risk assessment of chemical carcinogens is one major task in toxicology. Even though exposure has been mitigated 
effectively during the last decades, low levels of carcinogenic substances in food and at the workplace are still present 
and often not completely avoidable. The distinction between genotoxic and non-genotoxic carcinogens has traditionally 
been regarded as particularly relevant for risk assessment, with the assumption of the existence of no-effect concentrations 
(threshold levels) in case of the latter group. In contrast, genotoxic carcinogens, their metabolic precursors and DNA reac-
tive metabolites are considered to represent risk factors at all concentrations since even one or a few DNA lesions may in 
principle result in mutations and, thus, increase tumour risk. Within the current document, an updated risk evaluation for 
genotoxic carcinogens is proposed, based on mechanistic knowledge regarding the substance (group) under investigation, 
and taking into account recent improvements in analytical techniques used to quantify DNA lesions and mutations as well 
as “omics” approaches. Furthermore, wherever possible and appropriate, special attention is given to the integration of 
background levels of the same or comparable DNA lesions. Within part A, fundamental considerations highlight the terms 
hazard and risk with respect to DNA reactivity of genotoxic agents, as compared to non-genotoxic agents. Also, current 
methodologies used in genetic toxicology as well as in dosimetry of exposure are described. Special focus is given on the 
elucidation of modes of action (MOA) and on the relation between DNA damage and cancer risk. Part B addresses specific 
examples of genotoxic carcinogens, including those humans are exposed to exogenously and endogenously, such as formal-
dehyde, acetaldehyde and the corresponding alcohols as well as some alkylating agents, ethylene oxide, and acrylamide, but 
also examples resulting from exogenous sources like aflatoxin  B1, allylalkoxybenzenes, 2-amino-3,8-dimethylimidazo[4,5-f] 
quinoxaline (MeIQx), benzo[a]pyrene and pyrrolizidine alkaloids. Additionally, special attention is given to some carcino-
genic metal compounds, which are considered indirect genotoxins, by accelerating mutagenicity via interactions with the 
cellular response to DNA damage even at low exposure conditions. Part C finally encompasses conclusions and perspec-
tives, suggesting a refined strategy for the assessment of the carcinogenic risk associated with an exposure to genotoxic 
compounds and addressing research needs.
Keywords Genotoxicity · Carcinogens · Mutagens · Risk assessment · Mode of action · Endogenous exposure · Exogenous 
exposure · Toxicogenomics · Biomarker dosimetry
Preamble
The risk assessment of carcinogenic substances in food and 
at the workplace requires sustained scientific evaluation. 
These substances are usually ingested at trace concentra-
tions through food and are often not completely avoidable 
at the workplace. Therefore, a working group consisting of 
members of the SKLM (Senate Commission on Food Safety) 
and MAK (Senate Commission for the Investigation of 
Health Hazards of Chemical Compounds in the Work Area) 
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commissions of the German Research Foundation (Deutsche 
Forschungsgemeinschaft, DFG) was established to delineate 
a refined risk assessment of chemical carcinogens, based on 
their modes of action.
The document is structured into an introductory part, fol-
lowed by three main parts A, B and C.
Part A "Fundamental considerations" develops funda-
mental considerations highlighting the terms hazard and 
risk with respect to DNA reactivity of genotoxic agents, as 
compared to non-genotoxic agents. It further discusses bio-
logical consequences and the lessons for risk assessment. 
This is complemented by an in-depth analysis of the relation 
between DNA damage and cancer risk. These fundamental 
considerations are seconded by a more detailed descrip-
tion of current methodologies used in genetic toxicology, 
in dosimetry of exposure and for the elucidation of modes 
of action (MOA). Finally, a major consideration is given 
to the endogenous exposure and its association with back-
ground DNA damage in animal and human tissues/cells and 
its potential relevance for human health risk assessment.
Part B "Selected examples" addresses a series of specific 
examples of genotoxic carcinogens humans are exposed to 
as a result of their living conditions, encompassing work-
ing place associated exposures as well as those contributed 
exogenously from their environment and their consumption 
habits. In addition, endogenous exposure to such agents is 
taken into consideration, tracing back to endogenous energy 
metabolism. The latter aspect is reflected by a group of 
agents put together under the term “the aggregate exogenous 
and endogenous exposome”. It encompasses compounds 
humans are exposed to exogenously and endogenously, 
such as formaldehyde, acetaldehyde and the corresponding 
alcohols as well as some alkylating agents, ethylene oxide, 
and acrylamide (Sec. “Acetaldehyde and Ethanol” to Sec. 
“Formaldehyde”).
The second section of part B addresses compounds 
humans are exclusively exposed to by exogenous exposure. 
The third section of part B is devoted to carcinogenic metal 
compounds with special emphasis on cadmium and arsenic.
Part C "Conclusions and Perspectives" represents the 
final part of the document, encompassing conclusions and 
perspectives. This part reiterates the requirement for a 
MOA-driven risk assessment, exemplified by selected agents 
where the MOA categories apply and where consideration 
of an endogenous background is applicable. A flow chart 
suggesting a strategy for the assessment of the carcinogenic 
risk associated with an exposure to genotoxic compounds 
is presented. Furthermore, gaps in knowledge and research 
needs are discussed at the end.
Introduction
The distinction between genotoxic and non-genotoxic car-
cinogens has traditionally been regarded as particularly 
relevant for risk assessment. For the latter type of agents, 
which are often classified as “tumour promoters”, indepen-
dently of diverse underlying mechanisms, the existence of 
no-effect concentrations or threshold levels is assumed. In 
contrast, genotoxic carcinogens, their metabolic precursors 
and DNA reactive metabolites are classically conceived to 
represent a risk factor at all concentrations because even one 
or a few DNA lesions, according to the concept of a non-
threshold MOA may result in mutations and thus increase 
the tumour risk. Other substances may increase genomic 
instability by indirect genotoxic mechanisms, i.e. by not 
directly reacting with DNA, such as by interference with 
the cellular response to DNA damage (see part A below), so 
that again no-effect levels may exist. In the case of the direct 
genotoxic agents, risk managers have followed for a long 
time the so-called minimization principle (ALARA: As Low 
As Reasonably Achievable). From a practical point of view, 
however, this approach does not adequately take into account 
the MOA and thus may be overprotective in many cases. As 
a consequence, the plausibility of the linear-no-threshold 
hypothesis of cancer risk assessment has increasingly been 
scrutinized (Cohen et al. 2019; Costantini and Borremans 
2019; Doe et al. 2019; EPA 2005; EU 2009; Golden et al. 
2019; Greim and Albertini 2015; Kobets et al. 2019; Kob-
ets and Williams 2019; Preston and Williams 2005; Wil-
liams et al. 2005; Wolf et al. 2019). For example, threshold 
levels in experimental animal studies have been postulated 
for several carcinogens (Kobets and Williams 2019). Since 
most of the multiple key events in chemical carcinogenesis 
have a non-linear dose–response relationship intrinsic to 
the mechanism involved, tumor development will likely 
show an overall threshold. However, it has to be kept in 
mind that thresholds for tumorigenicity derived from long 
term animal experiments necessarily reflect approxima-
tions since the biological data observed are prone to many 
experimental variables and limitations in statistical power. 
Therefore, within this review, one main focus is given to the 
quantification of bioindicators of key toxic effects, including 
the induction of DNA damage, mutations, cell cycle con-
trol, enhanced cell proliferation and apoptosis. As detailed 
below, recent advancements in analytical and cell molecular 
technologies have markedly contributed to a better-informed 
risk evaluation. This applies for instance to the detection 
and quantification of DNA lesions and mutations but also to 
transcriptomic and other cellular responses, all contributing 
to a deeper mechanistic understanding of the key processes 
governing the respective adverse outcome. Scientific experi-
ence tells that the dose–response relationship for genotoxic 
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carcinogens in the low dose range and thus the existence of 
an apparent or true threshold is substance-specific and inevi-
tably depends on the biological effect considered and on the 
specific MOA(s) that are key for a given adverse outcome 
(in this case malignant transformation).
Within this manuscript, special attention is also given to 
background levels of DNA damage of selected substances, 
arising from endogenous and/or exogenous sources. It 
proposes, where applicable, to take this “physiological” 
background more into account when undertaking a risk 
assessment. These background levels are amenable to quan-
tification with utmost sensitivity and specificity and can be 
used as reference values against which to compare effects on 
the integrity of DNA potentially associated with low dose 
human exposure to genotoxic agents.
This strategy has been propagated already previously, e.g. 
for risk assessment of formaldehyde exposure (Clewell et al. 
2019; Farland et al. 2019). Taken together, instead of classi-
cal default linear extrapolation to a lifetime cancer risk level 
(e.g. 1/  106), an alternative, mechanistic data-based approach 
of risk assessment is proposed.
For many carcinogens (both genotoxic and non-geno-
toxic), the dose–response curves are not linear across the 
entire dose range. In fact, they often are at least biphasic, 
in the sense that a smooth (sometimes nearly flat) range is 
followed by a steep increase, as shown in Fig. 1. While the 
slope of range A is determined by the induction of DNA 
damage and its conversion into mutations under conditions 
where no additional promotional mechanisms are active, the 
steep increase in range B can be mechanistically explained 
by the saturation of detoxifying or repair mechanisms and/
or by the induction of any type of tumour promotion mecha-
nisms, which generally follow a non-linear (often threshold-
like) dose-/concentration-dependent response.
Toxicological risk assessment is particularly interested in 
the determination of the slope in the low dose range (range 
A in Fig. 1). Obviously, this slope is not accurately acces-
sible by the direct measurements of dose-dependent cancer 
incidences, neither in animal studies nor in human popula-
tion studies, since incidences of 1:1000 up to 1:100,000 are 
highly relevant for human risk evaluation, but out of scale in 
the experimental settings. Furthermore, this slope is also not 
accessible by extrapolation from the high-dose range (range 
B in Fig. 1) even when benchmark dose (BMD) methods or 
the calculation of a point of departure (POD) from the BMD 
is used (“top-down” models).
For theoretical reasons, the concentration dependence at 
very low doses is expected to be linear, since both chemical 
and physico-chemical reaction rates become pseudo-first-
order with respect to a reactant if its concentration is low 
enough. This may apply to adduct formation rates, detoxi-
fication rates, bioactivation rates and other factors, which 
ultimately determine the rate of cancer formation. The real 
slope can also be very close to zero in this low dose range. 
In practice, experimental data points in the low dose range 
often will result in a calculated slope that is statistically not 
significantly different from zero. This does not mean that 
the actual risk is zero or that the data are useless for risk 
assessment. Actually, they can be used to calculate a statis-
tical “maximum slope” in the low dose range and thereby 
a maximum value for the cancer risk for a given exposure.
How can toxicological risk assessment deal with this 
situation? Three different concepts can be distinguished, as 
outlined below.
1. The linear extrapolation of the experimentally accessible 
dose–response data (generally from range B in Fig. 1) 
may be taken as a worst-case scenario. In the “margin 
of exposure” (MOE) approach the whole dose–response 
range is considered and submitted to mathematical mod-
elling. The best-fitting model (or more conservatively 
the model average) is selected to define a benchmark 
response (BMR, usually 10% = BMD10, but a lower 
value may be used in certain cases). The lower bound 
of the confidence limit of the dose associated with the 
selected BMR, the BMDL, is used as a POD to iden-




















range A range B
Fig. 1  Schematic graph of an apparently non-linear dose–response 
as observed in many cancer risk studies. In a low dose range (“A”), 
in which promotional effects are absent and detoxification and 
repair mechanisms fully active, the cancer risk of genotoxic carcino-
gens is often too low to be quantified directly. A measurable (often 
steep) increase of the cancer incidence is observed in the high dose 
range (“B”) due to the onset of tumour promotion and/or saturation 
effects. If the slope of this range is used for risk assessment by (lin-
ear) extrapolation, the cancer risk in range “A” is likely to be overes-
timated.
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the dose giving 10% extra risk above background level 
 (BMDL10) divided by the estimated daily intake (EDI). 
If the commonly observed average exposure range in 
the population is at least 10,000-fold lower than the 
 BMDL10, this is equivalent to a MOE of > 10,000. For 
such a MOE, no serious health concerns or no priority 
for risk management measures are concluded (EFSA 
2009b). The MOE approach has been used by the Euro-
pean Food Safety Authority (EFSA) (EFSA 2005) e.g. to 
assess exposure to naturally occurring food constituents 
such as estragole or methyleugenol as well as to certain 
process-related food contaminants such as acrylamide 
and furan (EFSA 2015, 2017a). Alternatively, linear 
extrapolation (sometimes over several orders of mag-
nitude) can be used to define a so-called virtually safe 
dose (VSD), which is the dose estimated to be associ-
ated with an additional risk of one cancer in a million 
above background levels upon life-time exposure for the 
general population. For workplace exposure, respective 
“accepted” risk levels are not generally agreed on, but 
are usually higher as compared to those for the general 
population. Thus, one concept applied in Germany by 
the Committee on Hazardous Substances (Ausschuss 
für Gefahrstoffe, AGS) consists in calculating a tol-
erable (4:1000) or acceptable risk (4:10,000 down to 
4:100,000) by extrapolation from epidemiological data 
or from carcinogenicity studies.
2. The “mode of action” (MOA) concept is based on the 
understanding that experimental data for cancer risk cal-
culations very often result from a dose range at which 
the induction of non-linear “tumour promotion” mecha-
nisms (e.g. accelerated cell division due to irritation or 
inflammation) or the saturation of defence mechanisms 
are likely to play an important role. Thus, the data reflect 
range B of a dose–response curve as shown in Fig. 1. 
In all these cases, the type and dose-dependence of the 
supposed relevant non-linear, promotional mechanisms 
can be investigated in independent experiments, and 
the results can be exploited to estimate the lower end 
of range B in Fig. 1. This lower end of range B then 
will allow a calculation of a “maximum slope” for the 
(linear) dose–response curve in the (experimentally not 
accessible) low dose range A. The German MAK Com-
mission initiated MOA based risk assessments in 1998 
by the introduction of the categories 4 and 5 for those 
carcinogenic substances, for which a MAK (maximum 
workplace concentration) value can be derived. Cate-
gory 4 includes substances that cause cancer in humans 
or animals, where a non-genotoxic MOA is of prime 
importance for the observed carcinogenicity, and geno-
toxic effects play no or at most a minor part provided 
the MAK and BAT (biological tolerance) values are 
complied with. Under these conditions, no contribution 
to human cancer risk is expected. Category 5 applies 
to substances that cause cancer in humans or animals, 
for which a genotoxic MOA is of prime importance, 
but is considered to contribute only very slightly to 
human cancer risk, provided the MAK and BAT values 
are observed. Both categories require a detailed under-
standing on the MOA of the respective substances; for 
category 5, the cancer risk at the low dose level must 
be quantifiable and considered to be low. The relevant 
detoxification, repair and “damage response” mecha-
nisms for these MOA considerations as well as respec-
tive test systems and a toxicogenomics approach for their 
identification are discussed in more detail below (see 
part A "Fundamental considerations", chapters "DNA 
reactivity of chemicals: Hazard versus risk", "Protein 
adducts as human biomarkers", "Background DNA 
lesions in rodent and human tissues/body fluids").
3. Further carcinogenesis-related endpoints, in particular 
the frequency of DNA adducts and mutations as well 
as surrogate endpoints such as protein adduct levels, 
might be used to extend the experimentally acces-
sible exposure range for effect measurements thereby 
aiming at better risk estimates for the low dose range. 
Methodological progress, e.g. in the quantification of 
DNA adduct levels, has stimulated research in this area. 
In particular, endogenous background levels of DNA 
adducts have become available in some cases and may 
allow to calculate a risk increment caused by the expo-
sure to exogenous carcinogens. Although in its infancy, 
this approach appears promising, and may potentially 
pave the way to a more comprehensive evaluation of 
human health risk associated with aggregate exposures 
to the so-called exposome, designating, in this case, the 
whole array of electrophilic compounds of relevance 
to human exposure from both exogenous and endog-
enous sources. Moreover, with respect to a workplace 
exposure, reference values such as the BAR (Biological 
Reference Value) in Germany and the BGV (Biological 
Guidance Value) of SCOEL (Scientific Committee on 
Occupational Exposure Limits) referring to background 
levels of a given substance or its metabolite in the occu-
pationally unexposed population are increasingly being 
defined and can thus be used for evaluation of occu-
pational exposure if exceeded. The potential scope and 
limitations of these approaches are described below in 
more detail (see part A "Fundamental considerations", 
chapters "Toxicogenomics for hazard identification and 
risk assessment").
In this review, we will describe the mechanistic back-
ground of the various concepts and the ways in which they 
can be applied for a toxicological risk assessment, both in 
general terms (see part A "Fundamental considerations") 
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and in the case of selected examples (see part B "Selected 
examples"). Points to be considered when wanting to refine 
the risk assessment of chemical carcinogens in food and 
at the workplace are outlined in part C "Conclusions and 
Perspectives".
Part A: Fundamental considerations
DNA reactivity of chemicals: hazard versus risk
The process of carcinogenesis is outlined in Fig. 2. Every 
single step is expected to follow its own (often non-linear) 
dose-dependence and kinetics. It is important to note that 
environmental/xenobiotic substances are not only able to 
trigger the process at its origin by causing DNA damage, 
but potentially can influence all relevant steps and pathways 
shown in Fig. 2, either directly or indirectly, for example by 
inhibiting specific steps or by inducing an adaptive response. 
In the following paragraphs, some of the steps are discussed 
in greater detail, in particular with respect to their impact on 
risk assessment and risk evaluation.
The mutagenicity of chemical or physical agents is fre-
quently assessed by short-term mutagenicity assays either in 
bacteria (Ames-test) or in cultured mammalian cells. These 
test systems are designed to detect the ability of these agents 
to damage DNA and thus lead to mutations, yielding impor-
tant hints for hazard identification. However, in the frame of 
the risk assessment process, informed judgement is required 
in terms of relevance for human health. This also implies 
that positive findings in these in vitro models need follow-
up in in vivo models before a definite conclusion on their 
in vivo genotoxicity can be reached.
From exposure to DNA damage
There are several scenarios that would prevent the induction 
of significant levels of DNA damage by a potential mutagen 
in humans
• A substance is not absorbed in the gastrointestinal tract 
and is thus excreted unchanged. However, even though 
this would not lead to systemic bioavailability, this may 
Fig. 2  Schematic outline of 
causes and consequences of 
DNA damage (partly proposed 
previously by Thomas et al. 
2015) Left Endogenous and 
exogenous factors and cellular 
processes leading to DNA 
damage and increasing the risk 
of tumour development. Right 
Processes decreasing the extent 
of DNA damage, mutation 
induction and tumour develop-
ment
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lead to an exposure of the epithelium lining of the gas-
trointestinal tract.
• A substance or its metabolite may be so reactive that it 
preferentially reacts with proteins and/or other nucleo-
philes within cells or tissues, thereby not reaching the 
target tissue DNA in relevant concentrations or only 
reaching the upper cell layers and not the proliferative 
basal cells in a particular tissue (see part B "Selected 
examples", Sec. “Formaldehyde”).
• There may be effective detoxification mechanisms, 
such as conjugation with glutathione (GSH) or epoxide 
hydrolysis and other phase II metabolic processes, which 
scavenge the proximate/ultimate electrophiles and thus 
limit their availability for DNA interaction.
Whether or not significant levels of DNA damage are 
induced under defined exposure conditions needs to be 
determined by mechanistic in vitro/in vivo experiments 
and/or biomarker studies. Furthermore, if arising from the 
same reactive metabolite(s), following similar kinetics, pro-
tein adducts may be utilized as surrogate markers for DNA 
damage.
In addition, several DNA reactive metabolites also arise 
endogenously, e.g., during physiologic carbohydrate, lipid 
and amino acid metabolism. Examples are formaldehyde, 
acetaldehyde, ethylene oxide, acrylamide and certain alk-
enals generated from lipid peroxidation (see part B Sec. 
“Presence of endogenous background levels of the same or 
similar DNA lesions”). Furthermore, DNA is continuously 
damaged by endogenous processes, such as the generation 
of reactive oxygen radicals (ROS) and other electrophiles, in 
part due to leakage from the electron transport chain opera-
tive in cellular respiration and to electrophile leakage from 
physiological metabolism (Hakem 2008; Sharma et al. 2016; 
Valko et al. 2006). It thus becomes mandatory to assess the 
increment in health risk associated with exogenous exposure 
to genotoxic compounds from food, consumer products or 
workplace-exposure in relation to the natural variance of 
endogenous DNA damage.
Finally, the cell has quite efficient DNA repair systems, 
which may prevent the conversion of DNA lesions into 
mutations. In this context, it has been postulated that there 
is a general level of DNA lesions conceived not to be rel-
evant for mutations, due to efficient repair (EFSA 2005; Jen-
kins et al. 2010). Nevertheless, whether or not this general 
assumption of comprehensive repair in the low dose range 
holds true for all types of DNA lesions will be discussed 
below, both theoretically (in part A "Fundamental considera-
tions") and by considering different genotoxic substances (in 
part B "Selected examples").
From DNA damage to mutations
The maintenance of intact genetic information is essential 
for basically all cellular processes and for the prevention of 
tumour development. However, many environmental agents 
as well as genotoxic carcinogens/mutagens in food or at 
workplaces may compromise genetic stability by inducing 
different types of DNA lesions (see part B "Selected exam-
ples" for examples and details). DNA damage interferes with 
DNA transcription and replication; potential consequences 
are programmed cell death, mutagenesis and genomic insta-
bility, which may lead to cancer when occurring in somatic 
cells, but also to reproductive toxicity when affecting sperm 
or egg cells. To maintain the integrity of the genome and to 
keep the mutation rate low, a complex DNA damage response 
network has evolved (Camenisch and Naegeli 2009; Christ-
mann et al. 2003; Fousteri and Mullenders 2008; Roos et al. 
2016). It includes diverse DNA repair systems for different 
types of DNA lesions, cell cycle control mechanisms to pre-
vent replication of damaged DNA as well as the induction of 
apoptosis in case of heavily damaged DNA. Mutations arise 
by direct integration of incorrect DNA bases in the course 
of replication or by adaptive mechanisms, depending on the 
type of DNA lesion. One example for the direct induction 
of mutations is the presence of apurinic/apyrimidinic (AP) 
or abasic sites, where the base is missing and, therefore, the 
correct base pairing information. Further examples are meth-
ylated bases such as O6-methylguanine, which may induce 
direct miscoding during DNA replication. In case of bulky 
DNA lesions, replication on a damaged DNA template is 
prevented by the high fidelity of replicative polymerase delta 
and associated proofreading factors. Nevertheless, adaptive 
mechanisms allow for completion of DNA replication and 
thus for cell survival in spite of low levels of DNA damage. 
Besides homologous recombination, error-tolerating poly-
merases may be activated; this adaptation operates–depend-
ing on the type of DNA lesion–at the expense of genomic 
stability due to enhanced mutation rates (e.g. Thomas et al. 
2015) (summarized in Fig. 2).
DNA repair systems
As indicated above, DNA repair systems are most impor-
tant to largely prevent the conversion of DNA lesions into 
mutations, i.e. fixed changes of genetic information. In mam-
mals, there are only a few examples for direct DNA dam-
age reversal, such as the transfer of the methyl group from 
O6-methylguanine to the methylguanine methyltransferase 
(MGMT) and the oxidative dealkylation of 3-methylcytosine 
and 1-methyladenine by the human homolog of the bacterial 
AlkB, ABH2. In other cases, several different DNA repair 
pathways become selectively activated depending on the 
type of DNA damage (Fig. 3).
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Nucleotide excision repair (NER) NER is the most versatile 
repair system involved in the removal of structurally unre-
lated bulky base adducts, which cause significant helical 
distortions. It can be subdivided into global genome repair 
(GG-NER) and transcription-coupled nucleotide excision 
repair (TC-NER), which preferentially removes transcrip-
tion-blocking bulky DNA lesions. At least 30 different pro-
teins and enzymes are required in mammalian cells, includ-
ing those which are defective in patients suffering from the 
DNA repair disorder Xeroderma Pigmentosum (XP) com-
plementation groups A through G. The most crucial step 
is the damage recognition, followed by the incision at both 
sides of the lesion and the repair polymerisation leading to 
the displacement of the damaged oligonucleotide. Repair is 
completed by the ligation of the repair patch. Well investi-
gated substrates are UVC-induced pyrimidine dimers, but 
also DNA lesions induced by genotoxic chemicals such as 
benzo[a]pyrene and others (for reviews see e.g. Camenisch 
and Naegeli 2009; Christmann et al. 2003; de Boer and Hoei-
jmakers 2000; Fousteri and Mullenders 2008; Marteijn et al. 
2014). With respect to genomic stability, NER is an error-
free process, as long as only one strand of the DNA double 
helix is affected. The correct information is located on the 
intact strand and can be copied during repair replication. 
However, due to the heterogeneity of DNA repair, largely 
depending on the accessibility of the lesions in regions with 
different degrees of chromatin condensation, nucleotide 
excision repair is comparatively slow and may not be com-
pleted, especially in heterochromatic regions, before the cell 
divides (Feng et al. 2003; Mullenders et al. 1991).
Base excision repair (BER) In contrast to NER, which detects 
a rather broad spectrum of DNA lesions, BER is initiated 
by a specific class of DNA repair enzymes called glycosy-
lases, which specifically act on one or few substrates. BER 
is mainly responsible for the removal of different types of 
DNA lesions that are also generated by endogenous pro-
cesses, including oxidative DNA base modifications like 
8-hydroxy-deoxyguanosine (8-oxo-dG) or DNA alkylation, 
most frequently at the N7-position of guanine. The first step 
of BER generates AP sites, which are further processed in 
a multistep procedure with slight differences depending on 
the type of damage (Camenisch and Naegeli 2009; Christ-
mann et al. 2003; de Boer and Hoeijmakers 2000; Hakem 
2008; Kennedy et al. 2018). Compared to NER, lesions are 
repaired faster and also error-free; nevertheless, the occur-
rence of AP at the time of replication may be premutagenic.
Mismatch repair (MMR) Another DNA repair system of par-
ticular relevance for maintaining genomic stability is MMR. 
This evolutionary conserved pathway is responsible for the 
repair of mismatched normal bases after DNA replication, 
contributing significantly to the extraordinary fidelity of 
DNA replication. Cells deficient in MMR exhibit a “muta-
tor phenotype”, in which the rate of spontaneous mutations 
is greatly elevated, and defects in MMR are associated with 
an increased risk of different types of cancer. The MMR 
system also plays a key role in cell killing in response to 
alkylating agents, and MMR-deficient cells are about 100 
times more resistant to the cytotoxic effects of alkylating 
agents (Gupta and Heinen 2019; Hsieh and Yamane 2008; 
Liu et al. 2017; O’Brien and Brown 2006).
Fig. 3  Major causes of DNA 
damage and DNA repair 
pathways (adapted from de Laat 
et al. 1999); BER base excision 
repair, NER nucleotide excision 
repair, CPD cyclobutane-pyrim-
idine dimer cis-Pt cisplatin, 
MMC mitomycin C
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DNA double‑strand break repair DNA double-strand breaks 
(DSB) are induced by exogenous agents, including ionizing 
radiation, DNA crosslinking agents such as mitomycin C, and 
topoisomerase inhibitors, but also by endogenous processes, 
for example, ROS formation, replication on a damaged DNA 
template and meiotic recombination. They represent most 
critical DNA lesions since both DNA strands are affected. If 
not repaired, they lead to loss of large chromosomal regions 
and cell death. Broadly, two major principles of DSB repair 
can be discriminated, namely non-homologous end-joining 
(NHEJ), which does not require sequence homology, and 
homologous recombination (HR) which uses sister-chroma-
tids as homologous template to copy and restore the DNA 
sequence missing on the damaged chromatid. While NHEJ 
is active throughout the cell cycle, HR is restricted to the S- 
and G2-phase of the cell cycle; however, even in G2 NHEJ 
is the most active mode of DSB repair. Both types of DNA 
repair pathways also exert different impacts on genomic sta-
bility: While NHEJ protects from cytotoxicity, it is highly 
error-prone, and thus a pro-mutagenic process. In contrast, 
HR is largely error-free. Finally, microhomology-mediated 
end-joining (MMEJ) and single-strand annealing (SSA) 
may occur, for example in the case of defects in HR. DSB 
repair deficiencies are associated in different human disease 
syndromes with increased cancer susceptibility, neurologi-
cal abnormalities and immunodeficiency, including Ataxia 
telangiectasia and the Nijmegen Breakage syndrome. With 
regard to genomic instability, for example, women carrying 
mutations in the BRCA1/BRCA2 (breast cancer 1/2) genes 
resulting in HR deficiency exert increased cancer risk (for 
reviews see Aparicio et al. 2014; Bonetti et al. 2018; Chang 
et al. 2017).
Tumour suppressor functions
Besides DNA repair systems, further DNA damage 
responses are activated upon genotoxic stress in mammalian 
cells (Fig. 2). They include cell cycle control mechanisms, 
increasing the time for DNA repair, as well as apoptosis, 
thereby eliminating heavily damaged cells. The DNA dam-
age response is strictly coordinated, for example, by the 
tumour suppressor protein p53. p53 regulates cell cycle con-
trol and apoptosis by several coordinated pathways and thus 
exerts a pronounced impact on the processing of DNA dam-
age and on genomic stability (Hainaut and Hollstein 2000).
Consequences for chemical risk assessment
Taken together, the induction of DNA lesions and the fixa-
tion of mutations are separate processes, discriminated by 
mechanisms and kinetics. While the former may be repaired 
by the DNA damage response system, mutations are fixed 
changes in nucleotide sequence, which may or may not affect 
protein function. Nevertheless, the DNA damage response 
has to be recognized as a double-edged sword. While DNA 
repair systems are largely error-free, persisting DNA lesions 
may be tolerated at the expense of generating mutations.
With respect to the risk assessment of chemicals, DNA 
repair systems are protective by removing many types of 
lesions by base or nucleotide excision repair. However, sev-
eral chemicals have been shown to interfere with distinct 
steps of DNA repair pathways and, thus, may lead to relevant 
effects, similar to the increased genomic instability in repair-
defective cells. In some cases, the disturbance of DNA repair 
systems has been observed at very low compound concentra-
tions, which are relevant even under environmental exposure 
conditions, with arsenic and its metabolites as one prominent 
example (Hartwig 2013b) (see also part B "Selected exam-
ples"", Sec. “Carcinogenic metal compounds: Examples 
cadmium and arsenic”). In addition to DNA repair systems, 
cell cycle control and apoptosis also have to be considered 
as protective mechanisms in case of heavily damaged DNA, 
and, consequently, agents that interfere with the cell cycle 
control or inhibit apoptosis may increase genomic instabil-
ity and thus cancer risk. Finally, all events that promote cell 
division and growth, either via the induction of specific sig-
nalling pathways or via cytotoxicity or inflammation with 
subsequently accelerated cell proliferation, may indirectly 
impair genomic stability by decreasing the time window for 
repair and thus promoting replication of damaged DNA tem-
plates. Even though the interactions with the DNA damage 
response system are based on protein interactions, and may, 
therefore, follow non-linear dose–response relationships, 
safe concentration ranges need to be defined to prevent the 
corresponding interactions (Langie et al. 2015).
From mutations to cancer
Based on the current understanding of tumour development, 
DNA damage and mutations are key events in carcinogenic-
ity. Mutations that arise in critical genes like DNA repair 
genes increase the probability of further mutations in proto-
oncogenes and tumour suppressor genes or their regulatory 
sequences, leading to a gradual increase in genomic instabil-
ity (“mutator phenotype”) (Loeb 1991). At the cellular level, 
characteristic changes associated with malignant transfor-
mation can be observed. Thus, the “Hallmarks of Cancer” 
originally described by Hanahan and Weinberg (Hanahan 
and Weinberg 2000) comprise “sustaining proliferative 
signalling”, “evading growth suppressors”, “resisting cell 
death”, “inducing angiogenesis”, “replicative immortality” 
as well as “activating invasion and metastasis” (Hanahan and 
Weinberg 2000). They were complemented in 2011 by two 
additional hallmarks “deregulating cellular energetics” and 
“avoiding immune destruction”, with the consequences of 
“tumour-promoting inflammation” and “genome instability 
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and mutation” (Hanahan and Weinberg 2011). These cellular 
biological changes become evident in late stages of carcino-
genesis and may occur as a result of numerous selection pro-
cesses in the tumour tissue. Furthermore, epigenetic altera-
tions of DNA are also associated with tumour development. 
For example, hypo- or hypermethylation of promoter regions 
of critical genes may lead to the overexpression of onco-
genes or the suppression of tumour suppressor genes, and 
exposure towards some chemical carcinogens such as certain 
metal compounds may lead to changes in the methylation 
patterns. Moreover, interference with histone acetylation and 
deacetylation may also interfere with gene expression.
Test systems in genetic toxicology
General considerations
In the case of tumour initiation, in which genotoxicity is 
critically involved, tumour suppressor gene inactivation or 
oncogene activation is the decisive molecular event. How-
ever, up to now, these biologically meaningful genes do not 
lend themselves to a technically feasible analysis of muta-
tion frequencies. Thus, mainly for practical reasons, sur-
rogate genes are used to assess mutation frequency, and it 
is assumed that mutation induction is basically comparable 
across different parts of the genome. Whereas this certainly 
is a generalization, it is a valid assumption that whenever 
mutations or other types of genetic damage are induced in a 
gene used for mutation testing, the risk for cancer-relevant 
genetic lesions will rise as well. Under routine conditions, 
germline mutagenicity is estimated by read-across from 
somatic genotoxicity systems, assuming a likewise risk for 
germ cells if the risk has been identified in somatic tissue 
unless exposure of germline tissue can be excluded, but 
without conducting dedicated germline genotoxicity assays 
(Yauk et al. 2015).
For any test system, two fundamental characteristics 
need to be considered to define the appropriateness of the 
approach: (i) the genetic endpoint and (ii) the experimental 
model. Gene mutations and chromosome damage are used 
as endpoints in routine testing because they have been rec-
ognized as critical molecular events in tumour initiation. In 
addition, primary DNA lesions or other endpoints can be 
used to investigate genetic damage but in general are not 
used routinely. To measure gene mutations, biochemical cell 
functions such as enzyme activities or membrane receptors 
are analysed, whereas chromosome aberrations are mainly 
assessed by microscopic techniques or flow cytometry. 
Obviously, to investigate chromosomal integrity, eukaryotic 
systems are needed, whereas gene mutations can also be 
measured in bacterial cells. In this context, it is important 
to understand that a spectrum of genetic damage can lead to 
tumour initiation. For this reason, in most testing settings, 
a combination of tests is used, with the idea of covering 
all possible mechanisms that can lead to tumour initiation 
(MacGregor et al. 2000). Additional considerations of the 
appropriate applicable testing strategy are derived from the 
intended use of a chemical, i.e. whether a molecule is used 
as an industrial chemical, a pesticide or a pharmaceutical 
ingredient, or whether it is present therein as a component 
or an impurity, or in food or the environment. Accordingly, 
the regulatory context and the applicable guidances vary 
with respect to the rationale underlying the testing strategies 
and the stringency and scientific depth of the approaches. As 
an example of a highly regulated field, ICH (International 
Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use) guidance S2 describes the 
testing approach for novel pharmaceutical ingredients (ICH 
2011).
Strategies for genotoxicity assessment
According to this guidance, basic genotoxicity assessment 
consists of a bacterial mutation (Salmonella typhimurium 
reverse mutation) test to investigate the induction of gene 
mutations in vitro (OECD TG 471) (OECD 1997). In this 
test, like in all in vitro tests, an extracellular system is used 
to provide for metabolic activation of pre-mutagens. Rou-
tinely, this consists of a preparation from chemically induced 
rat liver, which contains cytosolic as well as microsomal 
enzymes plus co-substrates to mainly stimulate oxidative 
metabolism, to detect those mutagens that need metabolic 
activation to become DNA-reactive. Obviously, this experi-
mental design is not sufficient to cover all relevant activating 
conditions but has nonetheless shown to possess a remark-
able predictivity for genotoxic carcinogenesis (Kirkland 
et al. 2005). Moreover, since this test system is both sensi-
tive for mutagens of diverse chemical classes as well as not 
very prone to artefacts, it is considered a reliable predictor 
of relevant mutagenicity (Kirkland et al. 2005).
According to ICH M3 (R2), an assay for gene mutation 
is generally considered sufficient to support all single-dose 
clinical development trials (ICH 2009). ICH S2 provides two 
options for genotoxicity testing starting in the first place with 
the gene mutation assay in bacteria for both options. To sup-
port multiple-dose Phase I trials, an additional assessment 
capable of detecting chromosomal damage in a mamma-
lian system(s) should be completed. A complete battery of 
tests for genotoxicity should be performed before initiation 
of Phase II trials. However, if positive findings occur, an 
assessment and then possibly additional testing is needed.
Option 1 consists furthermore of a mammalian cell test 
in vitro, which is either a thymidine kinase (tk) gene muta-
tion test in L5178Y mouse lymphoma cells or a chromosome 
aberration or micronucleus test (MNT) in basically any cell 
type that is amenable to these endpoints. If positive only 
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under conditions in which human relevance can be convinc-
ingly excluded (e.g. excessive cytotoxicity) or negative, this 
package of two negative tests will allow the initiation of a 
clinical Phase I study with multiple dosing, and an in vivo 
test (chromosome aberration or MNT in rodent bone marrow 
or peripheral blood) is not needed before Phase II clinical 
studies. If positive, the relevance of the positive result(s) 
needs to be investigated. Relevance in this context can be 
demonstrated in various ways. Mostly, if an effect can be 
excluded under appropriate conditions in animals (e.g. suffi-
ciently high exposure in the absence of target tissue toxicity), 
this is a strong evidence of the absence of a risk in humans. 
In the case of a positive effect in the mentioned mamma-
lian tests, the applicable follow-up strategy would consist 
of a micronucleus or chromosome aberration test in rodent 
bone marrow or peripheral blood, plus a second test using a 
second endpoint and tissue. Due to ease of conductance and 
applicability to a variety of tissues the second endpoint will 
be in many cases the evaluation of primary DNA damage 
via the alkaline single cell gel electrophoresis (comet) assay. 
Tissue selection should be guided by scientific arguments 
specific to the situation, e.g. the liver if hepatic metabolic 
activation is suspected, the GI tract as a tissue of high local 
compound concentration in the case of the oral administra-
tion of the chemical, or organs in which toxic effects or drug 
accumulation have been observed. In the case of a positive 
effect in the Ames test, transgenic animals, the comet assay, 
or the Pig-A assay are available to investigate gene muta-
tions in vivo (Kirkland et al. 2019; OECD 2011). In any 
case, the conditions need to be appropriate to provide argu-
ments to exclude a human risk with sufficient stringency, for 
example with respect to doses and treatment schedules used. 
Accumulating experience has allowed ICH S2 to accept the 
combination of various endpoints into a single study, such 
as e.g. a micronucleus and comet test in the same animal. 
Whereas traditionally these tests were conducted under an 
acute treatment paradigm, it is now also accepted to use 
a subacute or subchronic treatment, provided a number of 
criteria are fulfilled to assure sufficient sensitivity, such as 
e.g. a highest dose level of at least 50% of a potential acute 
maximum tolerated dose (MTD).
Alternatively, as Option 2, ICH S2 allows the initiation 
of Phase II clinical trials without conducting a mammalian 
in vitro test. In this case, two in vivo tests are needed, similar 
to the situation in which the mammalian in vitro test is posi-
tive under Option 1.
Routinely, in drug development, screening tests will pre-
cede those tests intended to assess human risk, which allows 
an earlier prediction of the outcome of those regulatory tests 
important for the early selection of the right molecules. Fur-
thermore, computer-assisted prediction systems are widely 
used to predict bacterial mutagenicity and accomplish it 
with an acceptable precision (Naven et al. 2012). However, 
for other endpoints they have not matured to the level that 
would render them reliable enough for routine use. Gener-
ally, endpoints and test systems, which resemble those of 
the regulatory tests to ensure a sufficient predictivity, such 
as down-scaled versions of the Ames or MNT, are used. 
If other test systems, such as e.g. high-throughput test sys-
tems, are applied, thorough validation studies need to be 
performed to ensure their predictivity. If equivocal results 
are obtained in those standard approaches, exploratory 
methodologies are applied to clarify the situation. While 
the above examples of test strategies apply to pharmaceuti-
cal ingredients, the underlying principles are comparable to 
those in other areas, in which genotoxicity testing is applied 
(Eastmond et al. 2009; ECHA 2017; EFSA 2011b). For 
example, in the food and feed regulation field, as outlined 
by EFSA (2011b), a stepwise approach is recommended as 
well. Initially, a basic in vitro testing step will include the 
Salmonella reverse mutation test and an in vitro MNT in 
mammalian cells. This approach is more restrictive than for 
pharmaceuticals, in which case three tests (MNT, mouse 
lymphoma tk test and chromosome aberrations test) are 
offered as equivalent alternatives for assessing mammalian 
genotoxicity in vitro. If a positive result is obtained in vitro, 
one or several in vivo follow-up tests are recommended, fol-
lowing a similar logic as with e.g. pharmaceuticals, which 
includes a test using a comparable genetic endpoint as in 
the positive in vitro test. Similarly, if characteristics such 
as metabolism preclude a meaningful use of an in vitro test 
as the first step, the assessment could be done based on the 
in vivo testing alone. However, an a priori assessment using 
in vivo data alone, i.e. Option 2 (ICH S2)-like approach in 
the absence of arguments that would preclude the use of 
in vitro tests, is not foreseen by EFSA. In any case, for both 
ICH and EFSA, if the initial in vitro testing is overall nega-
tive in adequately conducted tests, this is sufficient to con-
clude on the absence of a genotoxic potential of the tested 
material. For EFSA purposes, this may be sufficient as a 
final conclusion for a chemical, whereas according to ICH an 
in vivo test will be needed as a final proof. Moreover, routine 
germline genotoxicity testing is deemed unnecessary under 
both regulations, and information obtained in the routine 
tests is considered sufficient to identify a risk in both somatic 
and reproductive tissue.
In contrast, for industrial chemicals as outlined in the 
REACH guidance (ECHA 2017), testing requirements are 
mainly triggered by annual tonnage, i.e. by the amount of 
the chemical that is marketed per year in the EU. This means 
that whenever a new level of tonnage is reached, additional 
tests are asked for. The underlying principle as to why this is 
feasible is that for chemicals, whenever a risk is identified, 
exposure to humans during production, transport and han-
dling can be restricted by technical measures if necessary, 
whereas this is not possible for drugs or food ingredients. 
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Therefore, the purpose of genotoxicity testing of industrial 
chemicals is mainly to support labelling and protection 
measures, whereas in the case of drugs, the purpose is for a 
risk/benefit consideration. Relevant genotoxicity is incom-
patible with the development and application of pharma-
ceuticals in most disease indications. In the case of food 
constituents and/or contaminants risk assessment is the key 
step. When for food the presence of trace levels of naturally 
occurring mutagens/carcinogens or those generated during 
food processing cannot be avoided, risk assessment with due 
consideration of exposure levels is mandatory.
In all cases, the conductance of all individual routine 
tests should follow the recommendations as outlined by the 
applicable OECD guidelines, which are specific for each 
test and layout test characteristics, which are essential for a 
meaningful result, such as e.g. the maximum concentration 
or dose that should be applied and criteria to define these.
While quantitative considerations have been unusual in 
genotoxicity testing, in carcinogenicity potency assessment 
it is an established factor to discuss risk determinants. A 
methodology to compare potencies is the benchmark dose 
(BMD), defined as the dose that corresponds to a specific 
change in an adverse response compared to the background. 
Often, the lower 95% confidence limit of the benchmark 
dose level (BMDL) is used, and guidance documents have 
been released e.g. by EPA (https ://www.epa.gov/raf/publi 
catio ns/bench markd ose.htm) or EFSA (2009b, 2017c). How-
ever, comparisons of endpoints of varying biological depth 
(i.e. for example DNA damage, mutation and cancer) are 
rare, and at the same time problematic due to the variability 
of potentially confounding influence factors. In addition, in 
general genotoxicity tests are not designed to derive quanti-
tative data, so that dose–response relationships are normally 
not worked out in much detail. Similarly, despite the fact that 
BMD considerations imply quantitative information, carci-
nogenicity studies are normally lacking a large number of 
dose levels, mainly due to the enormous effort associated 
with such an approach, so that detailed quantitative informa-
tion is often not available.
In an attempt to quantitatively compare different test 
systems and endpoints, a literature study was performed, 
using data from the in vivo comet assay, the MNT, and 
the in vivo transgenic rodent mutation assay (TG). These 
assays were chosen because they represent different stages 
of the mutagenicity process, i.e. the comet assay detects 
single- and double-DNA strand breaks, the MNT detects 
numerical and structural chromosomal aberrations, and the 
TG assay detects mutations. Only studies with two or more 
dose levels were included (Hernandez et al. 2011). Those 
data were compared to carcinogenicity data from the Gold 
Carcinogenicity Database, using IARC Class 1–3 carcino-
gens. In this study, data on 18 compounds tested in all four 
test systems were available. Of those 18 compounds, 15 had 
acceptable dose–response data from the MNT and the TG, 
but only 4 from the comet assay. Quantitative relationships 
were investigated by comparing  BMD10 values modelled 
from the available genotoxicity data (Comet, MNT, and 
TG) to  BMD10 values derived from carcinogenicity stud-
ies, acknowledging different administration routes between 
genotoxicity and carcinogenicity studies with a high num-
ber of compounds. Interestingly, despite these confounding 
factors, a relatively good correlation was observed between 
MNT and TG tests and the carcinogenicity data. The strong-
est correlation was found between the lowest  BMD10 from 
MNT or TG data (i.e., lowest genotoxicity  BMD10) and the 
tissue-matched tumour  BMD10, in that the strongest geno-
toxins were also the strongest carcinogens and vice versa, 
which corroborates the importance of these genotoxicity 
endpoints in predicting tumour initiation.
Thus, while in general a correlation between the potency 
of each endpoint can be assumed and has been demonstrated, 
the sensitivity of the test systems has not been systematically 
compared. Intuitively, a test system that is able to analyse 
early events in tumour induction should be more sensitive 
than a test system quantifying later events such as mutations, 
owing to the fact that many earlier events (e.g. DNA base 
modifications) are induced to initiate a lower number of the 
subsequent ones (e.g. mutations), culminating in a relatively 
low number of tumours per animal and dose group.
However, experimentally, DNA modifications as the 
first discernible endpoint of DNA damage were not always 
the most sensitive markers in certain experimental set-
tings, depending on the sensitivity of the analytical method 
applied. For example, in a study using L5178Y mouse lym-
phoma cells in vitro, 8-oxo-7,8-dihydro-2-deoxyguanosine 
(8-oxo-dG) and 1,N6-etheno-2-deoxyadenosine DNA base 
modifications were measured by LC-MS/MS after treatment 
with hydrogen peroxide or cumene hydroperoxide at con-
centrations of up to 500 µM or 10 µM, respectively (Brink 
et al. 2009). While at these concentrations no increase in 
either DNA modification levels were found, DNA damage 
as assessed in the comet assay as well as the MN and tk 
gene mutation frequencies were significantly elevated. In 
case of 8-oxo-dG this may be due to potential artefacts when 
measuring oxidatively induced DNA lesions by LC-MS/MS 
resulting from the unintended generation of DNA lesions 
during sample preparation (Gedik et al. 2005). In contrast, 
after treatment with methyl methanesulfonate (MMS), the 
induction of 7-methylguanine (7-MG) or O6-methyl-2′-
deoxyguanosine (O6-mdGuo) adducts occurred at a much 
lower concentration than those inducing the other genotoxic-
ity endpoints. Moreover, the authors caution that other fac-
tors may have contributed to this unexpected result. As such, 
it is only those two adducts that were determined but it is 
conceivable that other adducts or mechanisms not involving 
adduct formation are more relevant regarding the mutations 
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induced. Furthermore, no detailed time courses were cho-
sen for the various endpoints, so that optimal readouts may 
not have been obtained. Thus, based on these results, it was 
concluded that DNA adduct formation, like other endpoints, 
needs to be analysed on a case-by-case basis, using opti-
mized conditions and that there is no general correlation 
between DNA adduct levels at a given time point and the 
subsequent mutations.
Finally, novel test systems have been described to refine 
the available approaches. Among the most advanced, the 
Pig-A assay offers a promising potential. The assay is based 
on the cytometric visualization and quantitation of mark-
ers linked to cell surfaces via glycosylphosphatidylinositol 
(GPI)-anchored proteins. The gene of this anchor protein 
is X-linked and as such only haploid in mammalian cells, 
so that a mutational loss of that protein will generate cells 
lacking the attached phenotypic marker (Gollapudi et al. 
2015). Despite the fact that mutations that lead to a loss of 
GPI anchors have not been well characterized, it is a gene 
mutation that constitutes the genetic endpoint addressed so 
that this test could be a follow-up test to investigate posi-
tive Ames test results in vivo. Whereas this assay can be 
used in various animal species and cell types in vitro and 
in vivo (Olsen et al. 2017), it is currently being mostly used 
to quantify CD59-deficient (presumed Pig-a mutant) eryth-
rocytes in the peripheral blood of rats. Thus, it lends itself 
to being integrated into repeated-dose toxicity studies, since 
only a minimal amount of peripheral blood needs to be col-
lected for analysis so that even a longitudinal analysis is 
feasible (Godin-Ethier et al. 2015). The preparation of an 
OECD Guidance Document for this test is underway, based 
on recently published detailed experimental descriptions 
(Gollapudi et al. 2015).
Protein adducts as human biomarkers
Chemical carcinogens form covalent bonds with nucleo-
philic sites of physiological macromolecules, e.g. DNA, 
RNA and proteins. Resulting DNA adducts may lead to 
mutation events. However, the internal exposure to electro-
philic compounds in humans is usually not characterized by 
DNA adduct levels, mainly due to the limited accessibility 
of human DNA. Instead, techniques for the assessment of 
the internal exposure via quantification of protein adducts 
are well established in the case of haemoglobin (Hb) and 
serum albumin (SA) as preferred targets (dosimetry). Espe-
cially thiol groups of cysteine (Cys) residues as well as the 
nitrogen atoms of histidine (His) and the N-terminal valine 
(Val) in Hb undergo addition reactions and nucleophilic sub-
stitutions leading to the formation of covalent bonds. The 
resulting adducts may be suitable biomarkers for the inter-
nal dose of reactive metabolites. They are not only integral 
parameters, which reflect the actual intake regardless of the 
source and the uptake route. They also account for the wide 
substance-specific interindividual toxicokinetic variations 
in humans.
Analytical techniques for the adduct quantification were 
initially established as tools to monitor the occupational 
exposure to mutagens and carcinogens during work shifts, 
e.g. to ethylene oxide (Calleman et al. 1978) and aniline 
(Lewalter and Korallus 1985). More recently, the analytical 
assessment of protein adducts was introduced in molecular 
cancer epidemiology. A substance-specific biomarker that 
complements assessment of dietary exposure may be sup-
portive to uncover causal associations between the uptake 
of food-borne carcinogens and cancer risk.
The blood proteins Hb and SA are suitable targets for 
the analysis of the adduct load in humans. Both proteins 
are available in relatively large quantities (~ 150 mg Hb/ml 
blood, ~ 30 mg SA/ml blood). The time intervals of internal 
exposure monitoring to electrophilic compounds are primar-
ily determined by the lifespan of red blood cells for Hb (120 
d in humans) and the half-life of SA (t1/2 = 20 d in humans). 
Because of the relative longevity of Hb, monitoring of Hb 
adducts is preferred over that of SA adducts. However, since 
the number and accessibility of nucleophilic amino acid 
side chains on the protein surface determine their reactivity, 
monitoring of SA adducts may be a more sensitive parameter 
compared to those in Hb (Rappaport et al. 2012). Moreover, 
SA is biosynthesized in hepatocytes, in which the bioactiva-
tion of many carcinogens takes place.
To monitor short-term exposures, e.g. immediately after 
accidental scenarios or short term nutritional exposure, it 
may be advisable to quantify mercapturic acids. They are 
formed from glutathione conjugates of reactive metabo-
lites and are excreted in the urine. Mercapturic acids are 
detected shortly after the uptake of chemicals and are elimi-
nated usually within 24 h. As a consequence, they are sensi-
tive biomarkers of choice to monitor short-term exposures, 
which may not cause measurable changes of adduct levels in 
blood proteins (Mathias and B’Hymer 2014) (see also part 
B "Selected examples", Sec. “Acrylamide”).
Methodological aspects of protein adduct isolation
Among numerous techniques for the cleavage or the isola-
tion of adducts from proteins the most common methods 
are the Edman degradation of the N-terminal Val of Hb, the 
enzymatic hydrolysis of either Hb or SA (usually with the 
aim of extracting adducts from single amino acids) and the 
cleavage of sulfinamides to release aromatic amines from 
Cys adducts (Törnqvist et al. 2002). The concept of using 
Hb as a molecular dosimeter for alkylating agents was intro-
duced by Ehrenberg and co-workers (Ehrenberg et al. 1974; 
Osterman-Golkar et al. 1976). The most important reason 
for its wide applicability is the reactivity of the N-terminal 
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Val residues. The amino group of the free Val (pKa = 9.74) 
is expected to be largely protonated in the blood (pH ~ 7.4). 
In the protein environment of Hb the nitrogen acidity of the 
Val residues, which are somewhat shielded, is increased in 
the subunit α (pKa = 7.8) and β subunit (pKa = 6.8), thereby 
resulting in large fractions of unprotonated primary amine 
groups (Törnqvist et al. 2002). Due to its convenience, the 
Edman degradation of modified N-terminal Val residues is 
the most well-established technique for studying protein 
adducts in humans (Fennell et al. 2005; Rydberg et al. 2009; 
Törnqvist et al. 1986).
Alternatively, adducts may be quantified after the pro-
teolytic digestion of blood proteins to mixtures of peptides 
and single amino acids. In this case, serum proteins such 
as SA are the preferred molecular targets (Sabbioni and 
Turesky 2017; Skipper and Tannenbaum 1990; Yang et al. 
2014). The applicability of this method may be somewhat 
restricted due to the limited efficiency of the digestion. Peng 
and Turesky (2014) tested the proteolytic cleavage with five 
different mixtures of enzymes to analyse the adduct of the 
food carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)
pyridine (PhIP) at  Cys34 in SA. The results indicated that the 
complete enzymatic hydrolysis of SA to the level of single 
amino acids was not achieved, even with mixtures of vari-
ous proteolytic enzymes (Peng and Turesky 2014). These 
authors concluded that it is impossible to determine the 
digestion efficiency, which prohibits referring adduct levels 
determined by mass spectrometric means to the amount of 
protein used for the analysis.
A third method was specifically developed for the release 
of Hb adducts from carcinogenic aromatic amines and 
nitroarenes. Aromatic amines are exceptionally well studied 
due to their relevance in occupational health, e.g. aniline and 
toluidine (Teass et al. 1993), and their presence in tobacco 
smoke, e.g. 4-aminobiphenyl (Bryant et al. 1987). The com-
pounds are metabolized to arylhydroxylamines, which are 
oxidized to arylnitroso intermediates. These are prone to 
form sulfinamide adducts with Cys residues. The cleavage 
under acidic or alkaline conditions yields the free parent 
amines, which can be readily quantified by mass spectro-
metric methods (Skipper and Stillwell 1994).
The simultaneous analysis of multiple protein adducts
With the availability of increasingly sensitive GC-MS and 
LC-MS/MS techniques it became feasible to study the back-
ground levels of adducts originating from the continuous 
intake of low doses of environmental and food carcinogens. 
However, as yet there are only a few applications of protein 
adduct analysis in molecular epidemiology. In part, this is 
due to the perception that it is implausible to correlate low 
exposure to single carcinogens in the diet with tumour for-
mation. Such an association was seldom shown. An example 
is the case of aflatoxin B1 and hepatocellular carcinoma 
(Liu and Wu 2010; Wogan 1992) (see also part B "Selected 
examples", Sec. “Aflatoxin B1”). It is more probable that 
the internal exposure to the whole array of exposure rel-
evant compounds, the so-called exposome, and the subse-
quent global genotoxic insult may be responsible for tumour 
development. The challenge is to assess the internal doses of 
a wide range of electrophilic compounds, e.g. by simultane-
ous monitoring of protein adducts. First proof-of-principle 
studies focused on the adduct arrays of single amino acid 
hot spots in Hb (Carlsson et al. 2014) or SA (Li et al. 2011a; 
Osaki et al. 2014), e.g. the N-terminal Val in Hb or  Cys34 
in SA. Li et al. (2011a, b) described a mass spectrometric 
method for the profiling of adducts at  Cys34 after isolation 
and tryptic digest of SA from human blood samples. This 
allowed to discriminate blood samples of smokers and non-
smokers. However, the adducts and their biochemical ori-
gin were not characterized (Li et al. 2011a). Carlsson et al. 
(2014) presented a novel screening strategy for unknown Hb 
adducts using the modified Edman degradation with Fluo-
rescein-5-isothiocyanate (FITC) as the cleavage reagent for 
the N-terminal Val. The technique allowed detecting seven 
known and 19 unknown Val adducts in human Hb (Carlsson 
and Tornqvist 2017; Carlsson et al. 2014).
In summary, the progress in the area of simultaneous 
monitoring of protein adducts that reflect the internal expo-
sure to a range of reactive compounds is relatively slow. It 
becomes clear that the monitoring of a large range of elec-
trophilic compounds may require more than one technique of 
adduct isolation because different nucleophilic sites within a 
protein react with different classes of electrophiles. One of 
the methods in the toolbox for the future characterization of 
the human exposome may be the Edman degradation.
Protein adduct analyses in occupational medicine
Human biomonitoring (HBM) is used as a diagnostic tool 
to estimate the health risk resulting from the long-term 
exposure to a hazardous compound e.g. at the workplace. 
The MAK Commission of the German Research Founda-
tion (DFG) derived reference values for the concentrations 
of Hb adducts for some toxicologically relevant substances. 
For example, health-related parameters, e.g. so-called Bio-
logical Reference Values (BAR values) for workplace sub-
stances were determined to evaluate biomonitoring results 
of adducts from acrylamide (50 pmol/g Hb), acrylonitrile 
(10 pmol/g Hb), 1,2-epoxypropane (10 pmol/g Hb), 4-amin-
obiphenyl (after release from Hb, 15 ng/l) and 4,4´-diami-
nodiphenylmethane (after release from Hb, < 5 ng/l) (DFG 
2018). However, the BAR values exclusively reflect the 
background levels of protein adducts of environmental 
agents in the not occupationally exposed reference popula-
tion and thus cannot be used directly to assess the health 
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risk resulting from a particular exposure and increases of 
adduct levels.
In the case of carcinogenic compounds, there are usu-
ally no applicable risk-based exposure limits in occupational 
medicine. However, in some cases, acceptance and tolerance 
concentrations that result in an estimated excess tumour risk 
of 4:10,000 and 4:1000, respectively, after life-time inhala-
tive exposure to a specific compound at the workplace were 
derived by the Committee on Hazardous Substances (AGS) 
(AGS 2014). For some of the substances, the MAK Com-
mission also derived Exposure Equivalents for Cancerous 
Substances (EKA) values. Usually, the EKA values describe 
the correlation between the concentration of a carcinogen 
at the workplace air and of the substance or its metabolites 
in a biological sample. However, there are also EKA values 
including levels of Hb adducts as measures of the internal 
exposure of the carcinogenic substances (DFG 2018). Based 
on the combination of acceptance values or tolerance values 
and the EKA values risk-related parameters were derived 
for the acceptance concentration of Hb adducts (equiva-
lent value for an excess risk of 4:10,000) of acrylamide 
(400 pmol/g) and acrylonitrile (650 pmol/g) and for the tol-
erance concentration (equivalent value for an excess risk of 
4:1000) of Hb adducts of acrylonitrile (6500 pmol/g) and 
ethylene oxide (3900 pmol/g) (AGS 2014).
Protein adducts as exposure markers of dietary 
and environmental carcinogens
The correlations between intake of dietary and environmen-
tal carcinogens and the development of tumours in humans 
are difficult to study due to various problems. For example, 
the assessment of exact exposure levels over a long time is 
difficult and, in addition, there are wide substance-specific 
interindividual toxicokinetic variations. It is, therefore, 
reasonable to use biomarkers that reflect the actual intake 
and the toxicokinetic properties of a mutagenic substance. 
Early examples come from studies of inhalative exposure 
to tobacco smoke containing aromatic amines, which form 
sulfinamide linkages with Cys residues in Hb. High con-
centrations of Hb adducts derived from 4-aminobiphenyl 
and other arylamine-sulfinamides were associated with an 
increased risk of bladder cancer in smokers but also in non-
smokers (Skipper et al. 2003; Yu et al. 2002). The progress 
in the field of protein adduct analysis is demonstrated by 
recently developed mass spectrometric techniques for the 
determination of adducts from various mutagenic and carci-
nogenic substances in food, for example, from aflatoxin B1 
(Lys-AFB 1 in serum protein (McCoy et al. 2005)), from the 
glucosinolate neoglucobrassicin (N-(1-MIM)-His in Hb and 
SA of mice (Barknowitz et al. 2014)), benzo[a]pyrene (His-
adduct of the reactive ( ±)-anti-benzo[a]pyrene-7,8-diol-
9,10-epoxide (BPDE) in mouse SA (Westberg et al. 2014)), 
and from PhIP (the peptide  LQQC34(PhIP)PFEDHVK in 
SA (Peng and Turesky 2011) and from the heat-induced 
contaminants glycidol (Hielscher et al. 2017) and furfuryl 
alcohol (Sachse et al. 2017) (Val-adducts in Hb). However, 
there only are a few studies on the molecular epidemiol-
ogy of dietary compounds reporting associations between 
protein adduct levels and cancer risk. The Hb adducts of 
acrylamide and the reactive metabolite glycidamide at the 
N-terminal Val were used as biomarkers of the internal dose 
in a various nested case–control studies. For example, a 
weak positive association between levels of the acrylamide 
adduct N-(2-carbamoylethyl)Val from Hb in 269 breast can-
cer cases was reported from the “Danish Diet, Cancer and 
Health Study” with an incidence ratio of 2.7 fold per ten-
fold increase of N-(2-carbamoylethyl)Val (95% CI 1.1–6.6) 
(Olesen et al. 2008). In 170 prostate cancer patients from 
the “Cancer of the Prostate in Sweden Study” there was no 
correlation detected between Hb adduct levels of acrylamide 
and glycidamide and the tumour incidence (Wilson et al. 
2009). Moreover, there was no evidence for an association 
between the increased risk of epithelial ovarian cancer in 263 
cases and elevated levels of Hb adducts of acrylamide and 
glycidamide (Xie et al. 2013). It is important to note, that 
epidemiological studies have failed to demonstrate a corre-
lation between dietary acrylamide intake and an increased 
risk of tumour incidence (Lipworth et al. 2012). The dem-
onstration of a correlation between acrylamide intake and 
the formation of acrylamide and glycidamide adducts by 
future duplicate studies may support the detection of asso-
ciations in the field of cancer epidemiology. Another inter-
esting example for the application of a protein adduct as a 
biomarker for the internal exposure to an endogenous car-
cinogen is the quantification of Cys adducts of 17β-estradiol-
2,3-quinone and 17β-estradiol-3,4-quinone in Hb of blood 
samples from breast cancer patients in Taiwan. The analyses 
showed that the concentrations of estrogen quinone-derived 
adducts were on average six times higher in the group of 
patients than in the control group, thereby supporting the 
relationship between elevated estrogen plasma levels and 
breast cancer (Lin et al. 2014).
Future risk assessment using protein adducts of food 
and environmental carcinogens
Protein adducts formed by reactive xenobiotic carcino-
gens, their respective metabolites and some electrophiles of 
endogenous origin may not directly reflect the genetic dam-
age. Correlations between adduct levels in blood proteins 
and risks of tumour development in particular tissues should 
be considered with caution. One of the factors which might 
influence the adduct levels of plasma proteins is their biolog-
ical stability, e.g. resistance to proteolysis after modification. 
Proteolytic activities are influenced by individual factors as 
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genetics, lifestyle, age etc. The above-mentioned definition 
of acceptance concentrations and tolerance concentrations 
by the AGS are exceptions, in which protein adduct levels 
of occupationally relevant substances were associated with 
specific excess risks of tumour formation in the working 
population (AGS 2014).
An interesting case for a well-established correlation 
of exposure → protein adducts → cancer incidence was 
described for 4-aminobiphenyl. The levels of the sulfina-
mide adducts of the aromatic amine in Hb were shown to 
increase with the number of cigarettes smoked per day, and 
the protein adduct levels were correlated with the DNA 
adduct concentration of C8-(4-aminobiphenyl-N4-yl)-2′-
deoxyguanosine (dG-C8-4ABP) in exfoliated urothelial 
cells. Furthermore, the increase of the protein adduct con-
centration was correlated with increased bladder cancer risk 
(Turesky and Le Marchand 2011). However, such correla-
tions between external dose, biomarkers of internal exposure 
and tumorigenic effect are still an exception.
Risk assessment may also be supported by detailed infor-
mation on the correlation of external exposure and protein 
adducts. This may allow determining the external exposure 
from the measurement of protein adduct levels on an indi-
vidual basis. Recently, Abraham et al. described the dose-
specific increase of the adduct N-(2,3-dihydroxypropyl)
Val in Hb after intentional exposure to glycidyl esters in a 
human study (n = 11) using a commercially available fat. 
From this increase, a mathematical model was used to cal-
culate the external exposure in the group of participants in 
the 4 months prior to the start of the controlled exposure 
study. Of course, this approach seems only possible if the 
interindividual variations of bioactivation and detoxification 
of the substance in question are relatively small (Abraham 
et al. 2019).
One obstacle in the risk assessment of carcinogenic sub-
stances is the extrapolation of the association between dose 
and tumour incidence from 2-year bioassays to the human 
situation. This is not easy due to various reasons, for exam-
ple, because the metabolic capacities for activation and 
detoxification in animal models and humans are different. 
To support risk assessment, key enzymatic parameters may 
be determined in vitro at the level of individual enzymes 
or tissue samples (Sachse et al. 2016). Alternatively, pro-
tein adducts as biomarkers for the characterization of the 
species-dependent metabolic activation may allow to com-
pare the internal exposure resulting from a defined exter-
nal dose between animals and humans. With this approach, 
the internal exposure to 1,2:3,4-diepoxybutane, a reactive 
metabolite of the industrial building block 1,3-butadiene, 
was compared in mice, rats and humans. The metabolite 
forms the N,N-(2,3-dihydroxy-1,4-butadiyl)Val adduct at 
the N-terminus of Hb. A tryptic digest yields the peptide 
containing the modified Val (pyr-Val), which is readily 
quantified by LC–MS/MS (Boysen et al. 2004). After inha-
lative exposure to five different concentrations between 
0.1 ppm and 625 ppm 1,3-butadiene, mice had 10- to 60-fold 
higher levels of pyr-Val if compared to rats (Georgieva et al. 
2010). These findings supported the hypothesis that the rela-
tive tumour susceptibility of mice may partially be attributed 
to enhanced 1,3-butadiene bioactivation (NTP 2011). Geor-
gieva et al. (2010) analysed pyr-Val levels in a group of over 
300 industrially workers exposed to 1,3-butadiene. In animal 
models, the exposure to 0.1 to 1 ppm, which corresponds to 
the ambient 1,3-butadiene concentrations detected at work-
places, led to approximately tenfold and 100-fold higher 
levels of pyr-Val in rats and mice, respectively, compared to 
humans (Georgieva et al. 2010). These findings indicate that 
rodent models are more sensitive to 1,3-butadiene bioactiva-
tion when compared to humans. The future risk assessment 
of dietary carcinogens may be improved by replacing the 
external dose parameters by protein adduct monitoring in 
humans in, e.g., the margin of exposure calculation.
In summary, blood protein adducts are ideal biomarkers 
for the characterization of the internal exposure to electro-
philic compounds due to the relatively long lifetime of Hb 
and SA, their accessibility and their abundance. In the area 
of occupational health, protein adducts are routinely ana-
lysed to monitor the internal exposure to reactive metabolites 
of particular substances at the workplace. The biomonitoring 
results are usually evaluated using reference parameters, e.g. 
the BAR values of the German MAK Commission. Cur-
rently, efforts are directed towards the further development 
of the analytical techniques as well as the application of 
protein adduct analyses in other scientific areas. In molecular 
epidemiology, for example, protein adducts may comple-
ment or replace the parameter of external exposure to dietary 
and environmental carcinogens to support the detection of 
hitherto unknown associations between exposure and tumour 
development. Very few studies, mainly on dietary acryla-
mide exposure, have been published (Olesen et al. 2008; 
Wilson et al. 2009; Xie et al. 2013). They have limited sig-
nificance due to the small numbers of participants and analy-
ses of single blood drawings.
Protein adduct quantification may also support current 
routine procedures in risk assessment. The adduct concen-
tration resulting from a defined dose of a particular sub-
stance in humans may be compared to the same parameter 
in animal models, for which also carcinogenicity data may 
be available. This allows to compare the metabolic bioac-
tivation and detoxification rates in humans and animals to 
support risk assessment. A promising technical advancement 
is the implementation of mass spectrometric techniques for 
the simultaneous quantification of multiple protein adducts. 
Their incorporation into human biomonitoring may greatly 
increase our knowledge on the internal human exposure to 
common food and environmental carcinogens.
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Toxicogenomics for hazard identification and risk 
assessment
Elucidating the nature of the dose–response relationship, 
particularly in the low dose range, requires a detailed under-
standing of the biological response to xenobiotic exposure. 
Therefore, it seems promising to use a toxicogenomic 
approach which brings together the knowledge gained from 
toxicology, genomics and bioinformatics. The diverse tech-
nologies that are subsumed under the term “toxicogenomics” 
have been described in detail by Ellinger-Ziegelbauer and 
Ahr (2014). Confusingly, the term “toxicogenomics” is used 
in two ways, on the one hand it is used as a general term for 
omics techniques applied to toxicological studies, and on 
the other hand it refers to the analysis of gene expression 
profiles (transcriptomics). Further toxicogenomic techniques 
monitor, for instance, functionally relevant changes in the 
genome (epigenomics), global protein and/or post-transla-
tional modifications (proteomics) or metabolites (metabo-
lomics). To date, transcriptomics is the most frequently used 
omics technique with the most advanced quality standards, 
so that only this approach is described below (Kauffmann 
et al. 2017; Sauer et al. 2017).
However, the plethora of data collected by omics tech-
niques is challenging regarding the identification of patterns 
of genes, proteins or metabolites that report specific expo-
sures and their biological consequences. A reason for this 
lies in the fact that alterations in the expression or regulation 
of biomolecules do not necessarily indicate an adverse effect. 
To identify the biological event related to these changes, 
the toxicogenomic data have to be linked to toxicological 
or apical endpoints, the so-called “phenotypic anchoring” 
(Buesen et al. 2017; Paules 2003). Moreover, the application 
of bioinformatic tools such as principal component analysis, 
clustering, statistical comparison of classes, class prediction 
or the mechanistic analysis is an effective approach to extract 
patterns or signatures from toxicogenomic datasets that are 
differentially expressed (Afshari et al. 2011). Meanwhile, a 
framework has been developed to incorporate bioinformatics 
procedures in the whole processes of data generating and 
storage, data processing and data interpretation (Gant et al. 
2017). A common type of data interpretation entails compar-
ing sets of genes in terms of their functional annotations, for 
instance to identify functions that are enriched or depleted 
in particular subsets of genes, using Gene Ontology (GO) 
(Gaudet and Dessimoz 2017). Since this tool is based on 
existing knowledge, however, some bias may be introduced 
in the course of data interpretation and may compromise the 
detection of an essential but not yet intensively investigated 
process. Nevertheless, the ongoing work particularly in the 
field of mathematical modelling and linking pathway pertur-
bations measured at the omics level to apical endpoints will 
contribute to a process of constant improvement.
Hazard identification
Until now, toxicogenomics has traditionally been applied 
in regulatory toxicology for hazard identification with sig-
natures used to distinguish different chemical classes, in 
particular genotoxic and non-genotoxic carcinogens. This 
concept was first introduced by Nuwaysir et al. (1999). 
The authors intended to derive characteristic gene signa-
tures elicited by model compounds to enable the classifica-
tion of other compounds with unknown toxicity. In addi-
tion, they emphasized the potential of this technique to 
elucidate molecular mechanisms underlying toxicological 
effects. Subsequently, numerous groups have demonstrated 
the utility of toxicogenomics in classifying and predicting 
the carcinogenic potential of compounds (Eichner et al. 
2014; Ellinger-Ziegelbauer et al. 2004; Jackson et al. 2017; 
Rieswijk et al. 2015; Schaap et al. 2015; Suenaga et al. 
2013; Williams et al. 2015; Yauk et al. 2016). Using vari-
ous mathematic tools, they described signature gene sets 
which have the potential to predict the carcinogenic potential 
of chemical compounds even in in vitro systems, which is 
an important point in the view of the growing awareness of 
avoidable animal studies (Li et al. 2017). According to these 
studies, genotoxic carcinogens have a well-described MOA, 
which essentially leads to the activation of p53 tumour sup-
pressor gene products in response to DNA damage. This, in 
turn, will initiate a cascade of pathways such as DNA dam-
age response, DNA repair response, apoptosis or cell cycle 
arrest (Ellinger-Ziegelbauer et al. 2004). In contrast, non-
genotoxic carcinogens act through several distinct pathways 
including increased cell proliferation, decreased apoptosis, 
energy depletion or production of reactive oxygen species 
(Deferme et al. 2015). In addition, they have been shown 
to act as tumour promoters, e.g. by acting as peroxisome 
proliferators, endocrine disruptors, receptor mediators or 
immunosuppressants (Rieswijk et al. 2015). However, this 
dichotomous way of classification based on the genotoxic 
potential of a compound is primarily a qualitative hazard 
directed method reflecting the restriction of the predictive 
potential of toxicogenomic techniques.
Risk assessment
Hence, there is a growing demand for a shift/transi-
tion from qualitative hazard identification to quantitative 
dose–response analysis, which is crucial for the application 
of toxicogenomic data in the field of risk assessment. Only 
a quantitative approach enables the (mathematical) deter-
mination of the low dose–response relationship and, conse-
quently, of the point of departure (POD) both of which are 
essential for risk assessment and regulatory decision-making 
(Johnson et al. 2015; Li et al. 2017). Until now, few groups 
have attempted to evaluate the utility of toxicogenomics in 
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risk assessment and to compare this approach with the tra-
ditional one (Farmahin et al. 2017; McMullen et al. 2016; 
NTP 2018).
In basic work in this field, Thomas and co-workers 
exposed mice for 13 weeks to five chemical carcinogens 
(Thomas et al. 2011, 2012). In the first step, they calculated 
the BMDs for each gene to determine at which point of the 
dose–response curve the majority of pathways became tran-
scriptionally active. In the next step, a gene enrichment anal-
ysis was performed to determine which functional pathways, 
resp. processes (also termed GO category) were activated. 
Finally, the average BMD and BMDL values were calculated 
for each GO category. The pathway or GO category with the 
lowest median transcriptional BMD/BMDL—regardless of 
the biological function—was compared with the correspond-
ing values for the apical endpoints (such as liver weight or 
histological changes in target tissues, resp. incidence of com-
bined adenomas and carcinomas). The authors concluded 
that the transcriptional values showed a good correlation 
with the values derived from the traditional endpoints lead-
ing to the suggestion that the lowest transcriptional BMD/
BMDL value should be used as a POD.
The qualitative response to benzo[a]pyrene (B[a]P) was 
investigated in a comprehensive manner by integrated liter-
ature-based traditional data for apical endpoints with toxi-
cogenomic data derived from in vitro human cell cultures 
as well as from tissues, organ systems, or entire organisms 
(Moffat et al. 2015). The basis for the development of the 
MOA was the enrichment analysis of the genomic data to 
detect activated pathways as well as the doses and the time 
points at which they were affected. In the next step, based on 
these key events “mutations” were selected as the decisive/
irreversible step towards carcinogenesis and the preceding 
key event “DNA adducts and DNA damage” as the POD 
to adequately protect against the carcinogenic outcome. 
The calculated BMDL values for the traditional and tran-
scriptional approaches were in the same range (liver 1.2 vs. 
1.0 mg/kg bw/day; lung 0.8 vs. 3.7 mg/kg bw/day; forestom-
ach 0.5 vs. 7.4 mg/kg bw/day). The authors argued that the 
differences in the PODs concerning the forestomach could 
be due to the delay of three days between the last expo-
sure and transcriptional profiling. Applying the approach 
using GO-enrichment analysis described by Thomas et al. 
(2011, 2012), they obtained  BMDL10 values of 0.2 mg/kg 
bw/day for liver; 2.1 mg/kg bw/day for the lung and 4.5 mg/
kg bw/day for the forestomach. The authors concluded that 
the approach of Thomas et al. may be useful in preliminary 
studies with unknown or unclear MOA.
In subsequent studies, the group of Yauk applied this 
approach to derive PODs for furan and multi-walled carbon 
nanotubes (Dong et al. 2015; Labib et al. 2016). In both 
studies, transcriptional BMDs were comparable to tradi-
tional BMDs. Other groups also use this approach to derive 
PODs for various chemical compounds, such as naphthalene, 
nickel subsulfide or cholestatic drugs (Clewell et al. 2014; 
Efremenko et al. 2014; Kawamoto et al. 2017). An important 
and critical point in the application of toxicogenomics in this 
field is the determination of the best way to select predictive 
groups of genes. Farmahin et al. evaluated 11 approaches 
and compared the transcriptional BMD values with BMDs 
derived from apical endpoint changes. Four approaches led 
to BMDs showing a good concordance with apical BMD 
values (Farmahin et al. 2017).
A conservative approach is taken by groups that focus on 
the “No-Transcriptional-Effect-Level” (NOTEL), threshold 
at which no effect on the transcriptome is observed (Pisani 
et al. 2015; Quercioli et al. 2018; Zarbl et al. 2010). As to be 
expected, the derived NOTELs were considerably lower than 
the “No-Observed-Adverse-Effect-Levels” (NOAELs). One 
possible application could be the quick estimate of a bench-
mark dose of chemicals and mixtures, especially within the 
framework of large toxicology programs.
A slightly different approach was chosen by Ji and co-
workers (Ji et al. 2016) who determined what they called 
a “No-Observed-Genotoxic-Effect-Level” (NOGEL) based 
on blood reticulocyte micronuclei number of rats exposed 
to methyl methanesulfonate (MMS) and methylnitrosourea 
(MNU). Whole-genome transcript analysis of the liver dem-
onstrated no statistically significant gene alterations below 
the NOGEL.
Taken together, the studies show how toxicogenomic 
approaches may become a useful complement to hazard 
identification and risk assessment. These techniques, if 
properly used, provide information that can improve our 
mechanistic understanding of dose–response relationships 
and, in consequence, of biological thresholds. One advan-
tage of these approaches is the considerable amount of data 
which can be obtained in a time- and cost-optimized way 
when compared to 2-year rodent cancer bioassays, thus 
minimizing animal use. A considerable number of studies 
have demonstrated the utility of toxicogenomics to rapidly 
identify genotoxic and non-genotoxic carcinogens, even 
based on in vitro studies. In addition, it becomes apparent 
that patterns or signatures of genes can be used to develop 
MOAs and to identify key events, which in turn allow the 
calculation of PODs.
Nevertheless, several points need to be critically 
addressed. First, genes of unknown function are not included 
in pathway and enrichment analyses. This possible bias must 
be taken into account, as previously mentioned, since it can 
prevent the recognition of important pathways. In cases 
where metabolic activation of premutagens is required the 
choice of the metabolizing system is pivotal.
Second, POD calculation requires a clear definition 
regarding the BMDL to be selected. The selection of the 
lowest transcriptional BMDL is highly conservative and 
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does not necessarily reflect the dose–response relation and/
or the apical adverse effect (Farmahin et al. 2017). This may 
be improved by distinguishing adaptive from adverse effects 
and by ascertaining pathways, dose and exposure time that 
indicate or cause the transition from one state to another.
Third, to utilize toxicogenomic data in risk assessment, 
effects have to be quantified, particularly at low doses. Since 
the results of microarray analysis are only semi-quantitative, 
quantitative high throughput RT-qPCR analysis represents 
a serious alternative technique. A step in this direction was 
undertaken by Fischer et al. who analysed the expression of 
95 genes related to distinct pathways relevant for genomic 
stability by high-throughput RT-qPCR (Fischer et al. 2016).
In summary, toxicogenomic techniques have the potential 
to complement the existing approaches for hazard identifica-
tion and risk assessment. When reasonably applied to toxi-
cological issues and using appropriate experimental designs 
and quality standards, the information obtained by omics 
technologies can provide valuable insights into a variety of 
aspects of the toxic response. However, the low dose range 
is particularly important, but still largely unexplored by toxi-
cogenomic approaches.
Background DNA lesions in rodent and human 
tissues/body fluids
The ability to exactly identify and measure DNA lesions in 
tissues and body fluids has remarkably increased in recent 
years. Reliable dosimetry of DNA damage associated with 
exposure to minute traces of genotoxic contaminants in food 
and other consumer media can be achieved with present day 
advanced instrumental analysis. However, it is important to 
take into account that cells are continuously exposed to gen-
otoxic agents leaking from endogenous metabolic processes 
in the frame of normal physiological nutrient turnover. This 
encompasses not only reactive oxygen radicals (ROS) but 
also many other endogenous substrates, such as ethylene and 
its epoxide, formaldehyde, acetaldehyde, lipid peroxidation 
products, acrolein equivalents and others.
DNA adducts arising from endogenous processes
Lipid peroxidation products For example, aldehydes 
formed from lipid peroxidation are able to form DNA 
adducts such as etheno, propano and malondialdehyde 
adducts. The etheno adducts 1,N6-etheno-deoxyadenosine 
(εdA) and 3,N4-ethenodeoxycytidine (εdC), which are 
formed from reactions of DNA bases with 2,3-epoxyalde-
hydes of 4-hydroxy-2-nonenal or crotonaldehyde, were the 
most abundant adducts detected in human lung samples 
(De Bont and van Larebeke 2004; Swenberg et  al. 2011). 
Markedly different half-lives have been reported for etheno 
adducts. The N2,3-ethenoguanine (εG) adduct has by far 
the longest half-life (150 days in rats). In contrast, εdA is 
rapidly repaired with a half-life of ~ 24 h (Swenberg et al. 
2011). Another product of lipid peroxidation, malondialde-
hyde, mainly forms deoxyguanosine (dG) adducts such as 
pyrimido[1,2-a]-purin-10(3H)-one (M1G), to a lesser extent 
also deoxyadenosine (dA) and deoxycytidine (dC) adducts 
(De Bont and van Larebeke 2004).
Endogenous alkylating compounds In addition to ROS and 
lipid peroxidation products, several other reactive molecules 
with the propensity to interact with DNA as electrophiles are 
produced in the organism. The methyl group donor S-aden-
osylmethionine (SAM) is essential for physiological enzy-
matic methylation but may also contribute to endogenous 
DNA base methylation, including 7-methylguanine (7-MG), 
3-methyldA or O6-methyldG (Nakamura et al. 2014). 7-MG 
is the most frequent alkylation product but does not alter the 
coding specificity of the DNA base whereas O6-methyldG 
is highly promutagenic and can result in mismatches during 
DNA replication (Nakamura et al. 2014). Amongst others, 
the generation of ethylene from methionine oxidation, lipid 
peroxidation, and bacterial metabolism can give rise to eth-
ylene oxide, another endogenous electrophile that preferen-
tially reacts with the N7-position of guanine, forming the 
DNA lesion N7-(2-hydroxyethyl)guanine (7-HEG) (Swen-
berg et al. 2011). Although 7-MG and 7-HEG are not con-
sidered to be promutagenic by themselves, they may lead 
to abasic sites through depurination which eventually could 
result in a mutation if unrepaired (Swenberg et  al. 2011). 
Abasic sites are among the most frequent endogenous 
lesions found in DNA (De Bont and van Larebeke 2004).
Formaldehyde is a metabolic intermediate generated in all 
living cells from methanol, continuously generated during 
food digestion, but also from other precursors like serine, 
glycine, methionine, choline and/or by oxidative demeth-
ylation of a wide variety of substrates. Formaldehyde can 
induce DNA adducts including N2-hydroxymethyl-dG, 
N6-hydroxymethyl-dA, as well as N4-hydroxymethyl-dC 
and, in turn, DNA protein crosslinks. Those DNA adducts 
are considered to be promutagenic, as the amino groups 
participating in Watson–Crick base pairing are involved 
and DNA protein crosslinks are formed which give rise to 
double-strand breaks (Lai et al. 2016; Swenberg et al. 2011).
Steady‑state levels of endogenous DNA lesions
A compilation of steady-state levels of selected endogenous 
DNA lesions reported in the literature (Nakamura et al. 
2014; Swenberg et al. 2011) is given in Table 1. Concern-
ing 8-oxo-dG and abasic sites, the levels observed in earlier 
studies appear to be highly overestimated due to technical 
artefacts. A multicentre study comparing different methods 
to quantify 8-oxo-dG came to the conclusion that the actual 
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levels of this lesion in cultured mammalian cells are clearly 
below 100 lesions per  108 nucleotides (Collins et al. 2004; 
Gedik et al. 2005). In the case of abasic sites, the use of 
repair enzymes as probes revealed levels in cultured mam-
malian cells that are much lower than those of 8-oxo-dG 
and close to the detection limit. Data obtained from for-
mamidopyrimidine DNA glycosylase (Fpg) treatment sug-
gest approx. 5 lesions per  108 nucleotides (Andersen et al. 
2005; Sossou et al. 2005). The so-called "aldehyde reactive 
probes", which have frequently been employed in the quanti-
fication of abasic sites, have indicated, for example, in HeLa 
cells levels of 200 lesions per  108 nucleotides. Again, this 
method may suffer from considerable background problems 
and thus result in overestimation of levels of abasic sites 
(Wei et al. 2015). In view of these inconsistencies, Table 1 
exclusively lists well-defined adducts.
Selected DNA lesions in rodents and humans
Selected DNA lesions measured in human cells and body 
fluids are listed together with the putative causal agents in 
Table 2 and corresponding data in rodent cells and body 
fluids are listed in Table 3. Although not being exhaustive, 
the tables allow for an estimate of the overall endogenous 
adduct levels. However, levels of a specific adduct can eas-
ily vary by more than one order of magnitude, even within 
the same species and organ (Paini et al. 2011). In addition, 
depending on the type of adduct, adduct levels tend to be 
somewhat higher in humans than in laboratory rats kept 
under controlled housing conditions. This has been ascribed 
to lifestyle factors such as unknown dietary and environ-
mental sources of exposure to alkylating agents, smoking 
or oxidative/metabolic stress (Paini et  al. 2011). Thus, 
especially lesions derived from lipid peroxidation products 
such as 7-HEG, M1G and other cyclic adducts have been 
found to be about one order of magnitude higher in humans 
than in animals (see Tables2 and 3). For example, 7-HEG 
adduct levels (supposedly from ethylene oxide) have been 
reported to be 48–300 adducts/108 nucleotides in humans 
(Farmer and Shuker 1999; Wu et al. 1999a) versus 1–9 
adducts/108 nucleotides in rats (Marsden et al. 2009, 2007; 
Wu et al. 1999a; Zhao et al. 1999). Likewise, 14–110 M1G 
adducts/108 nucleotides were reported in human liver (De 
Bont and van Larebeke 2004; Farmer and Shuker 1999) ver-
sus 0.8–4.2 adducts/108 nucleotides in rat tissues including 
liver (Jeong et al. 2005). This also applies to some extent to 
other cyclic base adducts, especially etheno-dA and etheno-
dC adducts, which have been found in humans at levels of 
up to 36–80 adducts/108 nucleotides (Chen et al. 2010a; 
Monien et al. 2015), in rats at a level of 0.7–1.4 adducts/108 
nucleotides (Morinello et al. 2002; Swenberg et al. 2011).
Further examples of individual lesions in humans include 
7-ethyl-G (0.8 adducts/108 nucleotides) (Chen et al. 2007), 
and again cyclic adducts, such as 1,N2-propano-dG (0.3–0.4 
adducts/108 nucleotides) (Zhang et  al. 2006). Higher 
“background” DNA adduct levels have been reported for 
7-(2´-carboxyethyl)G (7.5 adducts/108 nucleotides) (Cheng 
et al. 2010) and N2-ethylidene-dG detected after reduction 
as N2-ethyl-dG (12.0 adducts/108 nucleotides) (Wang et al. 
2006).
Background levels of formaldehyde DNA adducts 
(N2-hydroxymethyl-dG and N6-hydroxymethyl-dA) have 
been detected in nasal DNA samples of rats at a level of 10.3 
adducts/108 nucleotides (Cheng et al. 2008; Lu et al. 2010; 
Swenberg et al. 2011). The formation of formaldehyde-
DNA adducts in humans has also been demonstrated. The 
endogenous N6-hydroxymethyl-dA level was determined to 
be ~ 0.47 adducts/108 nucleotides in human leukocytes from 
Table 1  Compilation of 
endogenous levels of DNA 
lesions estimated for human 
and animal cells (modified 
from Nakamura et al. (2014); 
Swenberg et al. (2011))
1 Nomenclature as indicated by the authors
2 Assuming 6 billion bp/ 12 billion nucleotides per diploid cell (https ://www.ncbi.nlm.nih.gov/genom e/51)
Endogenous DNA  lesions1 Number per cell Number per  108  nucleotides2
N7-(2-Hydroxyethyl)guanine (7-HEG) 3000 25
8-Oxo-dG 2400 20
N7-(2-Oxoethyl)guanine (7-OEG) 3000 25
Formaldehyde adducts 1000–4000 8–33
Acetaldehyde adducts 1000–5000 8–42
7-Methylguanine (7-MG) 2300 19
Acrolein-deoxyguanosine 120 1
Malondialdehyde-deoxyguanosine (M1G) 60 0.5
N2,3-Ethenoguanine (εG) 36 0.3
1,N2-Ethenodeoxyguanosine (1,N2-εdG) 30 0.25
1,N6-Ethenodeoxyadenosine (1,N6-εdA) 12 0.1
O6-Methyldeoxyguanosine 2 0.016
Total 13,000 + (13,000–20,000) 107 + (107–167)
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Table 2  Selected DNA lesions in human tissues/body fluids determined by high precision instrumental analysis
WBC white blood cells
1 Nomenclature as indicated by the authors
2 In part corrected from the number of adducts per parent base using a content of 22% G or C and 28% of A or T in mammalian DNA (Paini et al. 
2011)
3 After reduction with  NaBH3CN








Blood cells Ethanol/acetaldehyde: Balbo et al. (2008)
Non drinkers 59
Drinkers 116
Lung tissue Smokers & non-smokers 13 Singh et al. (2009b)
Granulocytes &
lymphocytes
Ethanol (0.05–0.07% blood 
ethanol)
150 (background level)
up to about fivefold after 
ethanol consumption
Balbo et al. (2012a); Balbo 
et al. (2012b)
Liver Acetaldehyde 12 Wang et al. (2006)
7-Ethyl-G 0.8 Chen et al. (2007)
7-(2´-Carboxyethyl)-G Liver Acrylic acid/acrolein 7.5 Cheng et al. (2010)
1,N2-Propano-dG Liver, lung Crotonaldehyde/
acetaldehyde







 ~ 36 (averaged mean 
values)
Chen et al. (2010a)
3,N4-Etheno-dC Lung Lipid peroxidation
products
 ~ 80 Monien et al. (2015)
1,N6-Etheno-dA Lung Lipid peroxidation
products
 ~ 48 Monien et al. (2015)
N2-(trans-Methylisoeuge-
nol-3‘-yl)-2‘-dG
Lung Methyleugenol  ~ 11 Monien et al. (2015)





Ethene (from methionine 
oxidation, lipid per-





300 Farmer and Shuker (1999)
7-Alkyl-G adducts
(combined 7-MG and 
7-HEG)
Lung (n = 2)





















De Bont and van Larebeke 
(2004)




0.47 Wang et al. (2009)
8-Oxo-dG Lymphocytes Oxidative damage, ROS 13–200 Epe (2002)
 < 100 Collins et al. (2004); Gedik 
et al. (2005)
Abasic sites Liver Alkylating agents,
oxidative damage
800–900 De Bont and van Larebeke 
(2004)
Liver, colon, brain, lung, 
kidney
370–1130 Barbin et al. (2003)
 ~ 5 Andersen et al. (2005);
Sossou et al. (2005)
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non-smokers (Wang et al. 2009). The overall endogenous 
background level of DNA lesions induced by alkylating low 
molecular weight electrophiles has been reported for human 
and rat tissues to range within about 10–100 adducts/108 
nucleotides (Farmer 2008; Paini et al. 2011; Swenberg et al. 
2008).
In rodents and humans, the oxidative damage usually is 
reported to exceed other endogenous DNA lesions such as 
those generated by alkylation or lipid oxidation (De Bont 
and van Larebeke 2004; Gupta and Lutz 1999; Paini et al. 
2011; Povey 2000). However, as indicated above for cultured 
cells, the reported basal levels for 8-oxo-dG and abasic sites 
(see Tables 2 and 3) may be overestimated. The quantifica-
tion of Fpg-sensitive sites, which include both 8-oxo-dG and 
abasic sites in the liver and various other tissues of untreated 
wild-type mice resulted in levels similar to those observed 
in the cultured cells, i.e. the sum of 8-oxo-dG and abasic 
sites was found at less than 50 lesions per  108 nucleotides 
(Osterod et al. 2001). These basal levels are supposed to 
reflect the equilibrium between the continuous generation 
and repair of the lesions, which both depend on the cell 
and tissue type. In proliferating primary human fibroblasts 
as well as melanoma cells, a half-life of approx. 4 h was 
reported for Fpg-sensitive modifications (Eiberger et al. 
2008). In primary human lymphocytes, however, the repair 
is very slow but accelerates after stimulation of cell pro-
liferation due to an induction of the expression of OGG1, 
the major repair glycosylase for 8-oxo-dG. In accordance 
with the expectation, this is associated with a decrease in the 
basal levels of Fpg-sensitive modifications (von der Lippen 
et al. 2015).
With the exception of methyleugenol, ingested through 
certain foods, herbs and spices, all agents listed in Table 2 
may arise from physiological nutrient/energy metabolism. 
They may as well result from exogenous exposure.
Development of a database on background DNA lesions
Clearly, the database on background DNA damage needs to 
be enlarged and substantiated. This requires to explore its 
Table 3  Selected DNA lesions in rodent tissues/body fluids and the respective causative genotoxic agent
1 Nomenclature as indicated by the authors
2 In part corrected from the number of adducts per parent base using a content of 22%G or C and 28% of A or T in mammalian DNA (Paini et al. 
2011)
3 Using a chaotropic DNA extraction procedure






Liver (rats) Lipid peroxidation products 1.3–4.4 Marsden et al. (2009); Marsden 
et al. (2007); Swenberg et al. 
(1995)
Lymphocytes, liver, kidney 
(rats)
Lipid peroxidation products 6–9 Zhao et al. (1999)
Liver, spleen, brain, lung 
(rats, mice)
Lipid peroxidation products 4.4–6.6 Wu et al. (1999a)
M1G (Pyrimido[1,2-a]-purin-
10(3H)-one)
Liver, brain, kidney, lung, 
heart (rats)
Lipid peroxidation products 0.8–4.2 Jeong et al. (2005)
Etheno-base adducts (N2,3-
Etheno-G)
Liver cells (rats): Lipid peroxidation products Morinello et al. (2002) Swen-
berg et al. (2011)Hepatocytes 0.7–1.2
Nonparenchymal cells 2
1,N6-Etheno-dA Liver (rats) Lipid peroxidation 1.4 Swenberg et al. (2011)
7-Methyl-G (7-MG) Lymphocytes, liver, kidney 
(rats)
Methyl group donors 21–27 Zhao et al. (1999)




N6-hydroxymethyl-dA Nasal DNA samples (rats) Formaldehyde 2.8–8.4 Cheng et al. (2008); Lu et al. 
(2010)
8-Oxo-dG Liver (rats) Oxidation 170–2503 Singh et al. (2009c)
8-Oxo-dA Liver (rats) Oxidation 22–263 Singh et al. (2009c)
7-(2-Oxoethyl)-G (OEG) Liver (rats) 44 Swenberg et al. (2011)
Abasic sites Brain (rats) 500 up to < 1000 Lan et al. (2003)
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individual/population associated variance and the potential 
influence of health and age, ethnicity, gender and living con-
ditions. More data are also required to better characterize the 
correlation between DNA damage and mutation induction. 
The intrinsic mutagenic potency of DNA modifications is 
vastly different and ranges over several orders of magnitude 
(Nestmann et al. 1996). For example, the mutagenic poten-
tial of N7-alkyl-dG-adducts is generally considered to be 
low or even absent. However, an exceptionally mutagenic 
N7-dG adduct is generated, by the mycotoxin aflatoxin B1 
(AFB1). AFB1 is a potent mutagen and carcinogen, primar-
ily reacting at the N7 position of deoxyguanosines in DNA 
to form, as secondary lesions, abasic sites and highly persis-
tent AFB1-formamidopyrimidines (see also part B "Selected 
example" Sec. “Aflatoxin B1”) (Smela et al. 2001). To cor-
relate DNA damage and mutation induction, extended case-
by-case studies for individual genotoxic agents are required. 
This may eventually offer the perspective of applying a 
read-across approach for closely related agents and/or DNA 
lesions. Thus, the development of a comprehensive database 
on DNA background damage in humans is considered of 
great value to inform future risk assessment. This so-called 
“bottom-up” approach, contrasts with the classical top-down 
extrapolation from cancer studies in experimental animals 
(Starr and Swenberg 2013, 2016). A refined example of this 
“bottom-up” approach has recently been published (Starr 
and Swenberg 2016). It utilizes background cancer risk and 
the background (endogenous) level of cancer-related bio-
markers in target tissues (e.g. formaldehyde DNA-adducts 
such as N2-hydroxymethyl-dG detected in nasal tissue and 
bone marrow of monkeys) to obtain a slope factor estimate. 
This estimate is utilized to define the added risk associated 
with incremental exogenous exposure to such genotoxic 
agents that invariably are also generated in the body as a 
result of normal physiologic processes (Starr and Swenberg 
2016). Of note, the “bottom-up” estimates of formalde-
hyde induced nasopharyngeal cancer and leukaemia were 
markedly smaller than those obtained by the US Environ-
mental Protection Agency (US EPA) with a conventional 
“top-down” approach on mortality data from a US worker 
cohort. However, the authors also state that this “bottom-
up” approach would likely not apply at exogenous exposures 
sufficiently high to induce nonlinear processes that amplify 
the carcinogenic response, such as saturation of metabolic 
pathways, cytotoxicity and tissue damage, and accelerated 
regenerative cell proliferation (Starr and Swenberg 2016).
The discrimination between endogenously generated DNA 
lesions and those induced by exogenous (e.g. nutritional or 
occupational) exposure requires novel approaches. A good 
choice appears to be nutritional intervention studies with vol-
unteers (see part C "Conclusions and Perspectives"). Such 
studies should allow for adequate wash-out periods without 
any exposure to the agent under investigation, prior to a tightly 
controlled intervention. It is mandatory for such an approach 
to ascertain that the endogenous background DNA damage 
can be measured without interference from exogenous expo-
sure. The subsequent nutritional intervention, e.g. with food 
containing known (predetermined) levels of a nutritional 
genotoxic agent present at levels of normal consumer expo-
sure, should provide a metric to discriminate endogenous 
from exogenous DNA damage (Goempel et al. 2017; Ruenz 
et al. 2016). Where feasible, this can also be achieved using 
isotope-labelled agents (Swenberg et al. 2011).
The following part B "Selected examples" of this doc-
ument discusses specific examples of genotoxic agents 
humans are exposed to as a result of their living condi-
tions. Living conditions include working place associated 
exposures as well as those contributed from the environ-
ment and from consumption habits. Where applicable, 
endogenous exposure to such agents is additionally taken 
into consideration, tracing back to physiological (endog-
enous) energy metabolism. Accordingly, this group encom-
passes compounds humans are exposed to exogenously 
and endogenously, such as formaldehyde, acetaldehyde 
and the corresponding alcohols as well as some alkylating 
agents, ethylene oxide, and acrylamide (Sec. “Acetaldehyde 
and Ethanol” to Sec. “Formaldehyde”). They are grouped 
together under the term “the aggregate exogenous and 
endogenous exposome”.
The second section of part B “Selected examples” (Sec. 
“Aflatoxin B1” to Sec. “Pyrrolizidine alkaloids”) addresses 
compounds humans are exclusively exposed to by exogenous 
exposure. The third section of part B “Selected examples” 
(Sec “Carcinogenic metal compounds: Examples cadmium 
and arsenic”) is devoted to carcinogenic metal compounds 
with special emphasis on cadmium and arsenic.
Part B: Selected examples
In the following, selected genotoxic compounds are 
described in more detail, covering a spectrum of carcinogens 
with different potency and MOAs, including metals. They 
Fig. 4  Structures of N2-ethyl-2′-deoxyguanosine (N2-ethyl-dG) and 
α-methyl-γ-hydroxy-1,N2-propano-2′-deoxyguanosine (α-Me-γ-OH-
PdG; 1,N2-PdG) (according to Brooks and Theruvathu 2005)
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comprise (1) substances exerting exogenous exposure on top 
of a significant component of endogenous background expo-
sure, (2) those for which endogenous exposure is not known 
but exerting lifestyle-associated, often unavoidable exoge-
nous background exposure, such as aflatoxins, benzo[a]pyr-
ene (BAP), heterocyclic aromatic amines (HAAs), allylben-
zenes, pyrrolizidine alkaloids, and (3) selected metals, acting 
mostly by indirect genotoxic MOAs. These examples have 
been selected based on the availability of data on aggre-
gate exposure levels and exposure biomarkers, on biologi-
cal effects and on underlying MOAs. Furthermore, gaps in 
knowledge and research needs are defined.
Presence of endogenous background levels 
of the same or similar DNA lesions
Acetaldehyde and ethanol
Introduction Besides their occurrence in food and bever-
ages and possible exposure at the workplace, ethanol and 
acetaldehyde are also endogenous substances with concen-
trations of about 2.2–6.5  µM (ca. 0.1–0.3  mg/l) in blood 
for ethanol (Greim 1998) and 2.2–3.6 µM (ca. 0.1 mg/l) in 
blood for acetaldehyde (Greim 2008). Endogenous acetal-
dehyde is produced in the intermediary metabolism by oxi-
dative decarboxylation of pyruvate, in the course of amino 
acid metabolism, and by other metabolic processes. It is also 
formed by intestinal bacteria. Most of it is converted to etha-
nol by alcohol dehydrogenase (ADH) (Greim 2008).
Chronic alcohol consumption is associated with several 
forms of cancer, especially of the upper aerodigestive tract 
(Yu et al. 2010). The most important mechanism for the 
carcinogenicity of ethanol seems to be the formation of acet-
aldehyde as its primary metabolite (Brooks and Theruvathu 
2005). Based on epidemiological data, the International 
Agency for Research on Cancer (IARC) concluded that 
there is sufficient evidence in humans for the carcinogenic-
ity of alcohol consumption and for the carcinogenicity of 
acetaldehyde associated with the consumption of alcoholic 
beverages, and both were classified in category 1 (IARC 
2010a; IARC 2012b).
In several animal studies with oral administration of etha-
nol, increased incidences of cancers of the head and neck 
and the liver and benign tumours of several organs in rats 
and liver tumours and mammary gland adenocarcinomas in 
mice were found (IARC 2012b).
In two studies with inhalation exposure in rats and ham-
sters, acetaldehyde showed carcinogenic effects in nose 
and larynx (Greim 2008). There is only one carcinogenic-
ity study in rats with the oral application of acetaldehyde. 
Increased incidences of several tumours were observed, but 
there was no obvious dose–response relationship (IARC 
2012b).
The German Commission for the Investigation of Health 
Hazards of Chemical Compounds in the Work Area (MAK 
Commission) classified ethanol and acetaldehyde in cat-
egory 5, which is defined for substances with carcinogenic 
and genotoxic effects which are considered to contribute 
very slightly to human cancer risk, provided the MAK and 
BAT values are observed (DFG 2018; Greim 1998). At the 
MAK value for ethanol of 200 ml/m3 (≙ 380 mg/m3) the 
average life-time body burden of ethanol is still within the 
range of variation of the endogenous body burden. The com-
mission, therefore, concluded that workplace exposure to 
concentrations up to 200 ml/m3 would contribute only little 
to cancer risk. A similar approach was chosen for acetalde-
hyde, where exposure levels up to the MAK value of 50 ml/
m3 (≙ 91 mg/m3) were estimated to lead to an additional 
body burden in the range of variation of the life-time endog-
enous body burden. Prevention of nasal tissue irritation was 
also considered for the derivation of the MAK value for 
acetaldehyde.
Genotoxicity and  DNA adduct formation Acetaldehyde is 
genotoxic in vitro and in vivo. In vitro tests for the induction 
of SCE, chromosomal aberrations and micronuclei as well 
as gene mutation tests gave positive results. In  vivo tests 
for the induction of SCE and micronuclei were also positive 
(Greim 2008). Ethanol exerted a weak genotoxic potential 
in vitro with metabolic activation and in vivo (Greim 1998). 
These effects are assumed to be predominantly related to 
acetaldehyde formation, but there are controversial reports 
about the genotoxicity of ethanol itself (Kayani and Parry 
2010).
Several DNA adducts are formed in vitro and in vivo after 
exposure to acetaldehyde. The main adduct is N2-ethylidene-
2′-deoxyguanosine (N2-ethylidene-dG), which is unstable in 
hydrolysed DNA (Wang et al. 2006). Therefore, it is chemi-
cally reduced during the analytical procedure to its stable 
reduction product N2-ethyl-2′-deoxyguanosine (N2-ethyl-dG) 
(Fig. 4), which has been used as a biomarker for acetalde-
hyde-induced DNA damage, but its biological significance 
for the carcinogenicity of acetaldehyde remains unclear 
(Brooks and Theruvathu 2005; Brooks and Zakhari 2014; 
Yu et al. 2010). In contrast, the α-methyl-γ-hydroxy-1,N2-
propano-2′-deoxyguanosine (α-Me-γ-OH-PdG; 1,N2-PdG) 
(Fig. 4) is considered a biologically relevant acetaldehyde-
derived adduct, because it has also been identified as being 
responsible for the mutagenic, genotoxic and carcinogenic 
properties of crotonaldehyde (Eder and Budiawan 2001). Its 
formation is stimulated by the presence of histones and cel-
lular polyamines (Brooks and Theruvathu 2005). Addition-
ally, the ring-opened form of 1,N2-PdG is a precursor lesion 
for the formation of DNA–protein or DNA-DNA cross-links 
(Yu et al. 2010). The formation of the 1,N2-PdG adduct from 
acetaldehyde has been shown in vitro and in vivo (Garcia 
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et al. 2011; Sanchez et al. 2018). Site-directed mutagen-
esis studies have shown that both the N2-ethyl-dG and the 
1,N2-PdG adducts have mutagenic potential (Choi and 
Guengerich 2006; Stein et al. 2006; Terashima et al. 2001; 
Upton et al. 2006a, 2006b). Further identified acetaldehyde-




10(3H)one (Yu et al. 2010).
Dose–response data for  DNA adduct formation, mutagen‑
icity and  clastogenicity in  vitro In vitro studies were con-
ducted with human lung fibroblasts (IMR90) and a human 
buccal epithelial cell line (SVpgC2a). In the latter, a dose-
dependent increase in N2-ethyl-dG adducts was measured 
(by reduction) after incubation with up to 100 mM acetal-
dehyde for 1 h (Vaca et  al. 1998). In the lung fibroblasts, 
exposure against acetaldehyde for 3 h led to increased levels 
of 1,N2-PdG adducts (Garcia et al. 2011).
In a study with a human leukaemia cell line (HL60), 
after incubation with 1.8 mM acetaldehyde for 1 or 2 h, 
N2-ethylidene-dG adducts were analysed (after reduction to 
N2-ethyl-dG). In the cells exposed for 1 h, the mean (± SD) 
levels immediately, 24 h, and 48 h after exposure were 121, 
82, and 67/108 nt, respectively, indicating about 50% repair 
within 48 h. In the control group, the mean levels were about 
33/108 nt at all time points. In the cells exposed for 2 h, the 
levels were 214, 105, and 98/108 nt, respectively. A half-life 
of N2-ethylidene-dG adducts of 35 h was calculated (Hori 
et al. 2012).
Further studies with human lymphoblastoid TK6 cells 
using  [13C2]-acetaldehyde in the range of 50 nM to 2 mM, 
incubated for 12 h, revealed an increase in exogenous N2-eth-
ylidene-dG formation (after reduction to N2-ethyl-dG) at 
exposure concentrations ≥ 1 μM, whereas the endogenous 
adducts remained nearly constant across all exposure con-
centrations, with an average of 6.6 adducts/108 nt. Levels of 
exogenous adducts were lower than endogenous adducts at 
concentrations ≤ 10 μM and were higher than endogenous 
adducts at concentrations ≥ 250 μM. The sum of endogenous 
and exogenous adducts reached a statistically significant 
increase over the endogenous background at 50 µM. Statis-
tically significant decreases in cell survival and increases in 
micronucleus formation occurred at ≥ 1000 μM acetaldehyde 
(Moeller et al. 2013).
In another study with TK6 cells, acetaldehyde induced 
a concentration dependent, statistically significant increase 
in apoptotic cells and in micronuclei formation beginning 
at 0.25 mM. In the low concentration range up to 0.05 mM, 
these effects did not occur. Similar results were obtained in 
the TK gene mutation assay, with acetaldehyde inducing 
a significantly increased mutation frequency at 0.05 mM 
and above. In the HPRT gene mutation test no significant 
increase in mutation frequency could be detected (Budinsky 
et al. 2013).
Dose–response data for  DNA adduct formation in  experi‑
mental animals and  the  impact of  genetic polymor‑
phisms The impact of aldehyde dehydrogenase (Aldh) 
genotype on adduct formation was tested in Aldh2-profi-
cient (+ / +), heterozygous ( ±) and knockout ( – / – ) mice. 
After repeated ethanol intake (about 23  g/kg bw and day 
for 5 weeks) N2-ethyl-dG adducts (after reduction) in liver 
and stomach increased genotype-dependently up to 40-fold 
in Aldh2-knockout animals and about tenfold in heterozy-
gous mice compared to untreated control animals. In Aldh2-
proficient mice, ethanol intake leads to an up to fourfold 
increase in N2-ethyl-dG adducts. In untreated mice, no 
significant differences in N2-ethyl-dG adducts between the 
different genotypes were detected. There were no treatment-
dependent changes in 1,N2-PdG adduct levels. N2-ethyl-dG 
adducts (without reduction) were not detected in any sample 
(Matsuda et al. 2007; Nagayoshi et al. 2009).
In another study in mice, basal mean N2-ethyl-dG adduct 
levels (after reduction) were about two times higher in the 
oesophagus and the tongue of Aldh2-knockout mice com-
pared with Aldh2-proficient animals. In the submandibular 
gland, basal levels of N2-ethyl-dG adducts in Aldh2-knock-
out animals were relatively low compared with those of 
Aldh2 proficient mice. Treatment with 8% ethanol in drink-
ing water for 14 months resulted in increased adduct levels, 
which were considerably higher in Aldh2-knockout com-
pared to Aldh2-proficient mice in all three tissues examined 
(Yu et al. 2012).
In Rhesus monkeys, the self-administered average etha-
nol consumption of 2.3 ± 0.8 g/kg bw and day for one year 
resulted in average N2-ethyl-dG levels (after reduction) of 
9.4/108 nt in oral mucosa (control: 3.3/108 nt) and 4.5/108 
nt in oesophageal mucosa (control: 2.9/108 nt). In mam-
mary gland tissue of female animals exposed to ethanol, 
no increase in average N2-ethyl-dG levels was found. The 
correlation between N2-ethyl-dG levels in oral mucosa DNA 
and amounts of alcohol consumed per day was investigated. 
Levels of the DNA adducts increased with amounts of alco-
hol consumed even though the trend was not significant. 
The presence of 1,N2-PdG was also investigated in the oral 
and oesophageal mucosa DNA samples. No quantifiable lev-
els of this DNA adduct were found in the samples analysed 
except for the oral mucosa sample of one animal, which had 
the highest level of N2-ethyl-dG adducts (33/108 nt) (Balbo 
et al. 2016).
In an inhalation study with Aldh2-proficient (+ / +) and 
knockout ( – / – ) mice, the animals were exposed to 0, 125 
or 500 ml acetaldehyde/m3 24 h per day for 14 days. For-
mation of N2-ethylidene-dG was analysed after reduction 
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to N2-ethyl-dG. In the liver, adduct levels in the knockout 
mice were always lower compared with the Aldh2-proficient 
animals, but these differences were not statistically signifi-
cant. However, Aldh2-knockout mice showed significantly 
higher adduct levels than Aldh2-proficient mice in the nasal 
epithelium at 125 ml/m3 and in dorsal skin at 500 ml/m3, 
the other concentrations were not analysed in these tissues. 
In the lung, there was a statistically significant increase in 
adduct levels only at the high concentration of 500 ml/m3 
with 171/108 bases (control 43.3/108 bases) for Aldh2-pro-
ficient and 283/108 bases (control 65.7/108 bases) for Aldh2 
knockout mice (Oyama et  al. 2010). Micronucleus fre-
quencies in reticulocytes were significantly increased after 
exposure to 125 or 500 ml acetaldehyde/m3 and after oral 
administration of 100 mg acetaldehyde/kg bw for 2 weeks in 
Aldh2-knockout mice only (Kunugita et al. 2008).
In an abstract, a dose-dependent increase in 1,N2-PdG 
adduct levels in the lungs of rats after inhalation exposure 
to acetaldehyde (12–96 ppb) for 50 days is reported (Garcia 
et al. 2014). However, no full study report has been pub-
lished so far.
Wistar rats were continuously exposed by inhalation to 
0 or 10 ppb (14 µg/m3) of  [13C2]-acetaldehyde for 50 days. 
Unlabelled endogenous 1,N2-PdG adducts were detected in 
the liver, brain and lungs in both groups. Due to the small 
sample size (n = 5), the quantification resulted in a high inter-
individual variation and no significant differences between 
the groups were reported. The  [13C2]-1,N
2-PdG adduct 
(from the addition of one molecule of labelled acetaldehyde 
and one unlabelled molecule) was detected in a percentage 
similar to the natural abundance of the isotope. Labelled 
exogenous  [13C4]-1,N
2-PdG adducts (from the addition of 
two molecules of labelled acetaldehyde) were detected in 
the brain and lungs of  [13C2]-acetaldehyde exposed animals, 
but the adduct levels were below the limit of quantification 
(Sanchez et al. 2018).
Taken together, the studies with oral uptake of ethanol 
in mice and monkeys showed an increase of N2-ethyl-dG 
adducts in the liver, stomach, and several tissues of the oral 
cavity. Inhalation exposure of mice and rats to acetaldehyde 
led to an increase of N2-ethyl-dG adducts in the lungs of 
mice and to the formation of 1,N2-PdG adducts in the brain 
and lungs of rats. Aldehyde dehydrogenase deficient ani-
mals are more susceptible to the generation of N2-ethyl-dG 
adducts after oral ethanol uptake and inhalation exposure to 
acetaldehyde.
DNA adduct levels and DNA adduct formation in humans Basal 
levels of N2-ethyl-dG adducts (after reduction) have been 
quantified in white blood cells of human volunteers as well 
as in human liver and lung tissue. In the blood cells of drink-
ers N2-ethyl-dG adduct levels were increased, whereas in the 
lung tissue of smokers no significant differences were detected 
compared with non-smokers (Balbo et al. 2008).
The 1,N2-PdG adduct was detected in low levels in 4 of 
23 human liver samples as well as in 16 of 45 human lung 
samples (Zhang et al. 2006).
In a group of 30 male non-smoking volunteers, levels 
of N2-ethyl-dG adducts (after reduction) in leukocyte DNA 
were analysed before and after the consumption of 150 mL 
of vodka (containing 42% ethanol). Baseline adduct lev-
els were 34.6 ± 21.9/108 nt. Average levels of N2-ethyl-dG 
observed at different time points up to 48 h following inges-
tion of alcohol were not statistically significant from the 
baseline level (Singh et al. 2012).
In a study with 10 human volunteers, the kinetics of for-
mation and repair of N2-ethyl-dG adducts (after reduction) 
was investigated after consumption of alcohol corresponding 
to blood alcohol levels of 0.03%, 0.05% and 0.07%. Average 
basal levels of N2-ethyl-dG adducts in DNA extracted from 
granulocytes and lymphocytes were determined. N2-ethyl-
dG adduct levels increased in all subjects after most of the 
doses. The increase was up to fivefold in granulocytes and 
lymphocytes and up to 100-fold in human oral cells. Peak 
levels were reached within 40 h in peripheral blood cells and 
within 4 to 6 h in the oral cells. The authors concluded that 
the observed substantial intraindividual variability indicates 
other important sources of this DNA adduct (Balbo et al. 
2012a, b).
Local effects of  ethanol and  acetaldehyde in  risk assess‑
ment Ethanol is also metabolised to acetaldehyde by oral 
microbes and mucosal cells. Because of inefficient detoxi-
fication due to locally different enzymatic capacities, acet-
aldehyde accumulates in saliva and gastric juice (Homann 
2001). Salivary acetaldehyde concentrations were found 
to be much higher than the blood acetaldehyde concentra-
tions after ingestion of alcoholic beverages (Yokoyama et al. 
2008). Additionally, deficient activity in ALDH2 plays an 
important role in increasing the risk for upper digestive tract 
cancer. Concentrations of acetaldehyde in saliva and gas-
tric juice of ALDH2-deficient persons is 2 times and about 
5 times higher than in ALDH2-proficient persons, respec-
tively (Lachenmeier and Salaspuro 2017; Maejima et  al. 
2015). Thus, for the risk assessment of ethanol and acetalde-
hyde, local concentrations and effects have to be considered 
additionally to systemic effects.
Additional mechanisms affecting genomic stability There 
is some evidence that acetaldehyde inhibits the activity of 
the direct DNA repair enzyme O6-methylguanine methyl-
transferase (MGMT) and also of DNA methyltransferase 
(DNMT), which plays a role in epigenetic gene regulation 
by the methylation at C5 of cytosine. A further potential 
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mechanism is the modification of genome function by direct 
adduction of histones (Brooks and Zakhari 2014).
Conclusion A dose-dependent increase in adduct levels 
in  vitro and in  vivo was observed in several studies for 
N2-ethyl-dG adducts. No treatment-dependent changes 
in 1,N2-PdG adduct levels were found in mice after oral 
exposure to ethanol, whereas increased 1,N2-PdG adduct 
levels in the lungs of rats after inhalation of acetaldehyde 
have been reported. Site-directed mutagenesis studies have 
shown that both the N2-ethyl-dG and the 1,N2-PdG adducts 
have mutagenic potential. However, the biological signifi-
cance of the identified adducts for mutagenicity and car-
cinogenicity of ethanol and acetaldehyde is still not fully 
elucidated, and additional mechanisms may also account for 
their carcinogenic effect. Further research is needed con-
cerning the dose-dependent correlation of DNA adducts 
and mutagenicity. It has to be taken into account, that both 
ethanol and acetaldehyde are endogenous substances origi-
nating mainly from amino acid metabolism. Any additional 
intake from exogenous sources within the range of variation 
of the endogenous body burden will contribute only little to 
cancer risk. However, this should be verified on the level of 
DNA adducts since local concentrations of acetaldehyde as 
well as local levels of acetaldehyde-derived DNA adducts 
in the upper aerodigestive tract seem to play a major role in 
the development of cancer from ethanol and acetaldehyde. 
Furthermore, tissue irritation by acetaldehyde needs to be 
prevented as a promotional event in carcinogenicity.
Acrylamide
Occurrence and  exposure Acrylamide (AA) is used inter 
alia as an industrial chemical e.g. in the production of poly-
acrylamides. Furthermore, it is formed during the heating 
of food. Various mechanisms of AA formation in food have 
been discussed. The reaction of reducing carbohydrates 
with amino acids, in particular asparagine, during non-
enzymatic browning (Maillard reaction) appears to repre-
sent the most important mechanism of formation of AA in 
foods (Guth et al. 2013). AA is mainly formed in carbohy-
drate-rich, heat-processed foods, such as for example French 
fries, potato chips/crisps and coffee (EFSA 2015; Guth et al. 
2013). Chronic dietary exposure of adults was estimated to 
be on average between 0.4 and 0.9 µg/kg bw/day (95th per-
centile 0.6–2.0 µg/kg bw/day) and of children between 0.5 
and 1.9  µg/kg bw/day (95th percentile 1.4–3.4  µg/kg bw/
day) (EFSA 2015).
Of note, there is compelling evidence from human inter-
vention studies using duplicate diet technology that in addi-
tion to exogenous (dietary) exposure there is clearly sus-
tained endogenous exposure to AA formed metabolically 
in the human body. This endogenous baseline exposure is 
estimated to account for about 0.2–0.4 µg AA/kg bw/day, 
quite close to the average dietary exposure level. The source 
of this endogenous background is not clear at present but it 
may well originate from the metabolism of the intestinal 
microbiota, as has recently been reported for acrolein that 
appears to be generated at about tenfold higher level than 
acrylamide (Goempel et al. 2017; Goerke et al. 2019; Ruenz 
et al. 2016; Ruenz et al. 2019).
AA is classified as a genotoxic carcinogen. For the risk 
characterization based on neoplastic effects, the margin of 
exposure (MOE) approach was used by EFSA. As the ref-
erence point, the benchmark dose lower confidence limit 
for 10% extra tumour incidence  (BMDL10) of 0.17 mg/kg 
bw/day was deduced from data on observed incidences of 
Harderian gland adenomas and adenocarcinomas in male 
B6C3F1 mice exposed to AA for two years in an NTP study 
(EFSA 2015). MOEs calculated are substantially lower than 
10 000, ranging from 425 to 89 for the mean exposure esti-
mates and from 283 to 50 for the 95th percentile exposure 
estimates, indicating a concern with respect to neoplastic 
effects.
Biotransformation After ingestion and absorption from the 
gastrointestinal tract, AA is rapidly distributed and exten-
sively metabolized, mainly by conjugation with glutathione 
(GSH) and reaction with other non-critical targets such as 
thiol or amino groups of proteins. To some extent, it is also 
converted by cytochrome P450 2E1 into the genotoxic epox-
ide glycidamide (GA) (Fig.  5). GA forms DNA adducts, 
primarily at N7 of guanine (N7-GA-Gua) which are found 
in experimental animals following AA exposure in various 
tissues. GA formation and its interaction with DNA are con-
sidered to represent the key event resulting in genotoxicity 
and carcinogenicity of AA (EFSA 2015). This has, however, 
to be reconciled with various experimental in vivo findings, 
indicating that formation of N7-GA-guanine DNA adducts 
at low exposure especially when approaching average pre-
sent day consumer exposure levels, is not or only barely 
detectable. Further details see below and Watzek et  al. 
(2012).
Conjugates of AA and GA with GSH after further bio-
transformation are excreted in urine as AA mercapturic 
acid (AAMA) and glycidamide mercapturic acid (GAMA) 
(Fig. 5). Comprehensive profiling in humans has also indi-
cated the formation of a sulfoxide of AAMA with the abbre-
viation AAMA-sul (Wang et al. 2016).
Hepatic biotransformation was studied in primary rat 
hepatocytes, incubated with AA (0.2–2,000 µM) for up to 
24 h. AA-GSH adducts became measurable much earlier 
than the genotoxic metabolite GA. The rate of AA-GSH for-
mation was found to be about 1.5–3 times higher than that 
of GA formation. N7-GA-Gua adducts in primary hepato-
cyte DNA were found only at the highest AA concentration 
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tested (2 mM) and at extended incubation times (6 h: 13 ± 3; 
16 h: 127 ± 60 adducts/108 nucleotides). Concomitant with 
reduced AA-GSH formation, GA content in the incuba-
tion medium increased and N7-GA-Gua adduct formation 
became measurable (Watzek et al. 2013).
Findings by several groups indicate that humans are less 
proficient than rodents in activating AA metabolically to GA 
and may be more proficient in detoxification reactions such 
as coupling to GSH (Berger et al. 2011; Fennell and Fried-
man 2005; Fuhr et al. 2006). In humans, only a minor part 
of an ingested dose is expected to account for the formation 
of GA, GAMA and glyceramide. These data suggest marked 
intra and interspecies differences concerning metabolism of 
AA to GA. Several studies have reported various approaches 
to physiologically based pharmacokinetic (PBPK) modelling 
of AA absorption, metabolism and disposition with the goal 
of predicting human internal exposures to AA and GA (i.e. 
area under the curve, AUC) and of reducing the uncertainty 
in risk assessment inherent in animal to human extrapola-
tions (EFSA 2015).
Carcinogenicity‑Observational studies Epidemiological stud-
ies which analysed the association between AA exposure 
through diet or at the working place and the incidence or 
mortality from cancer have recently been reviewed by EFSA 
(EFSA 2015). EFSA concluded that the epidemiological stud-
ies did not indicate AA to be a human carcinogen, although the 
margins of exposure determined using the  BMDL10 derived 
from animal tumor data indicated a concern. Furthermore, the 
two available epidemiological studies of occupational expo-
sure to AA (Marsh et al. 2007; Swaen et al. 2007) both did not 
indicate an increased risk of cancer.
Animal studies AA is carcinogenic in multiple tissues in 
both male and female mice and rats. In long-term studies in 
rats, a carcinogenic potential of AA was demonstrated after 
administration via drinking water at doses of 0.5–2  mg/
kg bw/day in male animals or at doses of up to 3  mg/kg 
bw/day in female animals. Enhanced occurrence of certain 
tumours such as mesotheliomas of the tunica vaginalis tes-
tis, mammary fibroadenomas and thyroid tumours (follicu-
lar adenomas) has been reported (reviewed by Guth et al. 
2013). The carcinogenic potential of AA was confirmed in a 
two-year NTP study (NTP 2012). In rats and mice tumours 
were found in different organs, some of them already at the 
lowest AA dose of 0.33–0.44 mg/kg bw (male and female 
rats) or 1.04–1.1 mg/kg bw (male and female mice), so that 
no threshold could be deduced in this study (Guth et  al. 
2013; NTP 2012). Of note, Fisher rats are known for their 
susceptibility to Leydig cell tumors and secondary induc-
acrylamide
mercapturic acids
Reaction with thiol or amino groups of proteins


















Fig. 5  Metabolic pathway of AA in the rat. Reprinted (adapted) with permission from (Watzek et al. 2012). Copyright (2012) American Chemi-
cal Society
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tion of tunica vaginalis mesotheliomas, in contrast to the 
Wistar strain (Maronpot et al. 2009; Shipp et al. 2006). In 
a guideline compliant two year study that included in utero 
exposure, pregnant, preweanling Wistar Han rats and the F1 
offspring animals were given AA in a dose range of 0.5–
3.0 mg/kg bw in drinking water, starting at gestation day 6. 
Potentially treatment-related tumors, as previously observed 
in earlier studies in Fisher 344 rats, were not observed in 
the Wistar strain. At the end of two years mammary gland 
fibroadenomas were observed in females (not significant 
and within published control range for Wistar rats) as well 
as thyroid follicular cell tumors in both sexes (Maronpot 
et al. 2015). For mammary fibroadenomas in rats, the luteo-
trophic effect of age-associated prolactinaemia is supposed 
to be causative. This MOA is considered not likely relevant 
to women where prolactin is not luteotrophic. Likewise, a 
role for hormonal dysregulation affecting the pituitary–thy-
roid axis and the rat specific thyroid homoeostasis is gener-
ally supposed as likely cause for follicular cell neoplasia in 
rat carcinogenicity studies and is considered a rat-specific 
response (Alison et  al. 1994; Bartsch et  al. 2018; Capen 
1997; Capen and Martin 1989; Khan et al. 1999; Maronpot 
et al. 2015; Neumann 1991). In summary, these target tis-
sue-specific neoplastic responses are accepted to represent 
rat-specific MOAs, not likely predictive for human cancer 
risk (Maronpot et al. 2015).
In mice, the major tumours produced by AA in females 
and males were Harderian gland adenomas and adenocar-
cinomas, lung alveolar and bronchiolar adenomas, kidney 
tumours and stomach and forestomach squamous cell papil-
lomas. In females also mammary gland adenoacanthomas 
and adenocarcinomas, benign ovary granulosa cell tumours 
and skin sarcomas have been observed. A  BMDL10 of 
0.17 mg/kg bw was calculated from induction of Harderian 
gland tumours in mice, the most sensitive lesion out of a 
spectrum of AA-induced rodent tumours (NTP 2012). Based 
on this  BMDL10, EFSA derived MOEs ranging from 283 
to 50 for the 95th percentile average exposure estimates. In 
view of such a low MOE range, EFSA expressed a human 
health concern (EFSA 2015).
A similar spectrum of tumours has been observed in rats 
and mice when equimolar concentrations of GA were admin-
istered in drinking water. It was concluded that the carcino-
genic activity of AA is due to its metabolic conversion to 
GA (EFSA 2015; NTP 2012).
Genotoxicity in vitro Genotoxic activity of GA was inves-
tigated in comparison to that of other activated forms of 
well-known carcinogens in the single-cell gel electrophore-
sis (Comet assay) in V79 cells and in human lymphocytes. 
GA induced DNA damage down to 300  µM concentra-
tion (4  h) (Baum et  al. 2008). By comparison, the preac-
tivated N-nitroso compound 3-N-nitroso-oxazolidine-2-one 
(NOZ-2) and ( ±)-anti-benzo[a]pyrene-7,8-dihydrodiol-
9,10-epoxide ( (±)-BPDE), were much stronger genotoxic 
agents, significantly inducing DNA damage already at 3 µM 
(15 min) (Baum et al. 2008). In the hPRT mutagenicity test 
in V79 cells, GA induced mutations only at concentrations 
of 800 µM and above, whereas NOZ-2 as well as ( ±)-BPDE 
significantly induced hPRT mutations already at > 200-fold 
lower concentration (Baum et al. 2005, 2008; Thielen et al. 
2006).
A comparison of the mutagenic potential of AA and GA 
in the hPRT assay in V79 cells to that of N-methyl-N’-nitro-
N-nitroso-guanidine (MNNG) as positive control showed 
marked mutagenic effectivity already at 0.5 µM for MNNG, 
whereas AA was inactive up to a concentration of 10 mM 
(Baum et al. 2005). GA showed a concentration-dependent 
induction of mutations at concentrations of 800 µM and 
higher. In another experiment, human blood was used as a 
model system to investigate genotoxic potential in lympho-
cytes by the comet assay and by measuring the induction of 
micronuclei (MN) with bleomycin (BL) as a positive control. 
AA did not induce significant genotoxicity or mutagenicity 
up to 6 mM (Baum et al. 2005). With GA, concentration-
dependent DNA damage was observed in the dose range of 
300–3000 µM after 4 h incubation. Significant MN-induc-
tion was not observed with AA (up to 5 mM) and GA (up 
to 1 mM), whereas BL induced significantly enhanced MN 
frequencies at 4 µM (Baum et al. 2005). Taken together these 
results revealed AA not to be genotoxic/mutagenic whereas 
GA can be considered a rather weak genotoxic mutagen, 
especially when compared to established mutagens and 
carcinogens like activated nitroso compounds or polycyclic 
aromatic hydrocarbons.
The finding that GA exerts a rather modest genotoxic and 
mutagenic activity may be a result of its preferential N7-gua-
nine alkylation. N7-guanine alkyl adducts are considered to 
exert only low or even no mutagenic effects as such.
Genotoxicity in vivo AA was given to rats at a daily intake 
level in AA-containing foods for up to 9 days, resulting in 
an exposure of 50 or 100 μg AA/kg bw/day (Berger et al. 
2011). Positive controls received the same dosages of AA 
in water, negative controls just water. As biomarkers uri-
nary mercapturic acids (MA), haemoglobin (Hb) adducts, 
plasma levels of AA and GA and induction of DNA dam-
age in white blood cells and hepatocytes were measured. 
Significant differences in overall bioavailability of AA from 
water and the different food matrices were not observed. 
Hb adducts of AA followed time/exposure-related dose–
response. In contrast, Hb adducts of GA were not enhanced 
above untreated control, although GAMA excretion in urine 
indicated significant GA formation. This suggests that at 
these dose levels any GA formed metabolically in the liver 
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is effectively scavenged by glutathione coupling (Berger 
et al. 2011).
In a further dose–response study AA was given orally in 
a single dosage of 0.1–10,000 μg/kg bw to female Sprague-
Dawley (SD) rats (Watzek et al. 2012). Formation of uri-
nary mercapturic acids and of N7-GA-Gua DNA adducts 
in liver, kidney, and lung were measured 16 h after appli-
cation, which had previously been determined as the time 
point of maximal N7-GA-Gua DNA concentration (Fig. 6). 
At this time point, urinary excretion of mercapturic acids 
is not complete yet. A mean of 37.0 ± 11.5% of a given AA 
dose was found as mercapturic acids in urine. MA excretion 
in urine of untreated controls indicated some background 
exposure from endogenous AA. N7-GA-Gua adduct forma-
tion was not detectable in any organ tested at 0.1 μg AA/
kg bw. At a dose of 1 μg/kg bw, adducts were found in kid-
ney (around 1 adduct/108 nucleotides) and lung (below 1 
adduct/108 nucleotides), but not in liver. At 10 and 100 μg/
kg bw, adducts were found in all three organs, at levels close 
to those found at 1 μg AA/kg, covering a range of about 1–2 
adducts/108 nucleotides. In the dose range from 0.1–100 µg/
kg bw/d no linear dose–response relationship was apparent 
(Fig. 6). DNA adduct levels from electrophilic genotoxic 
agents of various origin were found in human tissues at 
levels of up to about 200 specific adducts/108 nucleotides 
(Nakamura et al. 2014; Swenberg et al. 2011) (see also part 
A "Fundamental considerations", chapter “background DNA 
lesions”). An adduct considered closely related to N7-GA-
guanine, N7-carboxyethyl dGua, was found at a background 
level of about 8 adducts/108 nucleotides (Watzek et  al. 
2012). By comparison, N7-GA-Gua adduct levels within the 
dose range of 0.1–100 μg AA/kg bw were at the low end of 
human background. At the reported  BMDL10 (0.17 mg AA/
kg bw/day in mice), N7-GA-guanine adduct levels can be 
expected from this single dose–response study to not exceed 
around 3–4 adducts/108 nucleotides in rats, still not exceed-
ing comparable human background (Watzek et al. 2012).
Altogether these data do not provide compelling support 
for genotoxicity of AA being relevant for cancer endpoints 
in experimental animals. Likewise, novel toxicogenomic evi-
dence obtained from studies in F344 rats given AA at dos-
ages up to 12.0 mg/kg bw/day for different subchronic time 
periods does not convincingly support a genotoxic or hormo-
nal MOA. Instead, pronounced effects on calcium signalling 
and on cytoskeletal functions were observed in the thyroid, 
a tumour target organ in the male rat (Chepelev et al. 2017). 
Under the same experimental conditions, evidence for a 
similar MOA being operative in rat testes has been reported 
(Recio et al. 2017). In vivo mutagenicity studies using the 
Pig-a gene mutation assay and the micronucleus test in F344 
rats and in B6C3F1 mice under similar conditions gave neg-
ative to equivocal results. In addition, at dosages < 6.0 mg/
kg bw/day no in vivo mutagenicity was observed. This is 
in agreement with the perception of a non-genotoxic MOA 
being relevant for AA-induced tumorigenicity in the carci-
nogenic dose range in rodents (Hobbs et al. 2016).
Impact of  AA on  transcription and  gene expression pro‑
files Several toxicogenomic studies on rats and mice 
exposed to AA in a time- and dose-dependent manner were 
conducted (Chepelev et al. 2017, 2018; Recio et al. 2017). 
The group performed mRNA gene expression profiling to 
develop a MOA and to calculate transcriptional BMDLs 
for the most sensitive pathways, comparing these with data 
derived from traditional (apical) cancer studies. Concern-
ing the MOA, they observed no altered gene expressions 
of pathways associated with a genotoxic MOA (i.e. p53, 
DNA repair, cell cycle). Moreover, the findings pointed to 
an alternative MOA comprising perturbation of the calcium 
signalling as a key event in the AA-mediated carcinogen-
esis in rodents. Taken together, these results are in line with 
those mentioned above and not supportive of a key role of 
genotoxicity in the MOA of AA. The comparison of tran-
scriptional-derived PODs with those obtained from 2-year 
rodent studies revealed that the transcriptional BMDLs were 
around one to threefold of apical BMDLs.
Fig. 6  Dose–response relation of N7-GA-Gua adducts in rat kidney 
orally exposed to 0.1–10,000  μg AA/kg bw (R2 = 0.99)  (only kid-
ney shown in the linear-log plot for graphic clarity). Insert, linear–
linear plot of the low dose range (0.1–1000 μg AA/kg bw); shaded, 
range of DNA background of N7-carboxyethyl-dGua in human liver 
(see also part A "Fundamental considerations", chapter “background 
DNA lesions”). Values represent mean values ± SDs (n = 8 or n = 3). 
Reprinted with permission from (Watzek et  al. 2012), Copyright 
(2012) American Chemical Society
1816 Archives of Toxicology (2020) 94:1787–1877
1 3
Conclusion The totality of the evidence does not compel-
lingly support the note that AA induces malignant trans-
formation in animal experiments by virtue of a genotoxic 
MOA. AA itself clearly is non genotoxic, but can be con-
verted metabolically to the epoxide GA which may exert 
DNA damage by covalent binding. Such genetic damage 
may result in fixed mutations, eventually leading to neoplas-
tic transformation. Although this has been favoured in the 
past as most probable key event of AA-induced neoplastic 
transformation, compelling evidence is lacking. The geno-
toxicity of AA may be understood as a high dose effect but 
the overall evidence suggests a non-genotoxic MOA even 
at elevated dose levels. Summarizing major arguments, it is 
concluded that:
(1) the presumed genotoxic key metabolite GA is a rather 
poor mutagen, predominantly inducing N7-GA-Gua 
lesions, known to be of rather low promutagenic activ-
ity (Baum et al. 2008; Durling and Abramsson-Zet-
terberg 2005; Glatt et al. 2005; Johansson et al. 2005; 
Pottenger et al. 2009a; Puppel et al. 2005; Thielen 
et al. 2006). Accordingly, in vivo mutagenicity experi-
ments in rodents at dosages < 6.0 mg/kg  bw/day were 
reported not to induce a mutagenic response (Hobbs 
et al. 2016).
(2) in vivo, at realistic low exposure levels encompassing 
diet-related intake, AA induces only very minor DNA 
damage in rats. At single dosages up to at least 100 μg/
kg bw, adduct formation was not found dose-related 
and stayed within the human background of similar 
DNA lesions at N7-dG (Watzek et al. 2012).
(3) evidence is accumulating from toxicogenomic studies 
arguing for MOAs other than genotoxicity. This applies 
especially to the target organs of AA in rodent carci-
nogenicity studies, such as the thyroid, the testes, and 
the Harderian gland, where pronounced effects on cal-
cium signalling and on cytoskeletal functions have been 
observed, but no compelling support for a genotoxic or 
hormonal MOA was found (Chepelev et al. 2017, 2018; 
Recio et al. 2017).
Thus, the totality of evidence appears to argue for the 
existence of an AA exposure level not associated with induc-
tion of toxic or adverse health effects. If established, it may 
enable the definition of a tolerable daily intake level (TDI).
Gaps in knowledge and research needs Amongst the pro-
cess-related food contaminants, AA has contracted major 
attention of the research community and of major risk assess-
ing bodies, under the perception that AA is a process-related 
toxicant acting by a genotoxic mechanism of action. Recom-
mendations by risk management bodies were developed to 
limit consumers’ exposure as far as reasonably achievable 
(ALARA principle). Under the premise of AA being a geno-
toxic carcinogen, present day MOE ranges appear unsatis-
factory. However, in view of the accumulating evidence for 
a non-genotoxic MOA, TDIs may be considered.
For future risk assessment gaps in knowledge concerning 
the MOA of AA at realistic exposure levels need to be closed 
and the endogenous background of sustained AA formation 
in humans needs to be taken in due consideration.
With the help of toxicogenomics, PBPK modelling, 
advanced biomarker monitoring and reverse dosimetry it 
should be possible to:
(1) establish a compelling MOA for AA taken up at diet-
related dosage (genotoxic/ non genotoxic)
(2) create dependable correlations between exposure and 
biomarker levels
(3) elucidate the relative importance of endogenously gen-
erated AA versus AA taken up by exogenous pathways
(4) establish a comprehensive database on DNA back-
ground damage in humans
Alkylating agents
Alkylating agents are prototypic genotoxic carcinogens. 
The primary DNA modification consists of an alkylation of 
DNA bases, which typically lead to a base mispairing in the 
subsequent replication round and consequently a base-pair 
substitution mutation. Methyl and ethyl residues are typical 
transduced groups, and metabolic activation of these directly 
alkylating compounds is not required to render them reac-
tive. Of the possible modifications alkylation of the O6 and 
N7 positions of guanine are of major importance, with meth-
ylation or ethylation of the O6 position being a particularly 
premutagenic lesion, despite the fact that this modification 
accounts for less than 8% of the total alkylations (Beranek 
1990), in that it effectively leads to a GC→AT transition 
mutation. In mammalian cells, repair of this primary DNA 
modification occurs via a so-called suicide reaction by the 
enzyme methyl guanine methyl transferase (MGMT) (see 
part A Sec. “DNA reactivity of chemicals: Hazard versus 
Risk” `DNA reactivity of chemical substances´). The repair 
protein transfers the methyl group from the alkylated guano-
sine in a one-step reaction onto an internal cysteine residue 
in its active centre (Pegg et al. 1995), a reaction which leads 
to the inactivation of the enzyme which, therefore, needs 
to be regenerated. Obviously, since this reaction does not 
involve an additional DNA modification step it is essentially 
error-free. Further, since the DNA damage removal consists 
of basically a stoichiometric reaction of the repair protein 
with its substrate, followed by regeneration of the enzyme 
after inactivation by the reaction, a thresholded kinetic 
mechanism is readily conceivable considering the saturation 
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of the repair may occur when all enzyme is inactivated (Mül-
ler et al. 2009).
Insight into the existence of an apparent threshold in this 
reaction was provided by an extensive series of experiments 
conducted by the pharmaceutical company F.Hoffman-La 
Roche, Basel, Switzerland. Through a manufacturing acci-
dent, in 2007 a batch of Viracept (nelfinavir mesylate), an 
antiviral drug used for HIV treatment, had been in contact 
with cleaning ethanol for a prolonged time period, by which 
elevated levels of ethyl methane sulfonate (EMS) were 
formed without being discovered before exposing patients 
to this material. Obviously, the distribution of this batch was 
immediately suspended but a thorough risk assessment for 
treated subjects was needed (Müller et al. 2009). EMS is an 
alkylating agent which leads to the formation of DNA ethyl 
adducts. The hypothesis formed was based on the above con-
sideration, i.e. that of the intracellular MGMT level should 
provide for error-free repair up to a level of exhaustion of 
its pool, above which the repair kinetics can be expected to 
display a significantly different profile.
Key parameters to describe human exposure, based on 
therapeutic uptake of Viracept, were the following:
• Maximal content of EMS in Viracept: ca 2300 ppm
• Maximal content of EMS in tablets: ca 1000 ppm (TTC 
level: 0.6 ppm)
• → Maximal dose of EMS in patients: 0.055 mg/kg
• Maximal duration of exposure: 3 months
• Number of patients: < 40,000
The following experimental approaches were pursued:
1. A general repeated-dose oral toxicity study in rats with 
EMS, with the aim to establish basic knowledge of EMS 
organ toxicity and clinical chemistry/haematology in 
conjunction with toxicokinetic data to describe expo-
sure.
2. Genotoxicity:
  (a). Induction of chromosomal damage in the bone 
marrow of mice (bone marrow micronucleus test) after 
repeat dosing (7 days) with EMS and ethyl nitrosourea 
(ENU), with the aim to study the dose–response behav-
iour of EMS at low doses for chromosome damage 
compared to that of ENU, of which the DNA damage is 
known to be not efficiently repaired by MGMT (Kaina 
et al. 1991). Dose levels applied were 1.25, 2.5, 5, 20, 
80, 140, 200 and 260 mg/kg bw/day for EMS and 1.11, 
4.45 and 17.8 mg/kg bw/day for ENU, based on dose-
finding information.
  (b). Induction of LacZ gene mutations in Muta-
Mouse (transgenic model) after 28-day oral dosing 
with EMS and ENU, with the aim to characterize the 
dose–response for EMS in low doses for gene muta-
tions compared to the dose–response for ENU. Tissues 
analysed were bone marrow, liver and gastrointestinal 
tract, and dose levels applied were 1.56, 3.13, 5.25, 12.5, 
25, 50 and 100 mg/kg bw/day for EMS and 1.39, 5.56 
and 22.25 mg/kg bw/day for ENU. In addition, single 
doses of 350 mg/kg and 15.56 mg/kg of EMS and ENU, 
respectively, were administered to explore the difference 
between fractionated and combined administration of 
the same dose.
  (c). Exploration of data by statistical methods (Gocke 
and Wall 2009).
3. Determination of globin valine ethyl adducts in the bone 
marrow as a dosimetry parameter to confirm exposure 
to EMS.
4. Cross-species in vitro and in vivo evaluation of exposure 
to EMS (mouse, rat, monkey, human), with the aim to 
retrospectively facilitate exposure judgment in patients 
having been exposed to elevated levels of EMS via Vira-
cept treatment.
In summary, under all circumstances (i.e. both with using 
bone marrow micronucleus frequencies as well as lacZ 
mutations in bone marrow, liver or gastrointestinal tract), 
dose–responses indicative of thresholded relationships 
were obtained for EMS-treated animals, supported by vari-
ous statistical methods (Gocke and Wall 2009), while ENU 
showed a linear dose–response behaviour. Across organs and 
endpoints no-effect-levels were remarkably similar. Thus, 
daily doses of up to 25 mg EMS/kg bw/day (bone marrow, 
GI tract) or 50 mg EMS/kg bw/day (liver) did not induce 
mutations in the lacZ gene in the three organs tested. Doses 
up to 80 mg EMS/kg bw/day (7-day dosing regimen) did 
not induce micronuclei in mouse bone marrow (Gocke et al. 
2009). Thus, using two different endpoints (point mutations 
and chromosome aberrations) revealed roughly comparable 
thresholds for the induction of an effect, and also across 
different organs. In contrast, the induction of ethyl valine 
adducts determined in haemoglobin, considered as surrogate 
biomarkers for DNA damage, followed linear kinetics with 
no obvious threshold, which is in line with previous reports 
that showed that the induction of DNA alkylations follows a 
linear, non-thresholded relationship (Swenberg et al. 2008).
When the same total EMS dose was administered at once 
rather than in portions, a much steeper dose–response was 
observed. For ENU, which was used as the comparator com-
pound, no threshold was seen within the dose-range used, 
and dose fractionation and single-dose administration gave 
comparable dose–responses, which is an indication of that 
there is no exhaustible DNA repair system.
For EMS, safety margins to human exposure under the 
circumstances of treatment with the contaminated batch, 
using those threshold data, resulted in factors of 370 or 454, 
based on Cmax or dose, respectively, which was considered 
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sufficient evidence of the lack of a genotoxic and hence car-
cinogenic risk for the exposed persons.
Thresholded dose–response relationships have been 
described for EMS in vitro as well (Doak et al. 2007). In 
this study, human lymphoblastoid AHH-1 cells were treated 
with relatively closely spaced concentrations of EMS, MMS, 
MNU or ENU, and micronucleus frequencies were deter-
mined after cytokinesis block, or HPRT mutant frequencies 
to assess point mutations. In the micronucleus test, appar-
ent thresholds ranging between 0 and 0.80 µg/ml MMS and 
0–1.35 µg/ml EMS were seen. Above those concentrations, 
statistically significant increases in micronucleus frequen-
cies were detected, resulting in effect concentrations of 0.85 
and 1.40 µg/mL for MMS and EMS, respectively. For MNU 
and ENU, no thresholds were seen down to the lowest con-
centrations tested. Similarly, HPRT mutants were induced 
at 1.25 µg/mL MMS and 1.4 µg/mL EMS, but not below 
those concentrations, whereas for MNU and ENU again an 
increase in mutant frequency was seen down to the lowest 
concentration. Therefore, those data support the hypothesis, 
formulated within the Viracept investigations, that an essen-
tially error-free DNA repair enzyme is able to protect cells 
and tissues against ethylation and methylation by EMS and 
MMS. However, both investigations were unable to identify 
an apparent threshold for the nitrosoureas ENU and MNU, 
indicating that different repair may account for the protection 
against those agents. In all cases, the onset of increases in 
genotoxic response was not correlated to a shift in cytotoxic-
ity, so that this effect was excluded as the mechanism for a 
thresholded dose–response. Hypotheses formulated in this 
study imply that for alkyl methanesulfonate-induced DNA 
adducts, which consist mainly of N7-G adducts and less of 
O6-G adducts at low doses (Doak et al. 2007), BER may be 
responsible for removing the N7-alkyl-G lesions induced 
by MMS and EMS, whereas MGMT can cope with the low 
levels of O6-alkyl-G adducts, thus resulting in the observed 
threshold concentration ranges for the induction of chro-
mosomal damage. MNU and ENU also induce N7-alkyl-
G adducts that may be efficiently repaired by BER at low 
doses, but they also induce a comparatively larger propor-
tion of O6-alkyl-G lesions that may be too extensive for the 
MGMT enzyme to correct even at low doses. In addition, 
they induce adducts at O2- and O4-Thymine, which are both 
very poorly repaired; thus, the unrepaired O adducts may 
result in linear concentration-responses for these adducts 
(Doak et al. 2007).
Using the PIG-A system in erythrocytes and reticulocytes 
in rats in vivo, Dobo et al. (2011) confirmed the value for 
the apparent threshold seen in the Viracept studies and, by 
extending ENU treatment to lower doses, also observed an 
apparent threshold for this mutagen (Dobo et al. 2011). EMS 
dose levels up to 100 mg/kg bw/day were used for 28 daily 
treatments, and up to 700 mg/kg for single doses. ENU was 
used for up to 15 mg/kg bw/day for a 28-day study, and up 
to 28 mg/kg acutely. In both cases, subacute vs. acute dosing 
was used to investigate the existence of an exhaustible dam-
age removal system. For both compounds, a clear difference 
was seen in the numbers of induced mutations when a single 
high dose was compared to the same total dose adminis-
tered in 28 fractions, in that the acute doses induced clearly 
higher mutant frequencies; again an indication of a saturable 
defence system. Thresholds for EMS treatment, i.e. doses up 
to which no statistically significant increase over the concur-
rent background value is observed, were comparable to the 
values determined in the Viracept study, despite the fact that 
different endpoints were used.
Further reports are available which are confirming appar-
ent thresholds for alkylating agents. Thus, Jenkins et al. 
(2005) observed non-linear dose–response relationships 
for MMS treatment of cells in vitro and using ML-TK and 
HPRT mutations as well as micronuclei as the genotoxicity 
endpoints. Pottenger et al. (2009b), reported similar results 
for ML-TK mutations and DNA adducts in vitro.
Conclusion In conclusion, there is sufficient evidence to 
indicate that for alkylating agents, which will induce gen-
otoxic effects via direct interaction with DNA, low dose 
sublinear dose–response relationships do exist and can be 
described and quantified using various tests systems and 
endpoints. Hypotheses exist for the mechanisms of those 
apparent thresholds, the most prominent being saturable 
DNA repair systems, and there is little doubt that they are of 
biological relevance and should be taken into account when 
assessing the risk of low-dose exposure scenarios. However, 
open questions remain:
• What are the levels of DNA repair (e.g. MGMT) activi-
ties in different organs or species?
• What are the appropriate statistical methods to describe 
linearity or non-linearity?
• What is the relevance of the different endpoints, particu-
larly DNA adducts vs. mutations?
• What should be a minimum data set to claim an apparent 
threshold?
Ethylene oxide
Ethylene oxide is both, a high volume compound in chemical 
industries and a direct-acting carcinogen. This combination 
asks for an utmost precise risk assessment. On top, the com-
pound is also formed as an endogenous metabolite, raising 
the question whether the resulting natural exposure might 
serve as an orientation for the regulation of the occupational 
exposure.
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General information The estimated annual production vol-
ume of ethylene oxide is presently around 20 million tons, 
since 11% of the 150 million tons of ethylene, the organic 
entity with the highest annual production volume world-
wide (True 2013), is used for its synthesis (Ceresana 2010). 
The majority of ethylene oxide is used as a chemical build-
ing block for the synthesis of other compounds. However, 
around 20% are applied for sterilization purposes, such as 
decontamination of medical instruments. At ambient tem-
perature, the compound is a gas (boiling point 10.5 °C) and 
highly water-soluble, with a  logPo/w of  − 0.3, very similar to 
that of ethanol (PanGas 2012). This amphiphilic behaviour, 
in combination with the small molecular weight of 44, sug-
gests easy penetration of the compound across membrane 
barriers and thus unlimited access to all body compart-
ments, with a slight preference for aqueous compartments.
Ethylene oxide is electrophilically reactive, yet stable at 
room temperature in the absence of catalysts. Once initiated, 
it can undergo several types of substantially exothermic reac-
tions, from polymerisation to spontaneous decomposition. 
As a gas, it is explosive in the wide range of concentrations 
from 2.6 to 100%. Under neutral conditions, its hydrolysis 
rate in aqueous solution is very slow (t1/2 = 20 days at 20 °C) 
but is strongly accelerated by acidification (Brönsted et al. 
1929).
The odour detection threshold for ethylene oxide with 
300–700 ppm is very high (Ruth 1986). Above this, the 
compound has a sweetish, ethyl ether-like smell. This is 
already in the acutely toxic range: in an NTP mouse study, 
9 out of 10 animals died within the 4 h after the experiment 
when exposed to 800 ppm over a period of 6 h. Although 
not specified in this report a reasonable assumption is that 
the mice died from acute lung oedema. In a fourteen weeks 
study with repeated 6 h exposure, all animals of the 400 ppm 
exposure group died within the first 4 weeks (NTP 1987).
Kinetics and metabolism Endogenous formation of ethylene 
oxide is due to CYP-dependent ethylene oxidation, mainly 
driven by CYP2E1 (Li et al. 2011b). Ethylene is an endog-
enous metabolite but is also taken up from external sources, 
such as food. Its metabolism to ethylene oxide is limited by 
saturation at exposure concentrations ≥ 1000 ppm in ambi-
ent air (Filser and Bolt 1984) and partial self-inactivation of 
CYP by ethylene oxide formation (Li et al. 2011b), which 
results in a maximum production rate equivalent to an ethyl-
ene oxide exposure of 4–8 ppm. This might explain that eth-
ylene itself is not positive in carcinogenicity studies (Hamm 
et al. 1984), due to the limited sensitivity of such studies. In 
an attempt to estimate the lifetime risk for carcinogenesis 
due to ethylene-based endogenous ethylene oxide formation 
of approximately 1 nmol/hour for a 70 kg adult male (Filser 
et al. 1992), an approximate increase of 1 tumour per  104 
individuals has been communicated (Denk and Filser 1990).
One important metabolic route for ethylene oxide break-
down is glutathione conjugation (Li et al. 2011b), in man 
with a substantial contribution by the polymorphic GST T1 
isoenzyme (Pemble et al. 1994). Consequently, respective 
metabolite concentrations in urine after exposure to ethyl-
ene oxide correlate with the GST T1 genotype (Haufroid 
et al. 2007), but also demonstrate the presence of other GST 
isoenzymes for ethylene oxide conjugation that produce mer-
capturic acid conjugates in the absence of a functional GST 
T1 gene. Hydrolysis of ethylene oxide by epoxide hydrolases 
is the second metabolic route (Brown et al. 1996; Li et al. 
2011b). Its contribution to ethylene oxide elimination appar-
ently plays a minor role in rodents while in humans it con-
tributes substantially to ethylene oxide turnover. Physiologi-
cally based toxicokinetic modelling first predicted a ≥ 25% 
contribution of epoxide hydrolases to the overall human eth-
ylene oxide metabolism (Li et al. 2011b) while a recently 
refined model increases this prediction to 85% (Filser and 
Klein 2018). Surprisingly, exhalation is not a major route 
of elimination after acute exposure, because less than 10% 
ethylene oxide is exhaled unchanged after systemic uptake 
(Csanady et al. 2000). The speed of enzymatic ethylene 
oxide metabolism differs significantly between mouse, rat 
and human. Consequently, the half-life of ethylene oxide is 
with approximately 3 min (mouse), 12 min (rat) and 45 min 
(human) substantially different between these three species 
(Brown et al. 1996; Fennell and Brown 2001). In mouse, 
continuous ethylene oxide exposure above 200 ppm leads to 
an over proportional increase in ethylene oxide blood lev-
els explained by liver GSH depletion (Brown et al. 1998). 
Interestingly, different organs within the same animals were 
differentially affected, with lungs being more sensitive, i.e. 
displaying onset of GSH depletion already at 50 ppm and 
testis being less sensitive (onset of GSH depletion only at 
300 ppm), as compared to liver.
DNA and protein adduct formation Due to its electrophilic 
reactivity, ethylene oxide produces 2-hydroxyethyl adducts 
of DNA and proteins without metabolic activation. In vitro 
reaction of ethylene oxide with DNA led to the formation 
of at least five different adducts, the major one being the 
N7-guanosine adduct, followed by the N3-adenosine adduct 
(Segerback 1990). Substantial amounts of two adducts were 
observed that were suspected to represent the adenosine N7- 
and N1-adducts, and traces of O6-guanosine were detected 
(200-fold less than the amount of the N7 adduct). In vivo, 
the N7-guanosine hydroxyethyl adduct can be found in 
unexposed animals and human individuals and is ascribed 
to endogenous ethylene oxide formation. Interestingly, Wu 
et  al. reported a much lower background level in rodent 
organs (0.2–0.3 µmol/mol guanosine in livers, lungs, brains 
and spleens of mice and rat, equivalent to 5–7.5 adducts per 
 108 nt or 600–900 adducts per diploid cell) as compared 
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to human peripheral blood lymphocytes (0.9–7.4  µmol/
mol guanosine in 23 unexposed individuals, equivalent to 
20–200 adducts per  108 nt or 2500–20,000 adducts per dip-
loid cell) (Wu et al. 1999b). In a follow-up study, a dose-
dependent, yet non-linear adduct increase of 100–250-fold 
was observed in rats after 4 weeks of exposure to 100 ppm 
ethylene oxide for 6  h/day and 5  days a week (Wu et  al. 
1999a), with an over proportional adduct increase from 30 
to 100 ppm in brains and lungs. In similar experiments, the 
steady-state level for the adenosine N7 adduct was reached 
within approximately 1 ½ weeks, indicating an adduct half-
life of around 2 days (Walker et al. 2000).
Another valuable marker for ethylene oxide exposure is 
the adduct formed with the N-terminal valine of haemoglo-
bin in rats, mice and men (Segerback 1990). This N2 adduct 
is formed with similar efficacy with haemoglobin from all 
three species, while other amino adducts differ substantially 
between species in their formation rate. Because its survival 
time is equivalent to that of haemoglobin itself and thus 
around 126 days in human (this value is the basis for the cal-
culations cited below and is an accepted estimate, see Franco 
(2012)), the hydroxyethyl N2-valine adduct is a perfect inte-
grating measure for average long-term ethylene oxide expo-
sure. According to Boogaard (2002), an increment of 7 nmol 
hydroxyethyl valine per gram haemoglobin corresponds to 
an average continuous additional workplace exposure (40 h 
per week) of 1 ppm. Because this value was extrapolated 
from short term exposure to an 8 h per day exposure for 
126 days, neglecting the exposure-free weekends, this value 
should actually be 5 nmol/g, based on its linear correlation 
with exposure duration during erythrocyte lifetime. Recent 
modelling approaches (Csanady et al. 2000; Filser and Klein 
2018) predict the valine adduct burden of long-term expo-
sure to 1 ppm ethylene oxide to be 2.5 nmol/g haemoglobin, 
in reasonable agreement with the above experimental values. 
Compared to the average background of 20 pmol hydroxy-
ethyl valine per gram haemoglobin in non-exposed healthy 
non-smokers (Boogaard et al. 1999), such increase by almost 
three orders of magnitudes per ppm qualifies this lesion as 
a particularly sensitive marker of exposure.
Mutagenicity Assessment of the mutagenicity of ethyl-
ene oxide in standard bacterial mutagenicity tests is not a 
straightforward approach, due to its volatility. However, 
substantial mutagenic activity has been reported by Hughes 
et al. (1987) using a modified procedure of the Ames test. 
On the other hand, the mutagenic potential of the ethylene 
oxide-induced DNA adducts in mammalian/human cells 
appears to be quite weak (Tompkins et al. 2009), which is 
in line with the observed low in vivo mutagenic potency in 
rodents (Recio et al. 2004; Tates et al. 1999).
Genotoxicity and carcinogenicity Genotoxicity of ethylene 
oxide is well documented in vitro and in vivo (Appelgren 
et al. 1978; Farooqi et al. 1993; Tucker et al. 1986; Walker 
and Skopek 1993). Numerous epidemiologic studies clearly 
demonstrate that this is relevant for human workplace expo-
sure. Enhanced micronuclei formation, sister chromatid 
exchanges and chromosomal aberrations have been fre-
quently observed in studies with ethylene oxide workplace 
exposure levels above 0.5 ppm (Karelova et al. 1987; Rich-
mond et  al. 1985; Sarto et  al. 1984). A non-linear dose–
response relation has been observed in mice for heritable 
translocations beyond exposure concentrations of 100 ppm, 
yet this is paralleled by the non-linear ethylene oxide blood 
concentration in these animals, that is best explained by glu-
tathione depletion (Brown et al. 1998; Generoso et al. 1990).
Carcinogenicity of ethylene oxide has been observed in 
rodents under conditions simulating workplace exposure 
at the concentration at or beyond 33 ppm. In rats, brain 
tumours and spleen mononuclear cell leukaemia were 
increased (Snellings et al. 1984) while mice showed a higher 
incidence of lung tumours (NTP 1987).
Two cohort studies on cancer mortality in ethylene oxide 
exposed workers are widely used to calculate carcinogenic 
risk in human: the Union Carbide Company (UCC) study 
(Teta et al. 1993) and the NIOSH cohort study (Stayner 
et al. 1993). The UCC study followed 1896 male workers 
exposed to ethylene oxide during chemical manufacturing 
with an average cumulative exposure level of 67 ppm-years. 
The NIOSH study (Stayner et al. 1993) observed 18,235 
male (45%) and female (55%) sterilization workers that had 
a mean exposure level of 27 ppm-years, however, the median 
exposure in this study was only 5.6 ppm-years. Important 
(re-)analyses of the data of these studies have been per-
formed by several authors (Kirman et al. 2004; Steenland 
et al. 2004; Valdez-Flores et al. 2010). The general conclu-
sion of all of these studies is that there is little unequivocal 
evidence of increased incidence of malignancies due to the 
ethylene workplace exposure in these cohorts. Statistically 
significant (p < 0.05) is the increased incidence of bone 
tumours in the NIOSH cohort, that is, however, based on 6 
observed against 2 expected tumours in the 18,000-person 
cohort. Despite a lack of statistical significance for its induc-
tion by ethylene oxide exposure, lymphoid malignancies 
were explored by Valdez-Flores and colleagues to estimate 
the tumour risk, taken as a worst-case scenario. They con-
clude that exposure to 0.25 ppm ethylene oxide during work 
time for 40 years leads at most to an increased incidence of 
4 tumours in 100,000 workers (Valdez-Flores et al. 2010). 
This value is much lower than previous estimates by others 
(EPA 1985; OSHA 1984), yet is still a bit more conservative 
than a previous non-linear prediction model by the same 
group. The latter was based on mechanistic assumptions 
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that are scientifically sound yet lack the proof of practical 
relevance (Kirman et al. 2004).
Conclusions Despite a large pool of existing data, it is still 
very difficult to quantify the human risk for ethylene oxide 
exposure-related neoplasia at the workplace. The attempt by 
Valdez-Flores is an interesting approach but still falls short, 
as documented by the fact that the calculated risk of 4 in 
100,000 would not cover the observed, statistically signifi-
cant risk for bone malignancies, that, if the rather imprecise 
odds ratio of three would hold true, would come out to be 
approximately 8 in 100,000 at an exposure level of 0.25 ppm 
over the entire work life. However, taking the large human 
cohorts as the basis for the risk assessment appears to be 
the better approach than to take the animal experiments as 
the basis for risk calculation because the relevance of the 
latter for the human physiology is less evident. Because 
constant exposure to 0.25 ppm would increase the haemo-
globin adduct approximately 50-fold over background, this 
biomarker appears to be perfectly suited to assess the actual 
burden of workers in an exposure range that should not yet 
present a significant health risk.
Open questions One open question that has contributed to 
the uncertainty of ethylene oxide risk assessment is whether 
endogenous ethylene oxide production can be used as a 
starting point for setting limit values. This is based on the 
misleading statement that endogenous ethylene oxide pro-
duction would result in an increase in the individual risk for 
malignancy by 1 in 10,000 (see above). This is definitely 
a heavy overestimation. If we extrapolate the endogenous 
formation rate from the haemoglobin adduct frequency in 
unexposed human individuals by linear regression we arrive 
at a workplace exposure equivalent of 0.003  ppm, which 
should represent a lifetime tumour risk increase of far less 
than 1 in 100,000. Therefore, endogenous formation rate is 
no relevant risk factor and should not be considered as a 
starting point for setting limit values.
An interesting open question that might support risk 
assessment addresses the observed tissue selectivity of 
ethylene oxide in different animal models. Why is the lung 
a particularly sensitive organ in the mouse while brain is 
more susceptible to ethylene oxide-induced tumorigenesis 
in rats? This is not necessarily expected because ethylene 
oxide does not require metabolic activation and should easily 
penetrate into all, even the bradytrophic tissues. One possi-
ble reason could be species differences in the tissue-specific 
glutathione depletion, which would probably be an irrelevant 
high dose effect. Another, more important mechanism could 
be cell-type specific efficacy of DNA repair mechanisms, 
such as O6-methyl guanosine methyltransferase (MGMT) 
prevalence.
Formaldehyde
General information Formaldehyde exposure is attributed 
to exogenous sources (environment, indoor air, cosmetics, 
workplace) as well as to endogenous sources (metabolic 
intermediate). Due to the high chemical reactivity, formal-
dehyde causes local irritation and acute and chronic toxicity 
after direct contact in target tissues. Furthermore, formalde-
hyde is considered to be carcinogenic, inducing squamous 
cell carcinoma of the nose in experimental animals and with 
less compelling evidence nasopharyngeal carcinomas in 
humans. Also there is limited evidence for increased occur-
rence of leukaemia, nevertheless, without mechanistic or 
experimental support. On this database, formaldehyde was 
classified by IARC as a human carcinogen (Category 1). 
Considering the mode of action, the German MAK Com-
mission classified formaldehyde in Category 4 for carcino-
gens, i.e. carcinogenic substances for which an increase in 
cancer risk is not expected provided that the MAK value 
is observed. The basis for this decision is, in spite of the 
induction of DNA lesions down to the low-dose levels, the 
assumption that an increase in mutagenicity and carcino-
genicity is prevented as long as irritation and accelerated 
cell proliferation in the target cells are excluded. Therefore, 
a MAK value of 0.3 ppm (0.37 mg/m3) was established in 
2000. Since then a number of publications have appeared 
that deal with the quantification of DNA lesions in the target 
tissues and the relationship of endogenously induced DNA 
damage compared to the same DNA lesions caused by exog-
enous exposure.
Comparison of  endogenous formaldehyde formation 
with exogenous contribution from food sources The Euro-
pean Food and Safety Authority (EFSA) compared the 
endogenous formaldehyde levels in humans with exog-
enous contribution from food sources. Formaldehyde is an 
intermediate generated within amino acid metabolism; an 
intracellular concentration of around 12 mg formaldehyde/L 
(400 μM) was estimated from measurements in nasal tissue 
(EFSA 2013). This leads to an estimated dose of approxi-
mately 0.61–0.91 mg/kg bw per minute or 878–1310 mg/
kg bw per day, assuming a half-life of 1–1.5 min. Compared 
with formaldehyde turnover and the background levels of 
formaldehyde from food sources (1.7–1.4 mg/kg bw per day 
for a 60–70 kg person), including that from dietary metha-
nol, the relative contribution of exogenous formaldehyde 
from consumption of animal products (milk, meat) from 
animals exposed to formaldehyde-treated feed was negligi-
ble (< 0.001%) (EFSA 2014b).
In addition, gene expression profiles were used to investi-
gate whether a NOTEL (No Observed Transcriptional Effect 
Level) can be derived. The intent of the discussion in the 
joint working group of MAK and SKLM was to attain a risk 
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assessment for the carcinogenicity of formaldehyde at the 
low dose level, taking into account most recent data.
Dose–response relationship of the carcinogenicity of formal‑
dehyde The Committee for Risk Assessment (RAC) of the 
European Chemicals Agency (ECHA) considered in 2012 
all three industrial cohorts, comprising about 50 000 work-
ers exposed to formaldehyde (Coggon et al. 2003; Haupt-
mann et al. 2004; Marsh and Youk 2005; Pinkerton et  al. 
2004). It has been concluded that the hypothesis of a causal 
association between formaldehyde exposure and mortality 
from nasopharyngeal cancer is supported only by evidence 
coming from the investigation of 4261 workers employed in 
plant 1 (Wallingford plant), one of the 10 plants investigated 
within the National Cancer Institute cohort (Hauptmann 
et al. 2004; Marsh and Youk 2005). It is, however, possible 
that this unique grouping of nasopharyngeal tumour cases 
in this one plant influencing the outcome of the entire NCI 
cohort could be caused by factors other than exposure to for-
maldehyde since three workers of the Wallingford plant had 
acquired nasopharyngeal tumours after a very short period 
of employment on a job with formaldehyde exposure. The 
meta-analysis (Bachand et al. 2010) on formaldehyde expo-
sure and leukaemia demonstrates that there is little consist-
ent evidence for a causal relationship and that the overall 
increased risk previously reported was driven by PMR (Pro-
portionate Mortality Ratio) studies (ECHA 2012).
Regarding data from experimental animals, the infor-
mation on nasal carcinogenesis in rats after inhalation 
(McGregor et al. 2010) showed that the tumour incidence 
was slightly elevated at an exposure level of 6 ppm formal-
dehyde and clearly elevated at 10 ppm and above, whereas at 
0.7 and 2 ppm no additional nasal tumours occurred. Thus, 
there is a non-linear dose–response relationship. However, it 
must be considered that marginal increases in tumour rates 
cannot be detected with approximately 100 animals.
Gene polymorphism and  gene knockout No important 
gene polymorphism that caused increased susceptibility 
to formaldehyde as measured by DNA–protein cross-links 
and SCE-induction was identified in glutathione-dependent 
formaldehyde dehydrogenase (FDH), blood glutathione 
S-transferase (GST) M1 or GSTT1 of humans (Just et  al. 
2011; Zeller et al. 2011a, b, 2012).
In contrast, an association between genotoxicity biomark-
ers (CA, comet assay) and polymorphic genes coding for 
xenobiotic-metabolising or DNA repair enzymes was found 
in formaldehyde-exposed workers (84 anatomy pathology 
laboratory workers; 0.38 ppm formaldehyde ± 0.03 ppm) 
compared with controls. Regarding the effect of suscepti-
bility biomarkers, results suggest that polymorphisms in 
CYP2E1 and GSTP1 involved in metabolism as well as 
XRCC1 and PARP1 involved in DNA repair pathways are 
associated with higher genetic damage in formaldehyde-
exposed subjects (Costa et al. 2015).
Endogenous formaldehyde is removed by the enzyme 
alcohol dehydrogenase 5 (ADH5/GSNOR), and Adh5(-/-
)-deficient mice accumulate formaldehyde-induced DNA 
adducts. Repair in liver, kidney and blood stem cells is 
mediated by FANCD2, a DNA cross-link repair protein. 
Adh5(-/-)Fancd2(-/-) mice lacking protection show greatly 
reduced bone marrow cellularity and complete failure of 
haematopoiesis within 3–7 weeks after birth. Increased lev-
els of formaldehyde-induced DNA damage also cause karyo-
megaly and dysfunction of hepatocytes and nephrons. Bone 
marrow transplantation not only rescued haematopoiesis but, 
surprisingly, also preserved nephron function. Nevertheless, 
all of these animals eventually developed fatal malignancies. 
Formaldehyde, therefore, appears to be a relevant source of 
endogenous DNA damage that is counteracted in mammals 
by a conserved protection mechanism (Pontel et al. 2015).
Genotoxicity of formaldehyde Formaldehyde induces DNA 
base damage, DNA–protein cross-links as well as DNA-
DNA cross-links. DNA–protein cross-links and DNA-DNA 
cross-links occurred in rats starting from 0.3 ppm (0; 0.3; 
0.7; 2; 6; 10 ppm 14C-formaldehyde, 6 h (Casanova et  al. 
1989)) and in monkeys starting from 0.7  ppm (0; 0.7; 2 
or 6  ppm 14C-formaldehyde, 6  h (Casanova et  al. 1991)) 
(reviewed in Greim 2002; McGregor et al. 2010).
Using stable isotopes (13CD2-formaldehyde, combined 
with MS analysis), Swenberg et al. (2011) were able to dis-
tinguish between endogenously and exogenously induced 
N2-hydroxymethyl-dG adducts (Fig. 7). The endogenous 
steady-state level of DNA base damage accounts for 47 ± 18 
lesions/108 dG (12 ± 4.5 lesions/108 nucleotides) resulting 
from an endogenous formaldehyde burden of 100 µM per 
cell, measured in human blood and predominantly generated 
as an intermediate of the amino acid metabolism. In vivo 
formaldehyde exposure (6 h inhalation, rat) did not yield a 
threshold at which no additional base damage in the nose 
was detectable, but there was a sublinear dose–response 
relationship. Furthermore, the level of endogenous DNA 
lesions was exceeded only after exposure concentrations of 
10 ppm and above. In other organs such as blood and bone 
marrow, no additional DNA base lesions were detected (Lu 
et al. 2010; Swenberg et al. 2011; Yu et al. 2015).
N2-Hydroxymethyl-dG DNA adducts (N2-HOMe-dG) 
were also shown to be the main hydrolysis product of sev-
eral formaldehyde-induced DNA–protein cross-links inves-
tigated (Fig. 8). Both DNA lesions (N2-HOMe-dG and dG-
Me-Cys) were examined with ultrasensitive nano-liquid 
chromatography–tandem mass spectrometry. DNA adducts 
resulting from exogenous formaldehyde inhalation were 
found in the nasal respiratory epithelium in the rat study 
(28-day, 2 ppm exposure) as well as in the monkey study 
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(2-day, 6 ppm exposure), but not in any other tissue distant 
to the site of initial contact (Yu et al. 2015). Upon expo-
sure of rats to lower concentrations of 0.001, 0.03, 0.3 ppm 
 [13CD2]-formaldehyde for 28 days (6 h/day) by nose-only 
inhalation DNA adducts resulting from exogenous exposure 
were not detectable in any tissue sample, including the most 
susceptible nasal epithelium. Endogenous adducts were pre-
sent in all analysed tissues (nasal epithelium, bone marrow, 
peripheral blood mononuclear cells (PBMCs), trachea, liver, 
hippocampus, olfactory bulbs, cerebellum and lung). Alto-
gether, formaldehyde exposure at 0.001, 0.03 and 0.3 ppm 
did not alter the levels of endogenous formaldehyde induced 
DNA adducts or DNA–protein crosslinks (Leng et al. 2019). 
Therefore, the plausibility of the potential induction of leu-
kaemia induced upon inhalation of formaldehyde must be 
seriously questioned.
Moreover, the amounts of exogenous formaldehyde-
induced N2-HOMe-dG adducts were 3- to eightfold and 5- to 
11-fold lower than the average levels of endogenous formal-
dehyde-induced N2-HOMe-dG adducts in rat and monkey 
nasal respiratory epithelium, respectively (inhalation of 2 
or 6 ppm 13CD-formaldehyde, 6 h/d, 28 days). Thus, our 
advanced understanding of endogenous formaldehyde levels 
suggests that the risk of inhaled formaldehyde is apparently 
overestimated (Yu et al. 2015).
Fig. 7  Formation of hydroxymethyl DNA adducts induced by formaldehyde (Swenberg et al. 2011)
Fig. 8  Hydrolysis of DNA–pro-
tein cross-links (Yu et al. 2015)
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DNA–protein cross-link formation has been studied by 
an ultrasensitive and selective liquid chromatography-mass 
spectrometry method, where monkeys and rats were exposed 
to (13CD2)-labelled formaldehyde. This allowed the differ-
entiation between DNA–protein cross-links from inhaled 
formaldehyde and DNA–protein cross-links from endog-
enous (naturally) formaldehyde. Monkeys were exposed at 
6 ppm, 6 h per day for 2 days. Labelled DNA–protein cross-
links were detected in the nasal tissue, but not in peripheral 
blood mononuclear cells, bone marrow or liver. In the nasal 
tissue, formation of endogenous DNA–protein cross-links 
was about three times higher than the exogenously generated 
ones. Endogenous DNA–protein cross-links were detected 
in all investigated tissues in varying amounts. Thus, endog-
enous DNA–protein cross-links were almost threefold higher 
in the liver than in the nasal tissue. When rats were exposed 
at 15 ppm, 6 h per day up to 4 days, exogenously generated 
DNA–protein cross-links were again only detected in the 
nasal tissue. Extension of exposure to 7 days (2 ppm, 6 h 
per day) resulted in a more pronounced formation of exog-
enous DNA–protein cross-links in nasal tissues with a pro-
portion of nearly 50% relative to endogenous DNA–protein 
cross-links. In the post-exposure period, the amount of exog-
enously generated DNA–protein cross-links decreased by 
20% within the first 24 h, followed by an even slower repair 
(Lai et al. 2016). It is noted that inhaled formaldehyde only 
caused DNA–protein cross-link formation in the nasal tis-
sue; additional DNA–protein cross-link formation in internal 
organs was neither detected nor would it be plausible, due to 
the high reactivity of formaldehyde at the site of first contact 
(Nielsen et al. 2017). Rats were exposed by inhalation to 
either 0 or 2 ppm  [13C2H2]-formaldehyde for 7 or 28 days, or 
28 days followed by a 7-day recovery (6 h/day). Formation 
of exogenous  N6-formyllysine protein adducts was observed 
in nasal epithelium and to some extent in trachea but not in 
distant tissues of lung, bone marrow, or white blood cells, 
with a twofold increase over endogenous  N6-formyllysine 
over a 3-week exposure period. These results parallel the 
behaviour of DNA adducts and DNA–protein cross-links, 
with protein adducts cleared faster than DNA–protein cross-
links, and point to the potential utility of  N6-formyllysine 
protein adducts as biomarkers of formaldehyde (Edrissi et al. 
2017).
Repair of formaldehyde‑induced DNA lesions Repair of the 
formaldehyde-induced intra-strand cross-links is mediated 
by the nucleotide excision repair (NER) pathway (Kawani-
shi et  al. 2014). Formaldehyde-induced DNA–protein 
cross-links may be repaired by the NER repair combined 
with homologous recombination (HR) (de Graaf et al. 2009; 
Kawanishi et al. 2014; McHale et al. 2014). Furthermore, 
DNA–protein cross-links may partly be broken down by 
specific proteolytic enzymes, allowing translesion synthe-
sis polymerases (a potentially mutagenic pathway) to repli-
cate across DNA-peptide lesions. Additionally, a tolerance 
pathway also exists, allowing replication across unrepaired 
DNA–protein cross-links lesions that may generate DNA 
strand breaks as intermediates (potentially causing genomic 
rearrangements) followed by strand ligation (Stingele et al. 
2015). Not least, the Fanconi anaemia pathway is important 
in the repair of inter-strand DNA cross-links and DNA–pro-
tein cross-links (Kirsch-Volders et al. 2014; McHale et al. 
2014; Ren et al. 2013; Schneider et al. 2015).
Risk assessment for  carcinogenicity at  the  low dose level 
on  the  basis of  induction of  DNA base damage Swenberg 
et al. (2011) have undertaken a tumour risk assessment for 
formaldehyde under different “worst-case” assumptions. 
Assuming that (1) all nasal tumours are induced by formal-
dehyde exposure and (2) a linear increase of the tumour 
risk is accompanied by an increased number of DNA-dG 
adducts, the authors estimated a nearly tenfold lower tumour 
risk for nasal tumours than was derived by the US EPA (US 
Environmental Protection Agency) from the human formal-
dehyde-based carcinogenesis data after conservative linear 
extrapolation from the high dose level.
The new molecular dosimetry information for formal-
dehyde-induced DNA adducts in the bottom-up approach 
was used to estimate upper-bound lifetime human naso-
pharyngeal cancer and leukaemia risks that might arise from 
continuous inhalation exposure to 1 ppm formaldehyde. 
Comparison of the resulting bottom-up risk estimates with 
corresponding top-down estimates derived by US EPA from 
epidemiological data for exposed workers shows the latter 
to be markedly higher (Starr and Swenberg 2013). Updated 
estimates of added risk for leukaemia and nasopharyngeal 
cancer rely on robust estimates of tissue-specific endogenous 
and exogenous formaldehyde-induced DNA adducts in mon-
keys and of DNA-adduct elimination half-life in rats. The 
risk to humans from inhaled formaldehyde may have been 
overestimated with the top-down approach and the role of 
endogenous formaldehyde in the development and progres-
sion of bone marrow toxicity and leukaemia may have been 
underappreciated. It is, therefore, important to consider 
endogenous sources of DNA–protein cross-links and DNA 
mono-adducts with the bottom-up approach where there is 
little or no empirical evidence of a positive dose–response at 
low exogenous exposure levels. This approach can be used 
as a useful “reality check” during the risk assessment pro-
cess (Andersen et al. 2019; Farland et al. 2019; Starr and 
Swenberg 2016; Yu et al. 2015).
Uptake of formaldehyde in the nose of rats, monkeys and 
humans was estimated by means of an anatomically accurate 
computational fluid dynamics model, regarding net over-
all absorption and potential exhalation of formaldehyde on 
nasal airway walls. At ≥ 1 ppm, the predicted nasal uptake 
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was about 99, 87 and 85% for rats, monkeys and humans, 
respectively. At lower concentrations the predicted uptake 
was nonlinear. At an exposure concentration of 1  ppb, 
predicted nasal uptake was 17.5 and 42.8% in the rat and 
monkey model. However, based on this model, in case of 
humans, the exhalation would even exceed the inhalation, 
which does not appear to be plausible. Higher fluxes were 
predicted to occur in regions located in the more anterior 
sections of the nose (Schroeter et al. 2014).
DNA damage and  mutations in  target cells An important 
question concerns the target cells of formaldehyde-induced 
carcinogenesis. The relevant target cells for nasal tumours 
are the basal cells, whereas the development of DNA dam-
age is usually quantified in the entire nasal mucosa. For-
maldehyde is a highly reactive substance that undergoes 
rapid metabolism and may not reach the target cells of 
nasal carcinogenesis at the low dose level. Specific stud-
ies addressing the induction of any type of DNA damage, 
including DNA–protein cross-links and DNA–DNA cross-
links in basal cells are missing (Speit et al. 2011). Therefore, 
the biological relevance of the induced DNA damage and 
their potential conversion into mutations would depend on 
whether the relevant target cells (basal cells) are reached and 
to what extent these target cells are stimulated to prolifera-
tion. Also data on the induction of micronuclei can be used 
to support this theory. In studies with volunteers exposed 
to 0.7 ppm formaldehyde in the inhaled air (4 h/day, 5 days 
with 0.3–0.4 ppm and 4 peaks of 0.6–0.8 ppm for 15 min), 
an increase in the incidence of micronuclei was not detected 
in exfoliated nasal mucosa cells (Zeller et al. 2011a).
Impact of formaldehyde on transcription and gene expres‑
sion profiles One important aspect in formaldehyde-
induced carcinogenicity consists in its impact on cell pro-
liferation, which in rats is elevated at 6  ppm and above 
(McGregor et  al. 2010; Speit et  al. 2011). This raises the 
question whether transcriptional changes in the expression 
of genes related to cell growth may be used as sensitive 
markers, at the mRNA-level, which may serve for the deri-
vation of a NOTEL for cell proliferation at the target cells 
(Andersen et al. 2010; Zarbl et al. 2010). Rats were exposed 
to 0 (control), 0.7, 2, 6, 10 and 15 ppm formaldehyde 6 h/
day for 1, 4 or 13  weeks. Nasal tissue concentrations of 
formaldehyde acetal  (CH2(OH)2), GSH, GS-formaldehyde 
and DNA–protein cross-links were analysed by means of a 
pharmacokinetic model, taking into account the background 
formaldehyde acetal and GSH levels. For DNA–protein 
cross-links no background levels were predicted reproduc-
ing the observed data of Casanova et al. (1994). The cellular 
levels of formaldehyde acetal and DNA–protein cross-links 
only showed minor increases at exposures at 0.7 and 2 ppm 
formaldehyde. At these levels, GSH decreased slightly; 
above 4  ppm, the changes were more pronounced. Histo-
pathology showed nasal lesions at 2  ppm and epithelial 
cell proliferation at higher concentrations. The lowest tran-
scriptional benchmark dose (BMD) for significant changes 
in gene expression (sensitive response genes) was approxi-
mately 1 ppm in comparison to the transcriptional BMDs 
for significant changes in the cell cycle (3 ppm) and DNA 
damage pathways (4 ppm) after 13 weeks of exposure. At 
all exposure times at 6  ppm and above the expression of 
sensitive response genes was elevated and reached a plateau 
at 10 ppm. The authors concluded that formaldehyde levels 
below 1 or 2 ppm would not affect gene expression above 
effect potentially evoked by endogenous formaldehyde lev-
els within the epithelial cells (Andersen et al. 2010, 2008).
In addition to DNA damage and gene expression, formal-
dehyde exerts also epigenetic effects leading to the modifi-
cation of histone H3 (Yoshida and Ibuki 2014), as well as 
altered patterns of miRNA (Chappell et al. 2016; Chen et al. 
2017; Rager et al. 2011, 2013, 2014).
Non-human primates (cynomolgus macaques) were 
exposed for 6 h/day for 2 days to 0, 2, or 6 ppm formal-
dehyde and the miRNA expression profile of nasal tissue 
from the maxilloturbinate region was analysed. Based on 
the miRNA microarray analysis, the expression of four most 
altered miRNAs was confirmed by RT-PCR. In this analy-
sis, exposure to 2 ppm formaldehyde caused significantly 
increased expression of miR-125b and decreased expres-
sion of miR-145. In response to 6 ppm formaldehyde miR-
125b and miR-152 were significantly increased in expres-
sion whereas miR-145 and miR-142-3p were significantly 
decreased. The evaluation of predicted targets of miR-125b 
revealed decreased expression of genes involved in apoptosis 
signalling (Rager et al. 2013). Rats were exposed by inhala-
tion to either 0 or 2 ppm formaldehyde for 7 or 28 days, or 
28 days followed by a 7-day recovery (6 h/day). miRNAs 
showed altered expression in the nose (84, 59, 0 number of 
formaldehyde-responsive miRNAs, increased or decreased, 
in the three exposure groups) and circulating white blood 
cells (31, 8, 3) but not in the bone marrow. In the same study 
applying the same exposure scenario microarray analysis 
was performed to measure transcript levels. In nasal tissue 
expression levels of 830 mRNA transcripts was altered after 
7 days compared to 42 transcripts after 28 days of exposure. 
In white blood cells, the distribution was 96 and 130 altered 
mRNA transcripts, respectively. In the nose, the decreased 
expression of the let-7 family of miRNAs implicated a 
reduced activity of these tumour suppressors that act on 
apoptosis/cell proliferation pathways. Beside this, enrich-
ment analysis of miRNAs and mRNAs pointed to alteration 
in the inflammation and immune system in the examined 
tissues (Rager et al. 2014).
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Summary and  perspective Formaldehyde induces nasal 
tumours with a sublinear dose–response relationship. While 
IARC–based on hazard–assigned it to Group 1 (carcinogenic 
to humans), the German MAK Commission classified it in 
group 4, defining a MAK value which protects from carci-
nogenicity. The latter approach has been supported by recent 
developments in the quantification of both endogenous and 
exogenously induced DNA adducts. Thus, carcinogenicity 
is due to the induction of different types of DNA lesions 
as well as to an increase in cell proliferation. DNA damage 
is generated already at the low dose level. However, after 
inhalation, levels of DNA damage in internal organs indica-
tive for systemic toxicity, in a similar magnitude as levels 
derived from the endogenous formaldehyde burden were 
not reached until about 100 ppm. With respect to the nose 
as the critical target organ for nasal tumours, it is unclear 
whether inhaled formaldehyde at the low dose levels reaches 
the basal cells as target cells at all or whether it undergoes 
rapid metabolism and/or reaction in the upper cell layers. To 
clarify this aspect, further research is required. In addition 
to DNA damage, accelerated cell proliferation is needed 
for relevant conversion of DNA lesions into mutations. In 
this context, data from animal experiments analysing gene 
expression profiles revealed a transcriptional BMD at the 
mRNA level of 1 ppm for significant changes in sensitive 
response genes associated with cellular stress, inflamma-
tion, and cell proliferation. At miRNA level, 2 ppm induced 
transcriptional responses such as immune system/inflamma-
tion and apoptosis/proliferation. These data are in agreement 
with the irritation of the eye or nose and throat in human vol-
unteers observed at 0.5 or 1 ppm. Therefore, considering the 
currently available database it can be assumed that below 
the level of irritation, there is no relevant additional risk of 
nasal tumours at the low dose level, such as exposure at the 
MAK value of 0.3  ppm (0.37  mg/m3). Also, mechanistic 
and experimental data appear to exclude an elevated risk of 
internal organs, including lymphoma. This is supported by 
the bottom-up approach assessing the extent of DNA lesions 
due to endogenous and exogenous formaldehyde exposure, 
providing convincing evidence that added cancer risk from 
exposure to all airborne formaldehyde concentrations is far 
lower than risks estimated by linear extrapolation from high 
exposure levels. This approach can be used as a useful “real-
ity check” during the risk assessment process where there is 
little or no empirical evidence of a positive dose–response 
at low exogenous exposure levels.
Absence of endogenous background levels 
of the same or similar DNA lesions
Aflatoxin  B1
Introduction Aflatoxin  B1  (AFB1) is a mycotoxin produced, 
among other fungi, by Aspergillus flavus and contaminates a 
variety of food items including groundnuts, tree nuts, dried 
fruit, spices and figs. Human exposure to the mycotoxin is 
particularly high in those regions of the world in which the 
above-mentioned foods are improperly stored. Moreover, in 
these regions a high prevalence of hepatitis B virus infec-
tions is observed, and epidemiological studies support the 
view that  AFB1 and hepatitis B virus infections synergisti-
cally interact to induce hepatocellular carcinomas in humans. 
 AFB1 is per se biologically inactive, but following ingestion 
can be metabolically activated by cytochromes P450 1A2 
and 3A4 to  AFB1-8,9-epoxide (Fig. 9) in rats and humans 
(Busby and Wogan 1984; Croy et al. 1978; Croy and Wogan 
1981a; Croy and Wogan 1981b; Groopman et al. 1981; Lin 
et al. 1977; Martin and Garner 1977). The epoxide may react 
with DNA to form the primary  AFB1-DNA adduct 8,9-dihy-
dro-8-(N7-guanyl)-9-hydroxyaflatoxin  B1  (AFB1-N7-Gua), 
which in turn can give rise to two secondary lesions, an apu-
rinic site or the  AFB1-formamidopyrimidine  (AFB1-FAPY) 
adduct (Fig. 9). The highly persistent  AFB1-FAPY adduct 
that consists of an equilibrium mixture of two presumably 
rotameric forms is thought to be responsible for the strong 
genotoxicity and mutagenicity of the mycotoxin that ulti-
mately may lead to liver cancer (Smela et al. 2002).
AFB1‑mediated liver tumour induction in rats and rainbow 
trout Some strains of rats (e.g. the Fischer 344 strain) are 
particularly sensitive regarding liver tumour induction by 
 AFB1. In this context, a rather limited number of studies, in 
which  AFB1 was administered to rats p.o. and in which car-
cinogenicity data are available, have been published (Butler 
and Barnes 1968; Elashoff et al. 1987; Epstein et al. 1969; 
Newberne and Rogers 1973; Nixon et al. 1974; Wogan and 
Newberne 1967; Wogan et  al. 1974) and are summarized 
in Table 4. Taken together, these studies demonstrate that 
 AFB1 given orally induces liver tumours in rats in a dose-
dependent manner and that liver tumour induction definitely 
also occurs at concentrations well below 1  µg/kg bw/day, 
the only exception being a study by Elashoff et al. (1987), 
in which doses of 0.25 and 0.75  µg  AFB1/kg bw/day did 
not lead to liver tumours in male and female Fischer 344 
rats. However, as discussed by Benford et al. (Benford et al. 
2010), most of these studies are actually not suited for dose–
response modelling when wanting to assess the risk derived 
from the presence of  AFB1 in food, since  AFB1 was admin-
istered in a single dose or produced a 100% response in all 
treated animal groups. One study that was used for the cal-
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culation of margin of exposure values for  AFB1 (Benford 
et al. 2010) and in which human-relevant dietary  AFB1 lev-
els were tested was reported by Wogan et al. (1974). Male 
Fischer 344 rats were fed 1, 5, 15, 50 or 100 ppb  AFB1 (cor-
responding to a dose of 0.04, 0.2, 0.6, 2 and 4 µg  AFB1/
kg bw/day, respectively) for up to 104 weeks and a dose-
dependent liver tumour incidence was observed (Table 4), 
even the lowest dose used (0.04 µg/kg bw/day) being able to 
induce liver tumours in 2 out of 22 animals.
In contrast to rats, mice show a remarkable resistance 
towards  AFB1. This is due to the fact that mice constitutively 
express glutathione S-transferase Yc, which is extremely 
efficient in detoxifying the  AFB1-8,9-epoxide (Buetler and 
Eaton 1992; Buetler et al. 1992; Eaton and Gallagher 1994; 
Hayes et al. 1991; Ramsdell and Eaton 1990).
In rainbow trout (Oncorhynchus mykiss) the activation 
of  AFB1 to  AFB1-8,9-epoxide is mainly catalysed by CYP 
2K1 (Williams and Buhler 1983) and, as in mammals, 
 AFB1-N7-Gua is formed and spontaneously converted to 
 AFB1-FAPY (Bailey et al. 1988; Croy et al. 1980). Further-
more,  AFB1 is able to induce time- and dose-dependently 
liver tumours in rainbow trout (Bailey et al. 1996b). This 
has been documented in at least seven studies (Ayres et al. 
1971; Bailey et al. 1987, 1994, 1998; Dashwood et al. 1989; 
Lee et al. 1968, 1971) and Table 5 lists the data of five of 
them. In the other two studies (Bailey et al. 1998; Dashwood 
et al. 1989) a dose-dependent induction of liver tumours in 
rainbow trout was also shown, but the tumour incidence data 
were only documented in form of figures so that they could 
not be listed. Finally, more recently it has been documented 
that  AFB1 also elicits a linear dose–response curve when 
administered at ultra-low doses (Williams 2012; Williams 
et al. 2009). Although the latter study only reported prelimi-
nary results, which are in the process of being published, 
these demonstrate that the  AFB1 dose-tumour response is 
linear even at ultra-low doses. All in all, the studies clearly 
indicate that, as in the case of rats, there is no “threshold” 
for the hepatocarcinogenic effect of  AFB1 in rainbow trout.
AFB1‑DNA adduct formation in the liver of rats and rainbow 
trout In a study by Lutz (1987) tritiated  AFB1 was admin-
istered p.o. to Fischer 344 rats on 10 consecutive days, liver 
DNA was isolated 24 h after the last dose and  AFB1-DNA 
binding was determined. A linear dose–response relation-
ship was found over four orders of magnitude and particu-
larly in the low dose range, while in the high dose range a 
flattening out of the curve was seen, probably due to satu-
ration of the activating enzyme systems (Lutz 1987). The 
lowest dose used in this study was 1 ng  AFB1/kg bw, which 
corresponds to about 60 ng per man, i.e. a dose that is taken 
up daily in certain areas of Africa and Asia. In a later study 
by the above-mentioned research group (Buss et al. 1990) 
tritiated  AFB1 was administered p.o. to Fischer 344 rats at 
three exposure levels for 4, 6 or 8 weeks, liver DNA was 
isolated and  AFB1-DNA binding was determined. After 
4 weeks the  AFB1-DNA adduct level did not increase sig-
nificantly, thereby indicating that a steady-state for adduct 
formation and removal had nearly been reached, whereas 
Fig. 9  Metabolic activation 
of aflatoxin  B1  (AFB1) to 
 AFB1-8,9-epoxide and subse-
quent formation of the primary 
 AFB1-DNA adduct 8,9-dihydro-
8-(N7-guanyl)-9-hydroxyafla-
toxin  B1  (AFB1-N7-Gua), 
which can give rise to two 
secondary lesions, an apu-
rinic site or the ring-opened 
 AFB1-formamidopyrimidine 
(FAPY) adduct. CYP, 
cytochrome P450; dR, deoxy-
ribose
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after 8 weeks the  AFB1-DNA adduct level was proportional 
to the dose (Buss et  al. 1990). In a study by Cupid et  al. 
(2004) the levels of  AFB1-DNA adducts were quantified by 
accelerated mass spectrometry following the oral adminis-
tration of very low doses (i.e. dietary levels of exposure) of 
 AFB1 (0.16  ng/kg bw-12.3  µg/kg bw). It could be shown 
that  AFB1-DNA adduct formation was linear over the whole 
dose range (Cupid et al. 2004).
A dose-dependent linear increase in the number of liver 
 AFB1-DNA adducts was also observed after feeding rain-
bow trout with human-relevant concentrations of  AFB1 
over a period of one to four weeks (Bailey et  al. 1998, 
1994; Dashwood et al. 1988, 1989). The rate of repair of 
Table 4  Induction of liver tumours in rats after dietary administration of aflatoxin  B1 ( reproduced from EFSA 2007)
Rat strain/Sex Dose (µg/kg bw/
day)
Duration of dosing Tumour inci-
dence
Comments References no
Fischer 344/ male 0 80 w 0/25 Wogan and Newberne (1967)
0.75 68 w 12/12
15 35–52 w 6/20
50 35–41 w 18/22
50 2 w 1/16 after 82 w
Fischer 344/ female 0 80 w 0 Wogan and Newberne (1967)
0.75 68 w 13/13
15 60–70 w 11/11
50 64 w 4/4
50 2 w 1/13 after 82 w
Porton/female 0 104 w 0/34 Butler and Barnes (1968)
5 104 w 5/30
25 104 w 26/33
Porton/male 0 104 w 0/46 Butler and Barnes (1968)
4 104 w 17/34
25 104 w 25/25
Wistar/male 0 147 d 0/24 Epstein et al. (1969)
12.5 147 d 8/13 after 742 d
25 147 d 13/18 after 622 d
50 147 d 12/14 after 611 d
CDR/male 0 104 w 0/50 Newberne and Rogers (1973)
4 104 w 24/50
Fischer/female 0 104 w 0/15 Nixon et al. (1974)
1 104 w 1/15
Fischer/male 0 104 w 0/16 Nixon et al. (1974)
0.8 104 w 5/13
Fischer 344/male 0 0/18 Wogan et al. (1974)
0.04 104 w 2/22
0.2 93 w 1/22
0.6 96 w 4/21
2 82 w 20/25
4 54 w 28/28
Fischer 344/female 0 104 w 0/144 Elashoff et al. (1987)
0.25 104 w 0/24
0.75 104 w 0/24
2.25 104 w 1/24
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 AFB1-DNA adducts in trout is much slower than in mam-
mals: the “half-life” of the  AFB1-N7-Gua adduct is 7.5 h in 
rats, while it is about 21 days in trout (Bailey et al. 1988). 
As noted by Bailey et al. (1996b) the loss of  AFB1-N7-Gua 
adducts can be due to chemical conversion, depurination or 
enzymatic removal and is not a first-order process, so that 
the above-mentioned values do not reflect true half-lives. 
However, the long “pseudo half-life” of the  AFB1-N7-Gua 
adduct (21 days) in rainbow trout could largely be due to 
the decreased ability of this animal species to repair bulky 
DNA adducts.
AFB1-DNA adduct levels show a high correlation with 
tumour incidence in rats as well as rainbow trout (Bailey 
et al. 1998; Bechtel 1989; Dashwood et al. 1989; Otteneder 
and Lutz 1999). Based on these results it has been postulated 
that the adducts persisting in the liver of treated animals 
induce the formation of hepatic tumours with a similar effi-
ciency in both animal species (Bailey 1994; Bailey et al. 
1994; Dashwood et al. 1990; Dashwood et al. 1992). Moreo-
ver, Otteneder and Lutz (1999) analysed the DNA adduct 
levels after the repeated administration of 27 carcinogens, 
including  AFB1, to rats or mice and, to correlate them with 
tumour incidence, the DNA adduct levels measured at a 
given dose were normalized to the dose that results in a 50% 
tumour incidence under the conditions of a 2-year bioassay 
 (TD50). The lowest calculated adduct level leading to a 50% 
liver tumour incidence in rat liver (“adduct level at  TD50”) 
was that corresponding to  AFB1 (Otteneder and Lutz 1999). 
In this context, the fact that the adduct level at  TD50 for 
 AFB1 was 53 per  10
8 nucleotides and 2082 per  108 nucleo-
tides for dimethylnitrosamine was interpreted by Otteneder 
and Lutz (1999) to mean that the  AFB1-DNA adducts are 
about 40 times more potent in inducing liver tumours than 
the DNA adducts formed by dimethylnitrosamine. Boysen 
et al. (2009) reviewed the scientific literature to evaluate 
the mechanistic evidence for the involvement of N7-guanine 
adducts formed by nitrosourea compounds, nitrosamines, 
hydrazines and olefins in mutagenesis and concluded that 
there is little to no evidence that N7-guanine adducts or their 
depurination product, the apurinic sites, are the cause of 
mutations in cells and tissues. In contrast, the ring-opened 
lesions derived from N7-guanine adducts are much more 
persistent and have a higher mutagenic potency. This 
also applies to  AFB1: it has been shown that the mutation 
Table 5  Induction of liver tumours in rainbow trout after dietary administration of aflatoxin  B1
AFB1 level (ppb) Duration of 
dosing
Tumour incidence Comments References
0 12 mo 0/50 Croy et al. (1980)
4 12 mo 10/20
0 15 mo 0/50 Croy et al. (1980)
0.4 15 mo 15/106
4 15 mo 65/108
0 12 mo 0/20 Bailey et al. (1988)
4 12 mo 10/40
8 12 mo 40/57
20 12 mo 62/80
0 16 mo 0/40 Bailey et al. (1988)
4 16 mo 14/40
8 16 mo 32/57





0 4 w 0/49 sacrificed 11 mo after  AFB1 exposure Lee et al. (1968)
20 4 w 5/49
0 2 w 0/192 sacrificed 9 mo after onset of  AFB1 exposure Lee et al. (1971)
4 2 w 25/382
8 2 w 98/387
16 2 w 194/389
32 2 w 287/389
64 2 w 302/383
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frequency of  AFB1-N7-Gua is much lower (about sixfold) 
than that of  AFB1-FAPY (Bailey et al. 1996a; Smela et al. 
2002).
While no study relating cytotoxicity or cell proliferation 
rate to  AFB1-mediated liver tumour formation in rats has 
been published up to now, a report by Nunez et al. (1990) 
analysed the relationship between  AFB1 metabolism and 
cytotoxicity in rainbow trout treated with 0.05, 0.1, 0.25 or 
0.5 mg/l water for 30 min and sacrificed 1 or 2 weeks later. 
After two weeks 4 out of 11 animals exposed to 0.25 mg/l 
water exhibited severe hepatic cytotoxicity, while all 8 ani-
mals exposed to 0.5 mg/l water showed a severe cytotoxic 
response (Nunez et al. 1990). In contrast, fish exposed to 
0.05 or 0.1 mg/l water did not show any signs of cytotoxicity. 
Hence,  AFB1-mediated liver cytotoxicity in rainbow trout 
seems not to display a linear correlation with the admin-
istered amount of the mycotoxin. Moreover, it was shown 
that cytotoxicity is dependent on the activation of  AFB1 to 
 AFB1-8,9-epoxide (Nunez et al. 1990). The critical macro-
molecular targets leading to cytotoxicity were not named in 
that study (Nunez et al. 1990), but in a study by Jennings 
et al. (1994), in which freshly isolated rat hepatocytes were 
incubated with increasing concentrations of  AFB1, it could 
be shown that cytotoxicity correlated with a loss of glu-
tathione S-transferase activity. Up to now, a study correlat-
ing cytotoxicity with  AFB1-mediated hepatocarcinogenesis 
during the whole (i.e. at early and late stages of the) hepato-
carcinogenic process in a mammal or non-mammal animal 
species is missing.
p53 mutations, hepadnavirus infections, and  AFB1‑mediated 
liver cancer formation A number of studies have linked the 
formation of hepatocellular carcinomas in humans to a spe-
cific mutation in the  3rd base of codon 249 of the p53 gene 
induced by the dietary intake of  AFB1 (reviewed for exam-
ple in Hussain et al. (2007)). The codon 249 p53 mutation 
has been detected in up to 50% of hepatocellular carcinoma 
cases from regions highly exposed to  AFB1 such as Qidong 
and Tongan in China, India, Southern Africa, The Gam-
bia, Mozambique and Senegal (Katiyar et  al. 2000; Kirk 
et al. 2000; Rashid et al. 1999; Shimizu et al. 1999; Yang 
et al. 1997). In regions where exposure to  AFB1 is moder-
ate, e.g. Beijing, Shanghai, Xi’an, Hong Kong, Singapore, 
South Korea, Taiwan, Thailand, Vietnam, South Africa and 
Egypt, about 7–34% of the hepatocellular cases examined 
had mutations at the 3rd position of codon 249 of the p53 
gene (Chittmittrapap et  al. 2013; Lunn et  al. 1999, 1997; 
Qi et al. 2015; Shen and Ong 1996; Thongbai et al. 2013; 
Yang et al. 1997), whereas in regions with a low exposure 
to  AFB1 such as Australia, Europe, Japan and USA only 1% 
of the hepatocellular carcinoma samples analysed had the 
above-mentioned mutation (Boix-Ferrero et al. 1999; Hus-
sain et al. 2007; Rashid et al. 1999; Vautier et al. 1999).
Aguilar et al. (1994) examined normal liver samples from 
the United States, Thailand, and Qidong, i.e. from regions 
in which  AFB1 exposure is negligible, low and high, respec-
tively, for p53 gene mutations. The frequency of the AGG 
to AGT mutation at codon 249 of the p53 gene paralleled 
the level of  AFB1 exposure, which supports the hypothesis 
that this toxin plays a causative and early role in liver cancer 
development.
In those regions, in which AFB1 contamination of the 
food chain as well as the hepatocellular carcinoma incidence 
are high, as in Africa and China (see above), chronic viral 
hepatitis is widespread. In this context a number of studies 
have shown that the relative risk to develop liver cancer is 
significantly higher in the case of a concomitant high die-
tary  AFB1 exposure and a chronic hepatitis B virus (HBV) 
infection if compared to a high dietary  AFB1 exposure or a 
chronic HBV infection alone, i.e. both factors act synergis-
tically in hepatocarcinogenesis (Table 6) (Kew 2003; Lunn 
et al. 1997; Qian et al. 1994; Ross et al. 1992; Wang et al. 
1996). As to the possible mechanisms underlying the inter-
action between  AFB1 and HBV in liver carcinogenesis, a 
number of hypotheses have been postulated, among others 
the following: (1) enhanced hepatocyte necrosis and pro-
liferation caused by chronic HBV infection may increase 
the probability that  AFB1-induced mutations are gener-
ated and subsequently may lead to the clonal expansion of 
cells containing these mutations (Chisari et al. 1989); (2) 
a chronic necroinflammatory disease resulting from HBV 
infection results in the generation of oxygen and nitrogen 
reactive species, which in turn may induce gene mutations 
in liver cells (Liu et al. 1994; Ohshima and Bartsch 1994); 
(3) the HBx protein, an HBV protein that interferes with the 
nucleotide excision repair pathway (Jia et al. 1999), thereby 
favouring the persistence of  AFB1-DNA adducts and the 
induction of gene mutations. Studies in The Gambia (Gouas 
et al. 2012) and Thailand (Ortiz-Cuaran et al. 2013) showed 
that complete HBx sequences are often associated with the 
presence of the codon 249 p53 gene mutation. Although the 
combined high dietary  AFB1 exposure and HBV infection 
strongly increase the risk of developing liver cancer, HBV 
infection seems not to be required to induce the codon 249 
p53 gene mutation (Hsu et al. 1993; Stern et al. 2001).
In contrast to the situation in humans, p53 mutations have 
definitely not been detected in  AFB1-induced liver tumours 
in rats (Hulla et al. 1993; Lee et al. 1998; Liu et al. 1996; 
Tokusashi et al. 1994), and in rainbow trout this aspect has 
not been investigated up to the present time. One could argue 
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that in rats the site corresponding to codon 249 of the human 
p53 gene is CGG instead of AGG (Hulla et al. 1993) and that 
a change in the 3rd base would produce a silent mutation. 
However,  AFB1 binding to the second base of this codon 
could produce a change from arginine to leucine, and this 
effect has never been reported for  AFB1-induced rat liver 
tumours (Hulla et al. 1993; Lee et al. 1998; Liu et al. 1996; 
Tokusashi et al. 1994). Hence, at least in the rat p53 muta-
tions cannot be used at all to follow up the induction of liver 
tumours by  AFB1 in the low (or even the high) dose range.
Glutathione S‑transferase and  DNA repair enzyme poly‑
morphisms and  AFB1‑mediated liver cancer formation The 
highly reactive  AFB1-8,9-epoxide can efficiently be detoxi-
fied by conjugation with glutathione in a glutathione S-trans-
ferase (GST)-catalysed reaction, thereby protecting cellular 
DNA by preventing  AFB1-DNA adduct formation (Guenger-
ich et  al. 1998; Johnson et  al. 1997). Therefore, genetic 
polymorphisms affecting the expression of these enzymes 
may alter the mutagenicity and carcinogenicity of  AFB1 
at a given exposure level. Two GST isoenzymes, GSTM1 
and GSTT1, are able to conjugate the  AFB1-8,9-epoxide 
(Guengerich et al. 1998; Johnson et al. 1997) and exhibit a 
deletion polymorphism, which leads to a complete loss of 
expression of the GSTs at the protein level in individuals 
homozygous for the deletion. Whereas many studies could 
not demonstrate that the GSTM1 or GSTT1 null genotype 
was associated with an increased hepatocellular carcinoma 
risk, a number of studies reported an enhanced liver cancer 
risk associated with a high aflatoxin exposure in individuals 
with the GSTM1 or GSTT1 null genotype as well as with 
the double null genotype (Chen et  al. 1996, 2012, 2014; 
Kirk et  al. 2005; Liu et  al. 2013; Long et  al. 2006; Shen 
et al. 2014; Song et al. 2012; Sun et al. 2001; Wang et al. 
2010; Yu et al. 2011).
As mentioned in the introduction, the  AFB1-8,9-epoxide 
may give rise to the  AFB1-N7-Gua adduct. It is conceiv-
able that genetic polymorphisms affecting the expres-
sion of DNA repair enzymes, which could remove the 
 AFB1-N7-Gua adduct, could lead to an increased risk to 
develop a hepatocellular carcinoma. In this context, it has 
been reported that polymorphisms affecting the gene coding 
for the X-ray cross-complementing group 1 (XRCC1) pro-
tein was associated with a significant increase in the number 
of  AFB1-DNA adducts in Taiwanese subjects (Lunn et al. 
1999) and an increase in liver cancer risk in Taiwanese sub-
jects (Chen et al. 2005), with an increased p53 mutation 
frequency in codon 249 (Long et al. 2008a) and an increase 
in liver cancer risk in Chinese subjects (Long et al. 2006) 
and with an increase in liver cancer risk in Gambian sub-
jects (Kirk et al. 2005). In another study from Taiwan, it was 
reported that XRCC1 gene polymorphisms alone did not lead 
to a statistically significant increase in the risk to develop a 
hepatocellular carcinoma, whereas the liver cancer risk was 
significantly enhanced in subjects with a XRCC1 as well 
as a GSTT1 gene polymorphism (Yu et al. 2003). Moreo-
ver, it has been reported that polymorphisms affecting the 
genes coding for XRCC3 (Long et al. 2008b), XRCC4 (Long 
et al. 2013a, b), XRCC7 (Long et al. 2011), XPC (Long 
et al. 2010) and XPD (Long et al. 2009) were associated 
with an increased liver cancer risk and enhanced  AFB1 DNA 
adduct levels. A study in China (Yao et al. 2014) showed that 
XRCC1, XRCC3, XRCC4, XRCC7, XPC and XPD gene poly-
morphisms in combination with a high exposure to  AFB1 
(determined by measuring serum  AFB1-albumin adduct 
levels in peripheral blood cells) were associated with an 
increased risk of developing a hepatocellular carcinoma. A 
report from Taiwan (Chen et al. 2005) showed that a hMLH1 
polymorphism led to an enhanced liver cancer risk.
Conclusions 
• There is a linear relationship between the administered 
 AFB1 dose and the extent of  AFB1-DNA binding (i.e. 
amount of  AFB1-DNA adducts formed) in rat and rain-
bow trout liver, even in the low  AFB1 dose range.
• There is a linear relationship between the administered 
 AFB1 dose and the incidence of  AFB1-induced liver 
Table 6  Relative risk to develop liver cancer due to a chronic viral hepatitis B virus (HBV) infection alone, due to a dietary aflatoxin B1 (AFB1) 
exposure alone and due to a concomitant chronic HBV infection and a high dietary AFB1 exposure (HBV + AFB1) (reproduced from Kew 2003)
RR relative risk, CL confidence limits
Reference HBV alone RR (95% CL) AFB1 alone RR (95% CL) HBV + AFB1 RR (95% CL)
Ross et al. (1992) 4.8 (1.2–19.7) 1.9 (0.5–7.5) 60.1 (6.4–561.8)
Qian et al. (1994) 7.3 (2.2–24.4) 3.4 (1.1–10.0) 59.4 (15.6–212)
Wang et al. (1996) 17.4 (3.6–143.4) 0.3 (0–3.6) 70.0 (11.5–425.4)
Lunn et al. (1997) 17.0 (2.8–103.9) 17.4 (3.4–90.3) 67.6 (12.2–373.2)
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tumours in rat and rainbow trout liver, even in the low 
 AFB1 dose range.
• In the case of  AFB1 no threshold for the formation 
of hepatic DNA adducts was observed, even down to 
extremely low dosage (< 1 ng/kg bw)
• There is an obvious and strong influence of promotional 
effects as exerted by HBV infection (see Table 6)
Allylalkoxybenzenes
Allylalkoxybenzenes are natural ingredients of a variety of 
herbs and spices, including basil, nutmeg, fennel and many 
others. They are present in a variety of food items derived 
from these botanicals including products like pesto and 
food supplements (SCF 2001a, b, 2002; Van den Berg et al. 
2011). Especially alkoxy-substituted allylbenzenes including 
apiole, elemicin, estragole, methyleugenol, myristicin and 
safrole (Fig. 10) are converted by cytochrome P450- and 
sulfotransferase (SULT)-mediated biotransformation via 
their proximate carcinogenic 1′-hydroxymetabolites to DNA 
reactive and carcinogenic 1′-sulfooxymetabolites (Fig. 11) 
(Boberg et al. 1983; Drinkwater et al. 1976; Gardner et al. 
1997; Jeurissen et al. 2007; Miller et al. 1983; Phillips et al. 
1981; Smith et al. 2002; Wiseman et al. 1985, 1987). Table 7 
presents an overview of the genotoxicity and carcinogenicity 
data on the allylalkoxybenzenes indicating that these com-
pounds are genotoxic carcinogens. The important role for 
the 1′-sulfooxymetabolite in the DNA adduct and tumour 
formation by the allylalkoxybenzenes was derived from the 
observation that intraperitoneal administration of pentachlo-
rophenol, a potent sulfotransferase inhibitor, prior to treat-
ment with estragole, reduced the incidence of animals devel-
oping hepatomas to control levels (Wiseman et al. 1987).
DNA adducts of  allylalkoxybenzenes Several adducts are 
formed upon reaction of the 1′-sulfooxymetabolites of ally-
lalkoxybenzenes with DNA. As an example Fig. 11 presents 
the DNA adducts of 1′-sulfooxyestragole. These adducts 
include N2-(trans-isoestragol-3′-yl)-deoxyguanosine (E-3′-




N6-dA) (Ishii et  al. 2011; Phillips et  al. 1981; Punt et  al. 
2007; Suzuki et al. 2012). The major adduct formed with the 
guanine base is N2-(trans-isoestragol-3′-yl)-deoxyguanosine 
(E-3′-N2-dG) which is considered to play a role in the geno-
toxic and carcinogenic effects induced by estragole (Phillips 
et al. 1981; Smith et al. 2002). It was reported that adducts 
between estragole and adenine (E-3′-N6-dA) may also be 
formed to a significant extent in the liver of male rats (F344) 
exposed to estragole at a dose level of 600 mg/kg bw for 
4  weeks (Ishii et  al. 2011; Suzuki et  al. 2012). However, 
at a lower dose of 22 mg estragole/kg bw the major adduct 
measured was the E-3′-N2-dGuo (Suzuki et al. 2012). This 
indicates that dose-dependent changes can occur in the type 
of adduct formed, but that at dose-levels relevant for dietary 
human intake E-3′-N2-dGuo adducts may be most relevant.
Genotoxicity/mutagenicity of allylalkoxybenzenes In spite 
of this clear evidence for the formation of DNA adducts, 
allylalkoxybenzenes generally tested negative in most stand-
ard genotoxicity assays including the Ames test (Ding et al. 
2011; Mortelmans et  al. 1986; NTP 2000; SCF 2001a, b, 
2002; Sekizawa and Shibamoto 1982), and several in vivo 
genotoxicity tests (Ding et al. 2011; NTP 2000). For exam-
ple, a 14 week in vivo study, in which mice were dosed orally 
with methyleugenol, showed no increase in the frequency of 
Fig. 10  Structures of the related 
allylalkoxybenzenes
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micronucleated normochromatic erythrocytes (NTP 2000). 
The absence of positive results in genotoxicity tests may 
to some extent be ascribed to the absence of the relevant 
enzymes, especially the sulfotransferases (SULTs), required 
for conversion of the allylalkoxybenzenes into their ultimate 
carcinogenic 1′-sulfooxy metabolites (Fig.  11). This was 
confirmed by studies using Salmonella typhimurium TA100 
strains with the expression of human SULT which, espe-
cially upon expression of human SULT1A1 and SULT1C2, 
appeared able to activate 1′-hydroxymethyleugenol to DNA 
reactive metabolites resulting in positive Ames test results 
(Herrmann et al. 2012).
Role of DNA adduct formation in tumour formation by ally‑
lalkoxybenzenes DNA adduct formation, although involved 
in the process of tumour formation, is generally considered 
a biomarker of exposure rather than a biomarker of effect 
(Brink et al. 2009; La and Swenberg 1996; Swenberg et al. 
2008; Williams 2008) although it is also well recognized 
that increased levels of DNA adduct formation reflect a risk 
factor in cancer development. For the allylalkoxybenzenes 
the formation of DNA adducts is considered important in 
the mode of action underlying the tumour induction. Sev-
eral attempts have been made to correlate the occurrence 
of DNA adducts with the carcinogenic outcome, but the 
significance of their formation in the risk assessment, espe-
cially with respect to the discussion and justification of pos-
sible thresholds is a matter of ongoing debate (Jarabek et al. 
2009; Neumann 2009). Comparison of the level of DNA 
adducts estimated to be formed at the  BMD10 for methyl-
eugenol were actually below or close to the background 
DNA adduct level set at 100 adducts in  108 nt (Paini et al. 
2011). Theoretically this observation of DNA adduct forma-
tion at the  BMD10 at levels that are below the background 
levels of DNA adduct formation might reflect that either 
the DNA adducts formed are far more mutagenic and carci-
nogenic than the type of lesions present in the background 
levels or it might imply that the mode of action underly-
ing the tumour induction includes an additional mechanism 
in addition to DNA adduct formation such as for example 
cytotoxicity. For methyleugenol literature data point at a 
possible role for liver toxicity in addition to DNA adduct 
formation in the mechanism underlying tumour formation 
(FAO/WHO 2010).
(Non)‑linearity of  concentration‑ or  dose–response curves 
for  allylalkoxybenzenes In accordance with the current 
scientific view on low dose linearity for DNA adduct for-
mation (Neumann 2009; Paini et al. 2011; Swenberg et al. 
2008) the dose–response curve for DNA adduct formation 
of allylalkoxybenzenes seems to be linear through the ori-
gin (Ellis et  al. 2006; Paini et  al. 2011). Furthermore, in 
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N2-dG adduct formation also increased linearly through the 
origin with increasing concentration of 1′-hydroxyestragole 
(Paini et al. 2010). In addition, it was demonstrated that the 
level of E-3′-N2-dG adducts detected in the liver of male 
Sprague Dawley rats also showed a linear correlation with 
dose (Paini et al. 2012). In line with this the formation of the 
unstable  1′-sulfooxyestragole (in nmol/g liver), predicted 
by a rat physiologically based kinetic (PBK) model, also 
showed a linear dose–response curve (Paini et  al. 2012). 
These PBK models, by now developed and validated for 
a variety of related allylalkoxybenzenes (Al-Subeihi et  al. 
2012, 2011; Martati et  al. 2011, 2012; Punt et  al. 2008, 
2009; Van den Berg et al. 2012) have revealed that forma-
tion of the 1′-sulfooxymetabolites of allylalkoxybenzenes 
in human and rat liver is predicted to be linear from doses 
as low as the normal dietary human intake up to doses as 
high as the  BMD10 (benchmark dose that gives 10% extra 
cancer incidence) (Martati et al. 2012; Rietjens et al. 2010; 
Van den Berg et al. 2012) (Fig. 12). Whether this translates 
into linearity for tumour formation remains however to be 
established.
Fig. 11  Bioactivation of estragole and formation of the differ-
ent DNA adducts. N2-(trans-isoestragol-3′-yl)-deoxyguanosine 
(E-3′-N2-dG), N2-(estragol-1′-yl)-deoxyguanosine (E-1′-N2-dG), 
7-(trans-isoestragol-3′-yl)-deoxyguanosine (E-3′-7-dG), 8-(trans-
isoestragol-3′-yl)-deoxyguanosine (E-3′-8-dG), and N6-(trans-
isoestragol-3′-yl)-deoxyadenosine (E-3′-N6-dA)
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Conclusions 
– There is a linear relationship through the origin between 
the dose of an allylalkoxybenzene and its levels of bio-
activation to the DNA reactive metabolite and also to the 
level of DNA adduct formation in animal experiments
– This linearity holds from dose levels as high as the 
 BMD10 (benchmark dose that gives 10% extra cancer 
incidence) down to dose levels as low as dietary human 
intake.
– Genotoxicity/mutagenicity bioassays may give false-
negative results when adequate enzymes are lacking.
– Physiologically based kinetic (PBK) modelling provides 
insight in the form of the dose–response curve for the 
formation of unstable DNA reactive metabolites even at 
dose levels that are experimentally not accessible.
– In addition to DNA adduct formation, cytotoxicity may 
add to the mode of action underlying the tumour forma-
tion by allylalkoxybenzenes.
2‑Amino‑3,8‑dimethylimidazo[4,5‑f]quinoxaline (MeIQx)
Introduction Heterocyclic aromatic amines (HAA) are 
formed in red meat and fish during the cooking procedure 
at high temperatures for a long time or over an open fire 
through pyrolysis reactions between amino acids, glucose 
and creat(in)ine (Felton and Knize 1990; Knize et al. 1994; 
Skog and Jagerstad 1993; Wakabayashi et al. 1992). Under 
most of the cooking conditions and from a quantitative point 
of view 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline 
(MeIQx) is the second most prevalent HAA in heated food 
items (Felton and Knize 1990; Skog and Jagerstad 1993). 
MeIQx per se is biologically inactive. To exert its geno-
toxicity and carcinogenicity, it must first be metabolically 
activated (Fig.  13) (Turesky et  al. 2002). A cytochrome 
P450-mediated N-hydroxylation of MeIQx followed by 
conjugation of the N-hydroxy moiety to any of several leav-
ing groups, such as acetate or sulfate, results in covalent 
binding to DNA (Paehler et al. 2002; Rich et al. 1992; Sjo-
din et al. 1989; Solomon et al. 1996; Turesky et al. 1988, 
1991a, b, 1992). In  vitro N-(deoxyguanosin-8-yl)-MeIQx 
(dG-C8-MeIQx) is the major and 5-(deoxyguanosin-N2-yl)-
MeIQx the minor adduct (Turesky et al. 1992) (Fig. 14). In 
contrast, in vivo and in the case of administering a low dose 
of MeIQx to rats 5-(deoxyguanosin-N2-yl)-MeIQx (dG-
N2-MeIQx) seems to significantly contribute to the geno-
toxic damage elicited by MeIQx (Paehler et al. 2002).
MeIQx‑DNA adduct formation in the liver of rats Yamashita 
et al. (1990) analysed the formation of MeIQx-DNA adducts 
in the liver of male Fischer 344 rats after dietary administra-
tion of high to extremely high levels of MeIQx (i.e. 0.4, 4, 
40 and 400 ppm, equivalent to 0.036, 0.36, 3.6 and 36 mg/
kg bw/day) for up to 12 weeks by 32P-postlabeling. MeIQx-
DNA adducts in rat liver increased time-and dose-depend-
ently, the relationship between the administered dose of 
MeIQx and the detected MeIQx-DNA levels being clearly 
linear (Yamashita et  al. 1990). A later study by the same 
group showed that MeIQx-DNA adducts formed are very 
persistent, their removal occurring in a biphasic manner, 
i.e. an initial rapid removal is followed by a phase of slow 
changes in MeIQx-DNA adduct levels (Hirose et al. 1995b). 
If male Sprague–Dawley rats were exposed to very low 
dietary doses of MeIQx (dose range: 0.000001–0.034 ppm) 
for 1, 7 or 42 days, a linear correlation between the admin-
istered doses and the detected hepatic MeIQx-DNA adduct 
levels was again observed and the adducts persisted for at 
least 14 days after the exposure ceased (Frantz et al. 1995; 
Turteltaub et al. 1997).
It has been shown in the past that synthetic antioxidants 
are able to inhibit MeIQx-induced hepatocarcinogenesis in 
rats (Hirose et al. 1995a, 1998a, b). Based on these find-
ings, it has been suggested that oxygen-derived free radi-
cals may play an important role in MeIQx-mediated tumour 
development. In three studies, hepatic 8-hydroxyguanine 
levels have been measured following the dietary adminis-
tration of MeIQx to male Fischer 344 rats (Fukushima et al. 
2002; Kato et al. 1996; Murai et al. 2008). Kato et al. (1996) 
exposed rats to increasing concentrations (0.05, 0.2, 0.8, 3.2, 
12.5, 50 and 200 ppm, equivalent to 0.006, 0.024, 0.096, 
0.384, 1.5, 6 and 24 mg/kg bw/day) of MeIQx in the diet for 
six weeks and the animals were partially hepatectomised 
Fig. 12  PBK model-predicted dose-dependent formation of 1′-sul-
fooxyestragole in the liver of rat (─) and human (- -), also indicating 
the Benchmark dose 10  (BMD10) representing the dose level result-
ing in a tumour incidence of 10% above background level and the 
Virtual Safe Dose (VSD), calculated by linear extrapolation to rep-
resent a dose level causing one in a million tumour incidence above 
background level. Reproduced with permission from Rietjens et  al. 
(2010). Copyright (2009) WILEY–VCH Verlag GmbH & Co. KGaA, 
Weinheim
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1 week after beginning to expose the animals to MeIQx. 
The 8-hydroxyguanine levels in the resected liver samples 
(i.e. at week 1) increased in a concentration-dependent 
manner, but the correlation between the MeIQx doses and 
the 8-hydroguanine levels was not linear. Surprisingly, the 
hepatic 8-hydroxyguanine levels at the end of the exposure 
period (i.e. at week 6) were similar to those in control ani-
mals, independently of the administered dose. This might 
be due to an induction of DNA repair enzymes in the course 
of the 6-week feeding period, but this possibility has not 
been proven experimentally up to now. In a second study, 
Fukushima et al. (2002) fed rats MeIQx at dietary dose lev-
els of 0.001, 0.01, 0.1, 1, 10 and 100 ppm (equivalent to 
0.00005, 0.0005, 0.005, 0.05, 0.5 and 5 mg/kg bw/day) for 
16 or 32 weeks. A statistically significant increase in the 
8-hydroxyguanine levels when compared to those in con-
trol animals was only observed with 100 ppm MeIQx. In 
a third study, Murai et al. (2008) reported that in rats fed 
MeIQx at dietary levels of 0.001, 1 and 100 ppm (equivalent 
to 0.00005, 0.05 and 5 mg/kg bw/day) for up to 104 weeks 
the hepatic 8-hydroxyguanine levels did not increase at all 
if compared to those of control rats. Taken together, the data 
sets on the relationship between the administered MeIQx 
doses and the detected hepatic 8-hydroxyguanine levels are 
inconsistent and at this stage do not allow any conclusion on 
the relevance of the 8-hydroxyguanine levels in the MeIQx-
mediated hepatocarcinogenic process.
Induction of preneoplastic and neoplastic lesions in the liver 
of  MeIQx‑fed rats The hepatocarcinogenic potential of 
MeIQx was tested in male Fischer 344 rats exposed to die-
tary doses of 100, 200 and 400 ppm (equivalent to 5, 10 and 
20 mg/kg bw/day) (Kushida et al. 1994). The incidence of 
Fig. 13  Metabolic activation and detoxification of 2-amino-3,8-dimethylimidazo[4,5-f] quinoxaline (MeIQx). Reprinted from Turesky et  al. 
(2002), Copyright (2002), with permission from Elsevier.
Fig. 14  Structures of N-(deoxyguanosin-8-yl)-2-amino-3,8-
dimethylimidazo[4,5-f] quinoxaline (dG-C8-MeIQx) and 2-amino-
3,8-dimethylimidazo[4,5-f]quinoxaline (dG-N2-MeIQx) (reproduced 
from Paehler et al. 2002)
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hepatocellular carcinomas in these three groups was 0, 45 
and 94%, respectively, and based on these results the authors 
described the correlation between the administered MeIQx 
doses and the hepatocellular carcinoma incidences as non-
linear.
In later studies by Japanese researchers (Fukushima 
1999; Fukushima et al. 2003, 2016; Hoshi et al. 2004; Wei 
et al. 2006), MeIQx was tested at much lower doses, but 
the biological endpoint quantified in the above-mentioned 
studies was the number of glutathione S-transferase P (GST-
P)-positive foci per  cm2 hepatic tissue instead of the inci-
dence of hepatocellular carcinomas. GST-P-positive foci are 
described as being preneoplastic hepatic lesions that very 
well correlate with liver cancer induction in rats (Ogiso 
et al. 1990) and have the advantage that they are detected 
very early in the hepatocarcinogenic process (i.e. the feeding 
experiments can be strongly shortened). Fukushima (1999), 
Fukushima et al. (2016) and Hoshi et al. (2004) fed male Fis-
cher 344 0.001, 0.01, 0.1, 1, 10 or 100 ppm MeIQx (equiva-
lent to 0.00005, 0.0005, 0.005, 0.05, 0.5 or 5 mg MeIQx/kg 
bw/day) for 16 weeks. The number of GST-P-positive liver 
foci per  cm2 in animals fed 0.001–1 ppm MeIQx was similar 
to that in control rats, whereas it increased if animals were 
fed 10 or 100 ppm (Fukushima 1999; Hoshi et al. 2004) 
(only at 100 ppm in the case of Fukushima et al. (2016)). In 
male BN rats fed 0.1, 1, 5, 10 or 100 ppm MeIQx (equiva-
lent to 0.005, 0.05, 0.25, 0.5 or 5 mg MeIQx/kg bw/day) 
for 16 weeks, the number of GST-P-positive liver foci per 
 cm2 in animals fed 0.1–10 ppm MeIQx was similar to that 
in control rats, whereas it increased significantly in animals 
fed 100 ppm (Wei et al. 2006). If male Fischer 344 rats were 
fed 0.001, 0.01, 0.1, 1, 10 or 100 ppm MeIQx (equivalent to 
0.00012, 0.0012, 0.012, 0.12, 1.2 or 12 mg MeIQx/kg bw/
day) for 4 weeks and thereafter exposed to the tumour pro-
moter phenobarbital for 11 weeks (Fukushima et al. 2003), 
the number of GST-P-positive liver foci per  cm2 in animals 
fed 0.001–1 ppm MeIQx was similar to that in control rats, 
whereas it increased if animals were fed 10 or 100 ppm. 
The observation that MeIQx only induces liver tumours in 
rats when administered in extremely high (totally human-
irrelevant) doses is also observed with 2-amino-1-methyl-
6-phenylimidazo[4,5-b]pyridine (PhIP), the quantitatively 
most important HAA in strongly heated fish and meat sam-
ples (Fukushima et al. 2004; Hasegawa et al. 1993; Ito et al. 
1991).
Hoshi et al. (2004) reported that the mutation frequency 
in the liver of male Fischer 344 rats fed 0.001, 0.01, 0.1, 1, 
10 or 100 ppm MeIQx (equivalent to 0.00005, 0.0005, 0.005, 
0.05, 0.5 or 5 mg MeIQx/kg bw/day) for 16 weeks was 14.9, 
15.6, 19.9, 29.4, 51.4 and 641.5 mutants/106 nucleotides, 
respectively, only the values in the 10 and 100 ppm group 
being significantly increased when compared to the control 
group. Furthermore, the liver cell proliferation rate was simi-
lar in all experimental groups (Hoshi et al. 2004).
Based on the above-mentioned results (Fukushima 1999; 
Fukushima et al. 2016, 2003; Hoshi et al. 2004; Wei et al. 
2006) it has been claimed that a threshold for the induc-
tion of liver tumours does in fact exist. However, the results 
obtained may very well be explained by the fact that MeIQx 
either lacks or possesses a very weak tumour promoting 
activity. Kleman et al. (1993) showed that MeIQx was a 
weak initiator and did not promote the growth of diethyl-
nitrosamine-initiated GST-P-positive liver foci in a short-
term rat liver carcinogenesis model. Moreover, in a newborn 
mouse two-stage tumorigenesis assay the tumour promoting 
effect of MeIQx also proved to be weak (Miyauchi et al. 
1999). In line with these studies it has been demonstrated 
that low doses of MeIQx can indeed lead to the increased 
formation of GST-P-positive liver foci if a strong liver cell 
proliferation (i.e. a strong promoting effect) is induced in rats 
by carbon tetrachloride (Sone et al. 1992) or a choline-defi-
cient diet (Sone et al. 1993) or takes place as a consequence 
of a genetic alteration, as in Long-Evans with cinnamon-like 
coat colour (LEC) rats, which have a mutation in the copper 
transporting ATPase gene Atp7b, accumulate high levels of 
copper in the liver and suffer from hereditary hepatitis lead-
ing in the end to liver cancer (Sone et al. 1996). Moreover, 
as previously pointed out by Bailey et al. (2009) the absence 
of background corrections, the variability in response and 
the limited number of animals in the previously cited stud-
ies (Fukushima 1999; Fukushima et al. 2003; Hoshi et al. 
2004; Wei et al. 2006) does not allow to conclude that in the 
case of MeIQx a threshold for the induction of liver tumours 
exists.
Conclusions 
• There is a linear correlation between the administered 
MeIQx doses and the extent of MeIQx-DNA binding (i.e. 
amount of MeIQx-DNA adducts formed) in the liver of 
rats exposed to MeIQx, even in the low dose range.
• There is no clear-cut correlation between the adminis-
tered MeIQx doses and the 8-hydroxyguanine levels in 
the liver of rats exposed to MeIQx.
• Hepatic preneoplastic and neoplastic lesions were only 
induced if rats were exposed to very high doses of the 
HAA, i.e. in this case no linear correlation between the 
administered MeIQx doses and the induction of preneo-
plastic and neoplastic lesions in the rat liver is observed. 
This is most probably due to the fact that MeIQx lacks or 
only possesses a very weak tumour promoting activity. 
Moreover, it must be pointed out that the studies support-
ing the existence of a threshold for the MeIQx-mediated 
induction of liver tumours show serious methodological 
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limitations and, therefore, do not allow to reach such a 
conclusion.
Benzo[a]pyrene
Benzo[a]pyrene (BaP) belongs to the class of polycy-
clic aromatic hydrocarbons (PAH) which are widespread 
environmental and food contaminants. PAH are continu-
ously formed during incomplete combustion or pyrolysis 
of organic material and are thus present in the ambient air, 
water, soils and sediments. Major environmental sources 
are heating, motor-vehicle exhaust and industrial emissions, 
reaching levels of 1–30 ng/m3, with considerably higher lev-
els in road tunnels and large cities with extensive use of 
coal for residential heating. Significant exposures for the 
general population result furthermore from tobacco smoke 
and food, especially barbecued, grilled, broiled and smoke-
cured meats. Highest levels of workplace exposure to PAHs 
are observed in aluminium production (Söderberg process) 
with values up to 100 μg/m3. Mid-range levels are observed 
in roofing and paving (e.g. 10–20 μg/m3) and concentrations 
at or below 1 μg/m3 are observed in coal liquefaction, coal-
tar distillation, wood impregnation, chimney sweeping and 
power plants (IARC 2010b).
Carcinogenicity Since BaP is only one component of PAH 
mixtures of different compositions, no epidemiological data 
exist for BaP alone with respect to carcinogenicity. Never-
theless, based on strong and consistent evidence of carci-
nogenicity of BaP in many animal species after basically 
all routes of exposure, supported by consistent and coher-
ent mechanistic information, BaP has been classified as 
carcinogenic to humans (Group 1) by IARC (2010b) and 
in carcinogen group 2 by the German MAK Commission 
(Hartwig 2013c).
DNA adducts and  mutagenicity The carcinogenic activ-
ity of BaP is attributed to the formation of DNA adducts, 
resulting from electrophilic attack predominantly at guanine 
residues by metabolically activated intermediates formed 
from the parent hydrocarbon. Routes of metabolic activa-
tion include the formation of radical cations via P450 and/
or peroxidases and the formation of o-quinones via dihydro-
diol dehydrogenases (Fig. 15).
For carcinogenicity, the probably most relevant metabolic 
pathway is connected to the action of cytochromes P450 1A1 
and 1B1 and epoxide hydrolase, yielding syn- and anti-B[a]
P-7,8-diol 9,10-epoxides (BPDE), which form adducts at the 
N2 position of guanine. In contrast to BaP-induced lesions 
at positions N7 or C8 of purines derived from radical cati-
ons, which give rise to apurinic sites due to hydrolysis of 
the N-glycosidic bond, hydrolysis of BPDE-induced DNA 
adducts is very slow and they are considered to be stable on 
cellular conditions. These lesions are substrates of nucleo-
tide excision repair (NER) (Camenisch and Naegeli 2009; 
Hess et al. 1997). When DNA is replicated prior to their 
removal, they can lead to mutations and cancer (Melendez-
Colon et al. 1999).
Within a recent study we specifically addressed the ques-
tion on dose–response relationship in the low dose range 
for BaP-induced stable DNA adducts in the N2-position of 
guanine, their repair and the induction of mutations, and 
compared it to the onset of the DNA damage response on 
the transcriptional level (Piberger et al. 2017). All endpoints 
were investigated in the same cell line, namely TK6 cells. To 
exclude cellular detoxification of BaP preceding the induc-
tion of DNA lesions, cells were treated with its DNA reactive 
metabolite, ( +)-anti-benzo[a]pyrene 7,8-diol-9,10-epoxide 
(( +)-anti-BPDE). Mutations were quantified via the in vitro 
PIG-A mutagenicity test, which has been recently estab-
lished for TK6 cells (Krüger et al. 2015). Quantification of 
Fig. 15  Metabolism of 
Benzo[a]pyrene (Harvey et al. 
2005), reprinted by permis-
sion of the publisher (Taylor & 
Francis Ltd, https ://www.tandf 
onlin e.com)
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( +)-anti-BPDE-induced DNA adducts was performed via 
a highly sensitive HPLC-based assay coupled with fluores-
cence detection, enabling the detection of the respective tet-
rol I-1 upon hydrolysis of DNA adducts in the very low dose 
range (Schwerdtle et al. 2002). Finally, a high-throughput 
RT-qPCR approach was applied to quantitatively elucidate 
the onset of the transcriptional DNA damage response at the 
same conditions (Fischer et al. 2016). The results demon-
strate a linear dose–response relationship of DNA adducts, 
detectable at concentrations as low as 10 nM BPDE. Fur-
thermore, a linear increase in mutations was observed in the 
same dose range. In addition, a linear correlation between 
the amounts of DNA adducts and mutations was observed, 
indicating no threshold-like effect for the conversion of DNA 
adducts into mutations (Fig. 16).
To exclude that low-dose mutagenicity was due to dimin-
ished repair in this cell line, the time course of DNA lesion 
removal was elucidated. Within 8 h post-incubation time, 
only 30% of lesions were removed, and 40% were still left 
after 24 h. This repair course is in agreement with previous 
observations in A549 and HCT116 cells (Grosskopf et al. 
2010; Piberger et al. 2014; Schwerdtle et al. 2002), sup-
porting similar repair capacities in different cell lines. Inter-
estingly, repair kinetics were independent of the applied 
dose, indicating that within this low dose range of BPDE, 
no differences in relative repair were observed and thus no 
dose showed faster or even complete repair. This may be 
explained by specific features of NER mediating the repair 
of stable BPDE-DNA adducts. NER removes structurally 
unrelated bulky base adducts generating significant heli-
cal distortions. It involves at least 30 different proteins and 
enzymes in mammalian cells, including those which are 
defective in patients suffering from the DNA repair disorder 
Xeroderma Pigmentosum (XP) complementation groups A 
through G (de Boer and Hoeijmakers 2000). Two different 
pathways can be distinguished: the global genome repair 
(GG-NER) operating in all parts of the genome and the 
transcription-coupled repair (TC-NER) eliminating DNA 
damage from the transcribed strand of active genes. While 
TC-NER is usually fast and efficient to restore transcription, 
Fig. 16  BPDE-induced DNA adduct levels determined via HPLC/Fluorescence detection (a), mutation frequencies determined by PIG-A assay 
(b), and the correlation between DNA adducts and mutation frequencies (c). For details see Piberger et al. (2017)
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GG-NER on the other hand is slower and may be incom-
plete, leading to an accumulation of mutations in poorly 
repaired regions (Fousteri and Mullenders 2008; Mullenders 
et al. 1991). Accordingly, three levels of repair efficiencies 
have been identified in human fibroblasts after treatment 
with BPDE: The transcribed strand of the active HPRT gene 
was repaired fastest, followed by the non-transcribed strand, 
while only a small fraction of BPDE adducts were removed 
from the inactive locus 754 within 20 h (Chen et al. 1992). In 
addition, the rates of incision of stereochemically identical 
BPDE-induced DNA lesions catalysed by the prokaryotic 
UvrABC system was shown to be higher in the TG*T than 
in the CG*C sequence context (Ruan et al. 2007). The lon-
gevity of at least some PAH-induced DNA adducts was also 
shown in lung autopsy samples of non-smokers, ex-smokers, 
and smokers. Lowest frequencies of lesions were found in 
the first group, intermediate frequencies in the second, and 
highest values in the third group. Furthermore, almost all 
samples even of the non-smoking group had detectable lev-
els of PAH-induced DNA lesions, indicating that even low 
levels of environmental exposure lead to unrepaired DNA 
adducts (Lodovici et al. 1998).
Transcriptional response to  DNA damage To elucidate 
the transcriptional response to DNA damage on the same 
conditions in the same cell line, gene expression analysis 
was conducted in the very low concentration range of 10 to 
200  nM BPDE, by applying a high-throughput RT-qPCR 
technique, enabling quantitative time- and concentration-
dependent gene expression analyses for 96 samples in paral-
lel, and providing a comprehensive gene expression profile 
with respect to DNA damage response, DNA repair fac-
tors, oxidative stress response, cell cycle arrest, cell prolif-
eration, and apoptosis. As expected, treatment with BPDE 
induced genes coding for DNA damage signalling such as 
GADD45A, DNA repair factors involved in DNA damage 
recognition during NER, p53 and AP-1 dependent signal-
ling, as well as those coding for oxidative stress response 
and pro-apoptotic factors. However, almost all significant 
changes in gene expression were restricted to the two high-
est concentrations applied, 100 and 200 nM BPDE, while 
highly significant increases in mutation frequencies were 
observed at concentration levels 10- and 20-fold lower. 
Therefore, neither the induction of DNA repair genes nor 
for example p53-dependent cell cycle control or apoptotic 
genes were able to protect against BPDE-induced mutations 
in the very low dose range (Piberger et al. 2017).
Conclusions and Outlook Taken together, BPDE increased 
the level of GPI-deficient mutant cells in a dose-dependent 
manner, with no obvious deviation from linearity also at the 
lowest concentrations. Furthermore, there was a linear cor-
relation between DNA adduct formation and mutagenicity, 
again arguing against a “no effect” range in the low dose 
exposure towards BPDE. In contrast, the transcriptional 
response to DNA damage was restricted to higher, partly 
cytotoxic concentrations. One reason for the discrepancy 
between the linear correlation of DNA damage and muta-
tions shown here and the reported “threshold” in response 
to some alkylating agents appears to be the impact of dif-
ferent types of DNA lesions, especially also different types 
of DNA repair systems involved in their removal. Even 
though nucleotide excision repair is a largely error-free pro-
cess, which protects from mutagenicity, it has been shown 
to be slower and less effective as compared to base excision 
repair, due to heterogeneity of repair throughout the genome 
and also with respect to the DNA sequence in which the 
lesion is located. Nevertheless, even though DNA repair 
capacities were found to be similar in different cells lines, 
they may differ in vivo in different tissues; this needs to be 
further investigated. This aspect also accounts for the tran-
scriptional response to DNA damage. Whether or not our 
observations derived for treatment with BPDE also apply to 
other substrates of NER requires future research.
Pyrrolizidine alkaloids
Introduction Pyrrolizidine alkaloids (PAs) are a huge group 
of natural plant phytochemicals. Many PAs are known to be 
highly hepatotoxic, and some have been shown to be carci-
Fig. 17  Structures of the representative necine bases, retronecine, heliotridine, otonecine and platynecine, that form the basis of a variety of pyr-
rolizidine alkaloids
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nogenic in laboratory animals. PAs are found in many plants 
around the world, in particular in plants of the families Bor-
aginaceae, Asteraceae and Fabaceae. It is estimated that 
approximately 3% of the world’s flowering plants contain 
one or more toxic PAs (COT 2008; Fu et  al. 2004; Mat-
tocks 1986; Stegelmeier et al. 1999). Possible food sources 
of human exposure are herbal remedies and teas, contami-
nated foods such as grain crops and honey, as well as food 
supplements that contain PA-containing plants (BfR 2011, 
2013; EFSA 2011a).
PAs are heterocyclic compounds, sharing a basic struc-
ture derived from esters of four necine bases: retronecine, 
heliotridine, otonecine and platynecine (Fig. 17). The acid 
moieties of the esters are termed necic acid. To date, all of 
the known tumorigenic PAs are based upon a retronecine, 
heliotridine, or otonecine basic structure (Fu et al. 2004). A 
number of structural features determine the toxic properties 
of PAs (see Fig. 18). PAs correlated with adverse effects 
are esters of 1-hydroxymethyl-1,2-dehydropyrrolizidine 
(1,2-unsaturated PAs). There may be a second hydroxyl 
group at the C7 position. At least one of these hydroxyl 
groups must be esterified to exert toxicity and the acid moi-
ety of the ester linkage must contain a branched chain (COT 
2008).
PAs require metabolic activation to exert their genotoxic-
ity and tumorigenicity (Fig. 19). The activation pathway is 
oxidation at the C3 or C8 position of the necine base (cata-
lysed mainly by hepatic CYP) resulting in the formation of 
the corresponding pyrrolic esters, which are chemically reac-
tive and can act as alkylating agents towards proteins and 
DNA. Pyrrolic esters can undergo further biotransformation 
by glutathione conjugation (Phase II metabolism) or can be 
Fig. 18  Generic structure required for pyrrolizidine alkaloids to cause 
toxicity (reproduced from COT 2008)
Fig. 19  Metabolic activation 
and detoxification of pyr-
rolizidine alkaloids (Chen et al. 
2010b). Reprinted by permis-
sion of the publisher (John 
Wiley & Sons, Ltd)
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further hydrolysed at the ester bond to form the free pyrrole 
base, often referred as DHP (6,7-dihydro-7-hydroxy-1-hy-
droxymethyl-5[H]-pyrrolizine). While DHP is less reactive 
than the parent pyrrolic esters, it is still unstable in aqueous 
solutions and retains considerable alkylating activity. The 
PA detoxification pathways include the esterase-mediated 
cleavage of PA with the release of the necine base and necic 
acid(s). Furthermore, retronecine- and heliotridine-type PAs 
can undergo N-oxidation with the formation of highly water-
soluble N-oxides which are rapidly excreted in the urine. The 
activity of metabolic enzymes towards individual PAs plays 
an important role for the toxicity and varies between species, 
sexes and at different development stages (COT 2008; Fu 
et al. 2004; Fu et al. 2002; Huan et al. 1998).
In laboratory experiments, PAs showed the potential to 
induce genotoxicity in different model systems, and carci-
nogenicity was observed following chronic oral exposure 
to several PAs. The main carcinogenicity target for PAs in 
experimental animals is the liver, although tumours have 
been also found in other tissues. Today there are no human 
epidemiological data on PA carcinogenesis (EFSA 2011a; 
Fu et al. 2004).
Some PAs have been evaluated by the International 
Agency for Research on Cancer (IARC) (Table 8). Accord-
ing to IARC, for lasiocarpine, riddelliine and monocrotaline 
the available data gave sufficient evidence for carcinogenic-
ity to experimental animals. Consequently, IARC classi-
fied these PAs as being “possibly carcinogenic to humans” 
(Group 2B) (IARC 1983, 1987, 2002). The experimental 
results on isatidine, retrorsine, senkirkine were considered 
as “limited evidence for the carcinogenicity to experimental 
animals” and these PAs were evaluated as “not classifiable 
as to its carcinogenicity to humans” (Group 3) (IARC 1983, 
1987).
PAs‑mediated liver tumour induction in  rats Lasiocar-
pine and riddelliine are the two PAs with most available 
data regarding carcinogenicity. Both compounds have been 
found to induce liver tumours (haemangiosarcomas) in the 
National Toxicology Program (NTP) chronic tumorigenic-
ity bioassays (NTP 1978, 2003). Other PAs (monocrota-
line, senkirkine, symphytine, isatidine and retrorsine) have 
been also shown to induce tumours in laboratory animals 
(liver angiosarcomas or adenomas). However, these results 
were obtained only in non-standard carcinogenicity assays 
(reviewed in EFSA 2011a).
In the NTP-carcinogenicity study with lasiocarpine, 
groups of 24 male and 24 female Fischer 344 rats were fed 
with lasiocarpine doses of 0, 0.35, 0.75 and 1.5 mg/kg bw 
per day for 104 weeks (NTP 1978). All high dose females 
had died by week 69, and high dose males had died by week 
88, and a dose-related decrease in survival also occurred 
at the two lower doses. In male rats, the incidence of liver 
haemangiosarcomas (the most sensitive effect) was 21% 
(5/24), 48% (11/23) and 56.5% (13/23) in the corresponding 
three dose groups (low, middle and high). In its assessment 
from 2011, EFSA used these data on male rats for deriving 
a  BMDL10,
1 the recommended toxicological reference point 
for calculating the margin of exposure. The derived  BMDL10 
Table 8  Evaluation of PAs by IARC 
ND no adequate data, S sufficient evidence, L limited evidence, group 2B “possibly carcinogenic to humans”, group 3 “unclassifiable as to carci-
nogenicity in humans”
References: a(IARC 1976); b(IARC 1983); c(IARC 2002)




Hydroxysenkirkinea Insufficient data ND L 3
Isatidinea Carcinogenic in rats: liver tumours (oral administration, limited study) ND L 3
Jacobinea Insufficient data ND L 3
Lasiocarpinea
Lasiocarpinea
Carcinogenic in rats: tumours of the liver, skin, intestine (i.p. administration, NTP study) ND S 2B
Monocrotalinea Carcinogenic in rats: liver tumours, (oral administration, limited study) ND S 2B
Retrorsinea Carcinogenic in rats: tumours in liver and other organs (oral administration, limited 
study)
ND L 3
Riddelliinec Carcinogenic in rats and mice: tumours of the liver, respiratory organs (oral administra-
tion, NTP study)
ND S 2B
Seneciphyllinea No data ND L 3
Senkirkineb Carcinogenic in rats: liver adenomas (i.p. administration, limited study) ND L 3
Symphytineb Insufficient data ND L 3
1 BMDL10 = benchmark dose lower confidence limit for a benchmark 
response of 10%
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was 0.07 mg/kg bw (EFSA 2011a). No clear dose–response 
relationship was observed in the incidence of liver haeman-
giosarcomas in female rats: 36% (8/22), 29% (7/24) and 9% 
(2/23) incidence in the low, middle and high lasiocarpine 
dose group, respectively. However, the high early mortality, 
particularly in female rats, may hinder the adequate detec-
tion of the tumorigenic activity.
Riddelliine has been investigated in a two-year carcino-
genicity study in F344/N rats and B6C3F1 mice exposed by 
gavage (5 days/week) for 105 weeks (Chan et al. 2003; NTP 
2003). The formation of liver haemangiosarcomas was iden-
tified as the key effect. Mice appeared to be less sensitive to 
riddelliine than rats; and in rats, males were more sensitive 
than females. Male rats received only one riddelliine dose 
(1.0 mg/kg bw per day), and liver haemangiosarcomas were 
found in 43 of 50 animals of this group. The incidence of 
liver haemangiosarcomas in female rats, receiving riddelli-
ine doses of 0.01, 0.033, 0.1, 0.33 and 1.0 mg/kg bw mg/kg 
bw per day was 0% (0/50), 0% (0/50), 0% (0/50), 6% (3/50) 
and 76% (38/50), respectively. Due to the more adequate 
study design of the riddelliine study and updated guidelines 
regarding dose–response modelling, EFSA decided in its 
most recent risk assessment on PAs, to use these data on 
female rats for deriving the  BMDL10—instead of the data 
from the lasiocarpine study. A  BMDL10 of 0.237 mg/kg bw 
was derived (EFSA 2017b).
For other PAs (monocrotaline, senkirkine, symphytine, 
isatidine and retrorsine), positively tested for carcinogenicity 
in non-standard assays, no dose–response data is available 
(since only one dose was tested in each case).
Genotoxicity and  possible mechanisms of  tumour forma‑
tion The genotoxic mechanisms of PAs include DNA bind-
ing as well as DNA-DNA and DNA–protein cross-linking 
(Table 9). PAs have been shown to be clastogenic and muta-
genic (Table10). The metabolic activation of PAs to pyrrolic 
ester(s) and the subsequent binding to DNA is considered to 
be the key pathway leading to the genotoxic effects (EFSA 
2011a). Several PAs, including monocrotaline, riddelliine, 
lasiocarpine, clivorine, heliotrine and retrorsine, have been 
shown to form the same set of DHP-derived DNA adducts 
either in vivo or in vitro (Fu et al. 2004).
Yang et al. (2001) studied mechanisms of DNA adduct 
formation by the representative carcinogenic PA riddelli-
ine in female F344 rats. Metabolism of riddelliine by liver 
microsomes of F344 female rats in the presence of calf thy-
mus DNA resulted in the formation of eight DNA adducts, 
among which two were enantiomers of DHP-derived 
7′-deoxyguanosin-N2-yl adducts and the other six were 
DHP-modified dinucleotides. A similar DNA adduct profile 
was detected in the livers of F344 female rats fed riddelliine 
for 3 and 6 months. Furthermore, a dose–response relation-
ship was obtained between the dose administrated to the rats 
(0.01, 0.033, 0.1, 0.33 and 1.0 mg/kg bw) and the level of the 
riddelliine-induced DNA adducts. Authors concluded, that a 
genotoxic mechanism, mediated by DNA adduct formation, 
Table 9  Studies on reactions of PAs with DNA (based on Chen et al. 2010b; EFSA 2011a; He et al. 2017; Xia et al. 2013).
UDS unscheduled DNA synthesis. “ + ” positive result; “ –  ” negative result, empty cells not tested.








DNA strand breaks 
in vitro
UDS in vivo
Clivorine  + 
Heliotrine  +  + 
Heliotrine N-Oxide  + 
Isatidine  + 
Jacobine  +  +  – 
Lasiocarpine  +  + 
Lasiocarpine N-Oxide  + 
Lycopsamin  + 
Monocrotaline  +  +  +  +  ± 
Monocrotaline N-oxide  + 
Retrorsine  +  +  +  –  + 
Retrorsine N-Oxide  + 
Riddelliine  +  +  +  +  –  + 
Riddelliine N-Oxide  +  + 
Senecionine  +  +  +  –  + 
Seneciphylline  +  +  +  –  + 
Senkirkine  + 
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is involved in the induction of liver tumours in rats fed rid-
delliine (Yang et al. 2001).
In a mechanistic study by Chou et al. (2004), F344 rats 
and  B6C3F1 mice were treated by gavage (5 days per week, 
for 2 weeks) with 1 and 3 mg/kg bw riddelliine, respec-
tively, and DHP-derived DNA adduct levels were measured 
in purified DNA from rat and mouse liver parenchymal cells 
and liver endothelial cells (the cells of origin of haeman-
giosarcomas). Treatment resulted in significantly greater 
DHP-derived DNA adduct levels in the endothelial cells 
than in the parenchymal cells. It was concluded, that the 
DHP-derived DNA adducts are, at least partially, respon-
sible for the liver tumour development (Chou et al. 2004). 
In their review on the genotoxicity of PAs, Fu et al. (2004) 
concluded that the DHP-derived DNA adducts have the 
potential to be utilized as a biomarker of PA exposure and 
tumorigenicity.
Unfortunately, DNA adduct formation by lasiocarpine 
was studied only in vitro (Xia et al. 2006), and no informa-
tion is available about a possible relationship (correlation) 
between lasiocarpine-induced DNA adduct formation and 
tumorigenic responses in vivo. Since lasiocarpine is among 
the most toxic of the PAs that have been tested, such data 
would be of high relevance.
PA metabolites (pyrrolic ester(s) and DHP metabolites) 
contain several reactive sites in their molecule (C5/C7 and 
C9 positions of the necine base), that are able to bind to 
two sites of DNA or protein to form DNA or protein cross-
linking. Indeed, a number of PAs and their pyrrolic deriva-
tives have been found to form DNA-DNA and DNA–protein 
cross-links (Table 9) (Coulombe et al. 1999; Kim et al. 1995, 
1999). DNA-DNA and DNA–protein cross-links are also 
discussed as possible mechanisms leading to tumour induc-
tion by PAs. Unfortunately, the structures of these cross-
links have never been fully characterized; and the levels of 
their formation have not been correlated with the tumori-
genic potencies of rodents treated with PAs (Fu et al. 2004).
PAs are strongly clastogenic agents (Allemang et al. 2018; 
Chen et al. 2010b; EFSA 2011a; Louisse et al. 2019). Sev-
eral PAs have been shown to produce micronuclei in vitro 
with different potency (cultured rat or human hepatocytes) 
and in vivo (mouse bone marrow erythrocytes and peripheral 
blood cells). In a structure-dependent way some PAs induce 
the γH2AX in cell western assay in HepaRG human liver 
cells in vitro. In addition, PAs induce chromosomal aberra-
tions in mammalian cells or in mouse bone marrow (when 
they are appropriately metabolically activated). Further-
more, several PAs have been found to induce sister chroma-
tid exchange (SCE) (see Table 10). Altogether, the positive 
results of clastogenicity assays indicate a likely induction of 
chromosomal mutations by PAs.
Mutagenicity induced by PAs has been intensively stud-
ied in different biological assays, including bacteria (S. 
typhimurium, E. coli), Drosophila, and rodents. Several 
PAs were found to be mutagenic in S. typhimurium TA100 
in the presence of the S9 activation enzyme system (Mat-
tocks 1986; Rubiolo et al. 1992) (see Table 10). In addition, 
the mutagenicity of riddelliine in rat liver was investigated 
using Big Blue transgenic rats (Mei et al. 2004a, b). Groups 
of six female rats were treated by gavage (5 days per week, 
for 12 weeks) with 0.1, 0.3 and 1.0 mg/kg bw riddelliine. 
The two top doses have been shown to produce liver tumours 
in the NTP carcinogenicity study (NTP 2003). Treatment 
resulted in a significant and almost linear dose-dependent 
increase in mutant frequencies in the liver cII genes. Further 
investigation in the transgenic rats showed that endothelial 
cells (the cells of origin of haemangiosarcomas) had a sig-
nificantly higher cII mutation frequency in treated rats com-
pared to control rats, whereas parenchymal cells showed no 
difference, indicating that mutation by riddelliine is a key 
Table 10  Clastogenicity and mutagenicity of selected PAs (based on Allemang et al. 2018; Chen et al. 2010b; EFSA 2011a).
MN micronuclei, CA chromosomal aberrations, SCE sister chromatid exchange. “  +  ” positive result, “ –  ” negative result, empty cells not tested





Heliotrine  +  +  +  +  ±  + 
Isatidine  +  ±  – 
Integerrimine  +  +  + 
Lasiocarpine  +  +  + 
Monocrotaline  +  +  +  +  –  + 
Retrorsine  +  +  +  + 
Riddelliine  +  ±  +  +  ± 
Senecionine  –  + 
Seneciphylline  +  + ( +)  + 
Senkirkine  +  +  +  + 
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event in the carcinogenesis pathway. Moreover, a statistically 
significant difference was found between the mutational 
spectra from the riddelliine-treated and control animals. 
The major types of mutations induced by riddelliine were 
G:C → T:A transversion and a tandem base substitution of 
GG → TT and GG → AT. The types of mutations induced by 
riddelliine were consistent with riddelliine adducts involv-
ing G:C base pairs. The GG → TT and GG → AT tandem 
base substitutions were believed to result from intra-strand 
cross-links in adjacent guanine bases forming DHP-modified 
dimers (Chou et al. 2003). In summary, these results show 
that riddelliine is a genotoxic carcinogen in rat liver and that 
the types of mutations induced by riddelliine are consistent 
with riddelliine adducts involving G:C base pairs.
Conclusions Although the carcinogenesis by PAs has long 
been studied, the mechanisms for the tumour induction in 
experimental animals by PAs are not completely clear. This 
is probably due to the structural diversity of PAs. For future, 
it is necessary to elucidate structure–activity relationships 
referring to different endpoints to proper assess the risk of 
PAs for humans and livestock. This includes on the one 
hand clear data for oral bioavailability of mono-, di- and 
cyclic diesters at human-relevant doses in dependence of 
their respective structure. On the other hand, more data 
for the mode of action, especially in the target organ liver, 
are needed. Other molecular mechanisms resulting in toxic 
effects beside the genotoxic-acting properties are under 
investigation (e.g. Hessel-Pras et al. 2019).
The metabolic activation of PAs to reactive pyrrolic spe-
cies (DHP and related esters) with the subsequent binding to 
DNA leads to nucleoside adduct formation, DNA-DNA and 
DNA–protein cross-linking, which in turn result in gene and 
chromosomal damage. Both gene and chromosomal muta-
tions are important factors in the induction of tumours by 
PAs. Furthermore, PAs are considered to be more potent 
as chromosomal mutagens than as gene mutagens. Since 
mutations have been found in the target tissues of tumour 
formation and in oncogenes of PA-induced tumours, it was 
concluded that PAs induce tumours via a mutagenic mode 
of action.
There is limited information on dose–response relation-
ships for PA, especially in the low-dose range. In the case 
of riddelliine, the levels of the DHP-derived DNA adducts 
correlated closely with tumour formation in rats fed differ-
ent doses of riddelliine. Moreover, a linear correlation was 
observed between the administered riddelliine doses and 
mutation frequencies in liver cII genes of Big Blue trans-
genic rats fed carcinogenic riddelliine concentrations (Chou 
et al. 2003).
Carcinogenic metal compounds: Examples cadmium 
and arsenic
Metals and their compounds are ubiquitously distributed in 
the environment; however, industrial uses add significantly 
to human exposure. Many metal compounds are carcino-
genic to humans and to experimental animals. This applies 
not only to toxic metals or semi-metals like cadmium, lead, 
chromium(VI), arsenic and antimony but also to essential 
trace elements like nickel and cobalt on conditions of metal 
overload, exceeding the homeostatic capacity. Nevertheless, 
with the exception of Cr(VI), most metal compounds are not 
mutagenic in bacterial test systems and mutagenic responses 
in mammalian cells are rather weak. Therefore, again with 
the exception of Cr(VI), direct interactions of metal ions 
with DNA appear to be of minor importance (Beyersmann 
and Hartwig 2008). One mechanism frequently proposed 
to be involved in metal-induced tumour formation is an 
increase in reactive oxygen species and oxidatively dam-
aged DNA. Furthermore, the interference with the cellular 
response to DNA damage and with distinct signalling path-
ways has been identified for many metal compounds during 
the last years, including interactions with different types of 
DNA repair systems, cell cycle control and tumour suppres-
sor functions as well as with cell proliferation and cell death 
(Hartwig 2013b). In addition to interactions with distinct 
proteins involved in DNA repair, tumor suppressor func-
tions as well as transcription factors, epigenetic mechanisms 
may play an important role even at low exposure conditions 
(Arita and Costa 2009). However, especially with respect to 
occupational and/or environmental exposure limit values, 
in addition to carcinogenicity, non-cancer organ toxicity 
has been observed at low concentrations as well, relevant 
to environmental exposure, as described and discussed for 
cadmium in detail below. Within the frame of the present 
work, two examples are particularly relevant, namely cad-
mium and arsenic.
Cadmium
Cadmium is ubiquitously distributed throughout the environ-
ment, attributable to natural sources, agriculture and mani-
fold industrial uses. At workplaces, exposure occurs mainly 
via inhalation, while the general population is exposed 
predominantly via food, tobacco smoke and ambient air. 
Even though adverse health effects induced by cadmium 
have been known for decades, during recent years there has 
been an ongoing discussion on cadmium-induced toxicity, 
even at comparatively low exposure conditions. Two lines 
of toxicity appear to be relevant, the carcinogenicity as well 
as non-cancer organ toxicity. With respect to the latter, cad-
mium exposure is associated with bone demineralization, 
cardiovascular diseases and especially nephrotoxicity as 
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the most sensitive endpoint (Nawrot et al. 2010). Thus, the 
European Food Safety Authority (EFSA) has lowered the 
Provisional Tolerable Weekly Intake (PTWI) of 7 µg/kg bw 
established previously by the Joint FAO/WHO Expert Com-
mittee on Food Additives to a TWI of 2.5 µg/kg bw based 
on cadmium-induced nephrotoxicity (EFSA 2009c, 2011c).
Carcinogenicity Cadmium has been classified and con-
firmed as human carcinogen by several authorities and sci-
entific committees, including the International Agency for 
Research on cancer (IARC) and the German MAK Com-
mission (Greim 2006; IARC 2012a). For example, IARC 
based its decision on sufficient evidence for increased inci-
dences of lung tumours upon inhalation as well as limited 
evidence for kidney and prostate tumours in humans (IARC 
2012a). Furthermore, new data indicate that human cad-
mium exposure may also be associated with female breast 
and endometrial cancer, even though the causalities are not 
definitively established. In experimental animals, cadmium 
induces carcinomas of the lung after inhalation and cancers 
of the prostate and testis after ingestion or injection (for 
review see Hartwig 2013a, 2018) and references therein.
DNA damage, mutagenicity and  clastogenicity In most 
bacterial assays soluble cadmium compounds were not 
mutagenic. Also, in standard mammalian mutagenicity tests 
effects of cadmium salts are usually weak and/or restricted to 
comparatively high concentrations. In contrast, pronounced 
co-mutagenic effects in combination with DNA alkylating 
agents and with UVC radiation were observed both in bac-
teria and in mammalian cells. In addition, in mammalian 
cells cadmium compounds provoke clastogenic effects such 
as chromosomal aberrations and micronuclei (Filipic et al. 
2006; Greim 2006; Hartwig 2010; IARC 2012a). The clas-
togenic activity of cadmium compounds is moreover evident 
in vivo in exposed rodents, while evidence for chromosomal 
damage in cadmium-exposed humans via environmental or 
workplace exposure is equivocal, partly due to simultane-
ous exposure to other metal compounds (Greim 2006; IARC 
2012a; Verougstraete et  al. 2002). Furthermore, cadmium 
compounds increase the extent of oxidative DNA damage 
in cultured cells and in vivo, albeit by indirect mechanisms 
(see below).
Mechanisms in  cadmium‑induced carcinogenicity Since 
cadmium salts do not cause DNA damage in cell extracts or 
with isolated DNA (Valverde et al. 2001) but rather interact 
with proteins, the genotoxicity of cadmium is likely due to 
indirect mechanisms. Multiple indirect mechanisms appear 
to be relevant, (1) the increased formation of reactive oxy-
gen species, (2) interactions with the cellular DNA damage 
response system, such as DNA repair processes, cell cycle 
control and apoptosis as well as (3) epigenetic changes 
in DNA methylation patterns, leading to a high degree of 
genomic instability (Arita and Costa 2009; Beyersmann and 
Hartwig 2008; Fischer et al. 2016; Hartwig 2013a; Hartwig 
2013b; Hartwig 2018; Joseph 2009; Templeton and Liu 
2018).
Oxidative stress and oxidatively induced DNA lesions. 
Even though cadmium(II) is not able to participate in redox 
reactions under physiological conditions, increased levels 
of reactive oxygen species (ROS) have been observed both 
in vitro and in vivo (Liu et al. 2009), and their appearance 
is interpreted by the inhibitory effect of cadmium on anti-
oxidant enzymes such as catalase, superoxide dismutase, 
glutathione reductase, and glutathione peroxidase (Stohs 
et al. 2001; Valko et al. 2006). Furthermore, different cad-
mium compounds have been shown to induce DNA strand 
breaks and oxidatively induced DNA base modifications 
in mammalian cells, but effects were usually small and/or 
restricted to comparatively high concentrations (e.g., Dally 
and Hartwig 1997; Schwerdtle et al. 2010) and thus do not 
appear to be sufficient to explain the carcinogenicity of cad-
mium, and enhanced frequencies of oxidative DNA lesions 
in cells and in vivo may also be due to impaired removal of 
the respective lesions (see below).
Interactions with DNA repair and tumour suppressor 
functions. Cadmium has been shown to impair almost all 
major DNA repair pathways. Multiple evidence is available 
for its interference with nucleotide excision repair, base 
excision repair and mismatch repair, providing a plausible 
explanation for its co-mutagenicity in combination with dif-
ferent DNA damaging agents, including UVC radiation and 
DNA alkylation agents (reviewed in Hartwig 2013a). With 
respect to NER, impaired removal of UVC- and benzo[a]
pyrene-induced DNA damage has been demonstrated in cell 
culture systems, due to an impaired assembly/disassembly of 
the DNA damage recognition proteins XPC and XPA at the 
repair complex after UVC irradiation in cells (Schwerdtle 
et al. 2010). Regarding BER, low concentrations of cad-
mium inhibited the repair of oxidative DNA base damage as 
well as DNA alkylation damage in mammalian cells (Dally 
and Hartwig 1997; Fatur et al. 2003). When compared with 
the induction of oxidatively induced DNA base modifica-
tions such as 8-oxoguanine (8-oxoG), inhibitory effects on 
the repair of this lesion were observed at much lower cad-
mium concentrations. This has been observed by direct com-
parison in HeLa cells: While the induction of DNA strand 
breaks by cadmium was restricted to 10 µM and higher, the 
removal of oxidative DNA base modifications induced by 
visible light and recognized by the bacterial formamidopy-
rimidine DNA glycosylase (FPG) was inhibited starting at 
0.5 µM cadmium, yielding complete inhibition at 5 µM, a 
completely non-cytotoxic concentration in this test system 
(Dally and Hartwig 1997). Inhibitory effects of enzymes 
involved in the defence against oxidative DNA damage are 
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also evident in vivo: When investigating, for example, the 
impact of cadmium on rat testis, a target organ for cadmium 
carcinogenesis, a gradual decrease in testicular 8-oxo-
dGTPase activity was observed, accompanied with the 
progressive increase of 8-oxo-dG levels in testicular DNA 
(Bialkowski et al. 1999). Therefore, increases in oxidative 
DNA damage in vivo may at least in part be due to the repair 
inhibition of endogenously induced oxidative DNA lesions. 
In addition to excision repair, cadmium has been shown to 
impair DNA mismatch repair in different systems. It was first 
reported by Jin and co-workers that exposure towards low 
concentrations of cadmium resulted in pronounced hyper-
mutability in yeast, and the mutation specificity along with 
responses in proofreading-deficient and MMR-deficient 
mutants indicated a reduced capacity for MMR of small 
misalignments and base–base mismatches upon cadmium 
exposure. Furthermore, in extracts of human cells, cadmium 
inhibited at least one step leading to mismatch repair (Jin 
et al. 2003). Since then, different studies demonstrated the 
interference by cadmium with proteins involved in the ini-
tial step of MMR, i.e. damage recognition by MSH2-MSH6 
and MSH2-MSH3. Even though the exact mechanism is still 
not known at present, cadmium affected ATP binding and 
hydrolysis of MMR enzymes, reducing their DNA bind-
ing activity and their ability to discriminate between mis-
matched and matched DNA base pairing in isolated systems 
and in mammalian cells in culture (for review see Hartwig 
2010). In addition to manifold interference with DNA repair 
systems, cadmium has also been shown to disturb the func-
tion of the tumour suppressor protein p53 and thus interferes 
with cell cycle control in response to DNA damage (Méplan 
et al. 1999; Schwerdtle et al. 2010). Furthermore, cadmium-
induced malignant transformation of human prostate epithe-
lial cells acquired resistance to apoptosis (Qu et al. 2007). As 
a consequence, damaged cells could escape from elimination 
by apoptosis, allowing them to replicate damaged DNA with 
a high frequency of mutations, which may play an important 
role in cadmium-induced carcinogenicity (see below).
Impact on gene expression and deregulation of cell pro-
liferation. Cadmium interacts with the expression of a large 
number of genes, including stress response genes, immediate 
early response genes, transcription factors and translation 
factors. Major stress response genes induced by cadmium 
are those involved in the synthesis of metallothionein (MT), 
as well as those encoding heat shock proteins, glutathione 
(GSH) synthesis and homeostasis and oxidative stress 
response (Fischer et al. 2016; Joseph 2009; Waisberg et al. 
2003). Immediate early response genes induced by cadmium 
include proto-oncogenes like c-fos, c-jun and c-myc activated 
in response to mitotic stimuli and frequently found overex-
pressed in tumours. In a recent study, the impact of cadmium 
on the transcriptional oxidative stress and DNA response 
was investigated via a quantitative high-throughput PCR 
approach. Cadmium activated genes coding for the stress 
response, anti-oxidative defence, mitotic signalling and cell 
cycle control as well as the intrinsic apoptotic pathway. With 
respect to DNA damage induction and repair, it induced 
damage response genes like GADD45, but down-regulated 
genes coding for specific DNA repair proteins involved in all 
major DNA repair pathways (Fischer et al. 2016). All these 
interactions mirror the manifold interactions of cadmium 
supposed to be involved in cadmium-induced carcinogenic-
ity. With respect to transcription factors, cadmium expo-
sure may lead to activation or inactivation, depending on the 
actual transcription factor under investigation.
Molecular mechanisms. Independent of the actual cad-
mium compound applied,  Cd2+ appears to be the ultimate 
damaging species, and similar interactions have been 
observed in case of water soluble and particulate cadmium 
compounds. Repair inhibitory effects were strongly corre-
lated with cadmium levels in the nuclei (Schwerdtle et al. 
2010). Since cadmium ions exert high affinity towards SH 
groups, potential targets are zinc-binding proteins (Hartwig 
2001; Witkiewicz-Kucharczyk and Bal 2006). They com-
prise a family of proteins where zinc is complexed through 
four invariant cysteine and/or histidine residues forming a 
zinc finger domain, which is mostly involved in DNA bind-
ing, but also in protein–protein-interactions. Even though 
most zinc finger structures have been described as DNA 
binding motifs in transcription factors, they have also been 
identified in several DNA repair proteins required for basi-
cally all major DNA repair pathways as well as the tumour 
suppressor protein p53 and the DNA damage signalling 
enzyme poly(ADP)polymerase 1 (PARP1). Many of these 
proteins have been shown to be inhibited by cadmium in dif-
ferent experimental systems, presumably via displacement 
of zinc by cadmium, as evident from structural investiga-
tions elucidating interactions with the nucleotide excision 
repair protein XPA or a peptide resembling the zinc-binding 
domain of XPA (reviewed in Hartwig 2010). Additionally, 
cadmium ions may interfere with thiols in cysteines in criti-
cal positions outside zinc-binding structures as well; these 
structures are frequently redox-regulated for example in tran-
scription factors. In addition, especially moderately elevated 
levels of ROS have been implicated in cell proliferation due 
to mitotic stimuli and the activation of redox-sensitive tran-
scription factors (Valko et al. 2006). Therefore, enhanced 
oxidative stress induced by cadmium may deregulate cell 
growth and promote tumour growth depending on dose and 
time of interference. Altogether, an interference with redox-
regulation of cell growth may be one unifying mechanism 
in metal-induced carcinogenicity (Hartwig 2013b). Finally, 
cadmium also exerts epigenetic effects, evident by inhibi-
tion of DNA-(cytosine-5) methyltransferase and disturbed 
DNA methylation patterns during cadmium-induced cellular 
transformation (Arita and Costa 2009; Brocato and Costa 
1848 Archives of Toxicology (2020) 94:1787–1877
1 3
2013; Takiguchi et al. 2003). In conclusion, it is evident that 
cadmium interferes with cellular controls of proliferation 
in several ways, which all can contribute to the observed 
deregulation of cell growth by this metal.
Arsenic
Arsenic is a semi-metal and occurs in the oxidation 
states + 5, + 3, 0 and –3 in organic and inorganic spe-
cies. Both natural and anthropogenic sources are relevant. 
Depending on geological conditions, drinking water can be 
a significant source of exposure to arsenic. Here, arsenic is 
mostly present in inorganic form as arsenate (+ 5), under 
reducing conditions also as arsenite (+ 3). The concentration 
of arsenic in the groundwater is usually less than 10 μg/L, 
but in some areas of the world, as in India or Bangladesh, 
concentrations of more than 3000 μg/L are reached. Other 
significant sources towards inorganic arsenic are rice and 
rice products, which contain concentrations of 0.1–0.4 mg/
kg dry mass and sometimes clearly above. Even higher 
amounts of dietary intake arise from the consumption of 
fish and seafood, where arsenic is predominantly found in 
organic form as arsenobetaine in average concentrations of 
0.1–1.8 mg arsenic/kg. In algae, arsenic is predominantly 
present as arsenosugars, the concentrations usually being 
in the range of 2–50 mg arsenic/kg dry mass Occupational 
exposure to arsenic occurs in metal production and process-
ing. Arsenic and arsenic compounds are used in semicon-
ductors as gallium arsenide, in wood preservatives and in 
alloys. In the past, arsenic-containing pesticides added fur-
ther to human exposure. Another anthropogenic source for 
the release of arsenic into the environment is the burning 
of fossil fuels. From a toxicological point of view, espe-
cially inorganic arsenic such as arsenate (+ 5) and arsen-
ite (+ 3) exert adverse health effects, while organic arse-
nic appears to be less toxic. Inorganic arsenic compounds, 
especially arsenic trioxide  (As2O3), are famous as poison in 
many murder cases. While 0.1 g arsenic trioxide by the oral 
route is already fatal, small doses of 2 mg taken daily by 
so-called arsenic eaters were claimed to have a postulated 
performance-boosting effect and to protect from poisoning; 
from today’s point of view, however, clearly chronic toxic-
ity including carcinogenicity is associated with these intake 
levels. The acute toxic effects of arsenic and arsenic com-
pounds include gastrointestinal, cardiovascular, renal and 
neurotoxic effects. Trivalent inorganic arsenic compounds 
are usually more toxic than the pentavalent compounds. 
Organic arsenic compounds usually have a markedly lower 
acute toxicity. Today, more attention is paid to the chronic 
effects of arsenic. Besides exposure at the workplace, the 
chronic uptake of inorganic arsenic compounds with the 
drinking water and–especially for infants and children–rice 
and rice products can lead to toxic effects. These include 
skin changes and blood flow disorders (“blackfoot disease”), 
cardiovascular diseases, neurotoxicity as well as develop-
mental toxic effects, but also carcinogenicity at particularly 
low concentrations (for reviews see (EFSA 2014a; Greim 
2005; Hartwig and MAK Commission 2016; IARC 2012a).
Carcinogenicity As for arsenic in general, also for carci-
nogenicity exposure towards inorganic arsenic is most rel-
evant. After inhalation or ingestion, humans and many other 
mammals metabolize inorganic arsenic into organic forms. 
After reduction of arsenate, arsenite is metabolized to triva-
lent and pentavalent methylated species, namely monometh-
ylarsonous (MMA(III)) and dimethylarsinous (DMA(III)) 
acid, monomethylarsonic (MMA(V)) and dimethylarsinic 
(DMA(V)) acid, and especially the trivalent methylated 
species contribute to arsenic-induced genotoxicity and pre-
sumably carcinogenicity. Epidemiological studies provide 
reliable evidence for an increased incidence of lung tumours 
after inhalative and oral exposure towards inorganic arsenic. 
Thus, arsenic and its inorganic compounds have been clas-
sified as carcinogenic in humans by the IARC (Group 1) 
(IARC 2012a) and the MAK Commission (carcinogenicity 
category 1) (Greim 2006). A drinking water limit of 10 μg 
arsenic/L was established by the World Health Organiza-
tion (WHO) and the US Environmental Protection Agency 
(EPA). For oral uptake of inorganic arsenic via foodstuff, 
the European Food Safety Authority (EFSA) has identi-
fied a lower confidence limit for an additional risk for lung, 
skin and urinary bladder cancer of 1%  (BMDL01) of 0.3 to 
8 μg/kg bw and day based on dose–response relationships 
derived from epidemiological studies, by means of bench-
mark calculations. Since even in Europe the estimated aver-
age dietary exposure of the general population to inorganic 
arsenic is within this range, a possible cancer risk for con-
sumers cannot be excluded and a TDI value could not be 
derived (EFSA 2014a).
DNA damage, mutagenicity and  clastogenicity Arsenite 
does not induce point mutations in bacterial or mamma-
lian test systems. However, it increases the mutagenicity 
of other DNA damaging agents, such as UVC radiation. In 
contrast, the induction of micronuclei, chromosomal aberra-
tions, DNA strand breaks and oxidative DNA base damage 
is well documented and has been observed at comparatively 
low concentrations in cultured mammalian cell lines such as 
V79, CHO, A549, in human peripheral lymphocytes, buc-
cal and bladder cells after exposure to arsenite via drinking 
water as well as in mice after oral exposure to comparatively 
low concentrations of arsenite. With respect to the inorganic 
species, arsenate (with pentavalent As) and arsenite (with 
trivalent As), similar genotoxic effects have been observed, 
albeit at about tenfold higher concentrations of arsenate as 
compared to arsenite. Regarding the methylated species, 
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MMA(III) and DMA(III) are genotoxic at lower concentra-
tions than arsenite at all endpoints, while genotoxic effects 
of MMA(V) and DMA(V) are either absent or restricted to 
much higher concentrations (for review see Beyersmann and 
Hartwig 2008). As underlying mechanisms for co-mutagen-
icity and clastogenicity, interactions with DNA repair mech-
anisms and other DNA damage response systems appear to 
be most relevant.
Oxidative stress and oxidatively induced DNA lesions. 
Oxidative stress and thus elevated levels of ROS and RNS 
is thought to be an important mechanism in arsenic-induced 
carcinogenicity. Underlying mechanisms may be manifold 
and include their generation during metabolism, interactions 
with the respiratory chain, the release of iron from ferritin 
and modulation of NO synthases. Moreover, arsenicals have 
been shown to interfere with cellular redox homeostasis by 
decreasing the cellular GSH content, either by complexing 
thiol groups, resulting in GSH binding and depletion, con-
sumption of GSH during arsenic metabolism, or by inter-
actions with glutathione-related enzymes (Hartwig 2013b; 
Thomas 2007; Valko et al. 2006 and references therein).
Interactions with DNA repair and tumour suppressor 
functions. Similar to cadmium, one important mechanism 
in arsenic-induced carcinogenicity appears to be the inter-
action with DNA repair systems. Trivalent but not pentava-
lent arsenicals have also been shown to inhibit NER at low, 
non-cytotoxic concentrations. In this context, the removal 
of UVC- and benzo[a]pyrene diol epoxide-induced DNA 
lesions was impaired by arsenite and even more pronounced 
by MMA(III) and DMA(III) in cultured cells and laboratory 
animals. In addition, arsenite and its methylated metabo-
lites inhibited BER, evident for example in diminished 
hOGG function (for review see Beyersmann and Hartwig 
2008; Hartwig and Schwerdtle 2009 and references therein). 
The most sensitive target related to DNA repair affected by 
trivalent arsenicals, however, is poly(ADP-ribosyl)ation. 
Thus, low nanomolar concentrations of arsenite, MMA(III) 
and DMA(III) inhibited poly(ADP-ribosyl)ation in human 
HeLa cells, while the pentavalent species monomethylar-
sonic (MMA(V)) and dimethylarsinic (DMA(V)) were not 
inhibitory. Furthermore, all three trivalent arsenicals inhib-
ited the isolated PARP1, indicating a direct interaction with 
this enzyme (Hartwig et al. 2003; Walter et al. 2007; Zhou 
et al. 2011).
Impact on gene expression and deregulation of cell pro-
liferation. Arsenite has also been shown to activate several 
redox-regulated signalling pathways, including all three 
classes of mitogen-activated protein kinases (MAPKs). 
Thus, for example, in a mesencephalic cell line arsenite 
at low, non-cytotoxic concentrations activated NF-κB and 
AP-1 and induced phosphorylation of ERK1/2. One other 
transcription factor activated by arsenite is Nrf2, leading to 
the expression of antioxidant enzymes via ARE-responsive 
elements (for reviews see Druwe and Vaillancourt 2010; 
Hartwig 2013b; Kumagai and Sumi 2007).
Published data concerning the impact of arsenite on the 
tumour suppressor protein p53 are controversial and seem 
to depend on cell line and incubation time. Thus, arsenite-
induced accumulation of p53 in human fibroblasts and a 
human lymphoblastoid cell line via an ATM-dependent 
pathway (Menendez et al. 2001; Yih and Lee 2000). On the 
other hand, p53 function has been shown to be inactivated 
by arsenite and MMA(III). Thus, MMA(III) led to a marked 
impairment of p53 induction in response to benzo[a]pyrene 
diol-epoxide and reduced p53 DNA binding, presumably 
involved in arsenical-induced NER inhibition (Nollen et al. 
2009; Shen et al. 2008). This may be due to the unfolding 
of the zinc-binding domain of p53, yielding the so-called 
mutant conformation, as has been shown after treatment of 
human SV-40 immortalized uroepithelial cells after treat-
ment with arsenite (Chai et al. 2007). Interestingly, after 
long-term exposure of human skin keratinocytes an inac-
tivation of p53 was found to be mediated via poly(ADP-
ribosyl)ation of p53, in spite of a globally reduced level of 
poly(ADP-ribosyl)ation (Komissarova and Rossman 2010).
With regard to changes in gene expression, one other 
mechanism consists in epigenetic alterations provoked by 
arsenite, both in cellular systems as well as in exposed 
humans, leading to both hypomethylation and hypermeth-
ylation, with the consequence of the activation of oncogene 
expression and silencing of tumour suppressor genes. One 
underlying mechanism appears to be an inactivation of DNA 
methyltransferases; however, since hyper- and hypomethyla-
tions are observed, interactions appear to be complex and are 
currently not completely understood (for review see Brocato 
and Costa 2013; Reichard and Puga 2010).
Molecular mechanisms. In general, trivalent arsenicals 
such as arsenite and MMA(III) exert higher affinities for 
dithiol or trithiol sites in proteins as compared to monothiol 
sites. Therefore, zinc-binding structures in DNA repair pro-
teins, in the tumour suppressor protein p53 as well as in 
transcription factors may be particularly sensitive targets. 
Structural investigations further revealed a selective inter-
action with zinc-binding structures containing three or four 
cysteine residues (Zhou et al. 2011). This may explain the 
inactivation of DNA repair systems at very low concen-
trations. Thus, for example, poly(ADP-ribose)polymerase 
I contains three zinc-binding structures involved in DNA 
damage recognition and interactions with further DNA 
repair proteins. Recent evidence suggests that especially zinc 
finger I may not be saturated with zinc on normal cellular 
conditions, rendering it potentially very sensitive towards 
arsenite (Bossak et al. 2015). Also with regard to the inhibi-
tion of DNA repair systems interactions with zinc-binding 
NER proteins may be plausible. Thus, trivalent but not pen-
tavalent arsenicals have been shown to release zinc from a 
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37 amino acid peptide resembling the zinc finger domain of 
the human XPA protein (XPAzf) (Schwerdtle et al. 2003), 
albeit by different mechanisms. While equimolar concentra-
tions of MMA(III) mediated zinc release, forming mono- 
and diarsenical derivatives of XPAzf, a tenfold excess of 
arsenite was required to partially oxidize XPAzf, yielding 
one or two disulfide bonds (Piatek et al. 2008). With regard 
to the inhibition of NER in cells, arsenite and—again at even 
lower concentrations—MMA(III) were shown to inhibit the 
association of the damage recognition protein XPC to the 
site of UVC-induced DNA damage. Along with diminished 
gene expression of XPC and XPE and a reduced XPC pro-
tein level, this may be explained by reduced p53 activity, 
perhaps due to unfolding of the zinc-binding structure within 
the DNA binding domain described above. Regarding inter-
ference with signal transduction pathways, reactions with 
critical cysteine residues and thus interference with redox 
regulation of transcription factors appear to be the dominant 
mechanism, demonstrated for example for the Keap1-Nrf2 
system (reviewed in Hartwig 2013b). In addition, also epige-
netic mechanisms appear to be relevant (Brocato and Costa 
2013; Reichard and Puga 2010), but molecular mechanisms 
remain to be elucidated.
Conclusions and in vivo relevance
In the case of cadmium and arsenic, direct interactions 
with DNA appear to be not relevant in the low-dose range, 
also supported by missing direct mutagenicity. Neverthe-
less, the frequency of mutations may be elevated by indi-
rect mechanisms, such as via interference with basically 
all major DNA repair systems. Since DNA damage is not 
only induced by exogenous mutagens but also continuously 
due to endogenous processes as described above, this may 
even lead to pronounced hypermutability of exposed cells. 
In addition, further targets have been identified with rel-
evance for genomic stability, such as an inhibition of anti-
oxidative defense systems, an inactivation of tumor sup-
pressor functions and altered signal transduction processes. 
While in some cases distinct proteins have been identified 
as molecular targets, also epigenetic mechanisms appear to 
be relevant. All these features taken alone could contribute 
to carcinogenicity, but most likely their combination seems 
to be of particular importance. Thus, for example, long-term 
exposure to low concentrations of cadmium leads to adapted 
cells exerting increased cadmium accumulation, increased 
proliferation, diminished DNA repair and cell cycle con-
trol as well as resistance to apoptosis (reviewed in Hartwig 
2018). In principle, all the above-mentioned mechanisms 
are mediated via interactions with proteins, and a threshold 
is likely. However, for both metals, there are only limited 
in vivo data available which allow a clear distinction of 
mechanisms relevant or irrelevant of exposed humans, but 
some interactions have been observed at particularly low 
concentrations, which are found in either environmentally 
or occupationally exposed humans.
In case of cadmium, levels in blood and urine are usually 
low, in the nanomolar concentration range (Borjesson et al. 
1997), and thus considerably lower when compared with, 
for example, DNA repair inhibitory concentrations in cell 
culture systems in the low micromolar concentration range. 
However, far higher concentrations are found in organs like 
liver and kidney, reaching–based on the wet weight in the 
respective organs–up to 90 µM in the liver and up to 0.5 mM 
in the kidney, already in the general population not addi-
tionally exposed at the workplace (Lech and Sadlik 2017). 
Even millimolar concentrations have been reported in the 
kidney cortex as well as high micromolar concentrations 
in the liver of cadmium-exposed workers (Borjesson et al. 
1997). However, in these organs, exposure-related induction 
of metallthioneins (MT) a family of small cysteine-rich pro-
teins occurs. MTs exert high binding affinity to metal ions 
such as cadmium via SH groups, thereby achieving effec-
tive cellular protection. Nevertheless, while clearly protect-
ing from acute toxicity, binding of cadmium ions to MTs 
in vivo leads to very long half-lives of up to several decades. 
This is most apparent in the case of cadmium accumulation 
and retention in the kidney, as evident from MT-knockout 
mice (reviewed in Klaassen et al. 2009). As a consequence, 
MT-mediated adaptation may lead to reduced DNA repair 
activities as well as suppressed apoptosis (Hart et al. 2001; 
Singh et al. 2009a). Even though cadmium binding to MT 
is thermodynamically very stable, toxic metal ions may be 
released, for example under conditions of oxidative stress, 
thereby becoming available for interaction with critical cel-
lular structures (for review see e.g., Namdarghanbari et al. 
2011). Of note, indications for DNA repair inhibition were 
observed in lymphocytes of cadmium-exposed workers 
(Hengstler et al. 2003). Thus, research is needed on cad-
mium levels that may lead to cellular interactions leading to 
genomic instability in exposed humans.
However, with regard to limit values for cadmium 
exposure, there is clear evidence that non-cancer effects 
in humans may be relevant at even lower concentrations. 
Thus, as evaluated by EFSA and detailed above, nephrotox-
icity was selected as the most sensitive endpoint to deter-
mine the tolerable weekly intake (TWI) of 2.5 µg Cd per 
kg body weight for cadmium. This value is almost within 
daily uptake levels, even without additional workplace expo-
sure and may be exceeded by some population groups with 
high food intake (EFSA 2009c, 2011c). In consequence, in 
the case of oral cadmium exposure, kidney toxicity appears 
most relevant, occurring within an exposure range close to 
environmental exposure. Thus, exposure levels protecting 
from kidney toxicity upon oral exposure as well as from 
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lung toxicity after inhalation presumably also protect from 
carcinogenicity.
In case of arsenite, the situation is different. Here, rel-
evant cancer risks appear to be associated already with envi-
ronmental exposure levels (EFSA 2014a). Thus, as detailed 
above, for oral uptake, EFSA has identified an additional risk 
for lung, skin and urinary bladder cancer of 1%  (BMDL01) 
for uptake levels of 0.3 to 8 μg/kg bw and day which is 
within the estimated average dietary exposure of the general 
population. Therefore, an elevated cancer risk for consumers 
cannot be excluded and a TDI value could not be derived 
(EFSA 2014a). Levels of inorganic arsenic in urine of the 
general population are around 6.7 nM (Ochsmann et al. 
2018). Therefore, on the molecular level, especially those 
interactions observed at particularly low, nanomolar or even 
sub-nanomolar concentrations in cellular test systems will 
likely be relevant also in vivo. This includes an interference 
with poly(ADP-ribosyl)ation involved in DNA repair, cell 
cycle control and apoptosis observed at sub-nanomolar con-
centrations. In addition, also epigenetic alterations leading 
to gene expression changes appear to be relevant at very low 
concentrations (e.g. States 2017). Thus, for risk assessment 
of arsenite, even though a threshold-like mechanism has 
been demonstrated, it may not be possible to define health-
based exposure levels protecting from respective interac-
tions and thus from carcinogenicity, or, if so, they may be 
expected to be below present environmental exposure levels; 
again, research is still needed to clarify this aspect.
Part C: Conclusions and Perspectives
General considerations
In general, toxicological cancer risk assessment is intended 
to quantitatively link exposure levels (or doses) with the 
associated cancer risk or incidence. The risk assessment of 
carcinogenic substances in food and at the workplace is an 
issue of ongoing scientific scrutiny since the exposure, in 
particular at trace levels, to these compounds is not com-
pletely avoidable.
The current risk assessment paradigm relies on the differ-
entiation between genotoxic and non-genotoxic carcinogens. 
For non-genotoxic carcinogens, which are often classified as 
“promotors”, no observed adverse effect levels (NOAELs) 
are accepted to exist, and threshold values are frequently 
proposed. In contrast, genotoxic agents, their metabolic pre-
cursors and DNA reactive metabolites are assumed to rep-
resent risk factors at all concentrations because in principle 
even one or a few DNA lesions may result in mutations and 
thus increase tumour risk. Frequently, a linear extrapola-
tion from the high dose range (for example resulting in 25% 
tumour risk in animal studies) down to low dose levels is 
applied to assess the cancer risk under low exposure condi-
tions. For most substances, however, this may result in a 
significant overestimation of the low dose risk, since tumour 
formation by genotoxic carcinogens is often drastically 
enhanced in the high dose range because: (1) defense mech-
anisms become saturated (2) various types of promotional 
mechanisms are activated. Examples include regenerative 
growth due to cytotoxic effects of the agents (for details, see 
part A "Fundamental considerations", chapter "DNA reac-
tivity of chemicals: Hazard versus Risk"and "Test systems 
in genetic toxicology"). This gives rise to a biphasic shape 
of the dose–response curve (part A "Fundamental consid-
erations", Fig. 1), with the implication that under realistic 
exposure conditions only the slope of the first (low dose) 
range in most cases is relevant for the risk assessment (part 
A "Fundamental considerations", chapter “Introduction”). 
Moreover, some agents exert their genotoxicity via indirect 
interactions, such as interference with the cellular response 
to DNA damage including DNA repair processes, cell cycle 
control and tumour suppressor functions, giving rise to non-
linear dose–response relationships.
As a consequence, for genotoxic carcinogens, a mecha-
nism-driven risk assessment is proposed that considers key 
events leading to the apical outcomes, mutation and malig-
nant transformation. Every single key event is expected to 
follow its own (maybe non-linear) dose dependence and 
kinetics.
Identification of the mode of action (MoA) of chemical 
carcinogens
In general, combinations of genotoxicity tests are used to 
evaluate the genotoxic potential of a compound, with the aim 
of covering all possible mechanisms that can lead to tumour 
initiation. In addition to rather “classical” test systems for 
mutagenicity and clastogenicity (e.g., Ames, HPRT, mouse 
lymphoma, chromosomal aberrations or micronucleus tests), 
novel test systems, which provide more comprehensive 
mechanistic information on key events and toxicological 
“fingerprints” leading to genotoxicity and/or mutagenic-
ity in vitro and in vivo, are under development (see part 
A "Fundamental considerations", chapter "Protein adducts 
as human biomarkers"). Furthermore, mechanistic studies 
are required to discriminate between direct and indirect 
genotoxicity.
The induction of genomic damage (such as DNA and 
chromosomal lesions or chromosomal mutations) is the ini-
tial event in a chain of steps that eventually may lead to the 
formation of a tumour. The ability to exactly identify and 
quantify DNA lesions in tissues and body fluids has remark-
ably increased in recent years (see part A "Fundamental con-
siderations", chapter "Toxicogenomics for hazard identifi-
cation and risk assessment"). Reliable dosimetry of DNA 
1852 Archives of Toxicology (2020) 94:1787–1877
1 3
damage associated with exposure to minute traces of geno-
toxic contaminants in food and other consumer media can be 
achieved with present day advanced instrumental analysis. 
Of note, DNA is also continuously damaged by endogenous 
processes, in which reactive oxygen species (ROS) and other 
electrophiles are generated, in part due to leakage from the 
electron transport chain operative in cellular respiration and 
to electrophile leakage from physiological metabolism but 
also in part by regular metabolic intermediates such as for-
maldehyde, acetaldehyde and ethylene oxide (see also part 
B “Selected examples”, chapter “Presence of endogenous 
background levels of the same or similar DNA lesions”). 
This leads to measurable steady-state levels of different 
types of DNA lesions, such as oxidized bases and alkyla-
tion products, in apparently all types of cells and tissues (see 
part A “Fundamental considerations”, chapter "Background 
DNA lesions in rodent and human tissues/body fluids"). In 
exposed humans, several cellular defence mechanisms and 
scenarios may counteract or even prevent the induction of 
significant levels of DNA damage. It is, therefore, of crucial 
importance to measure steady-state levels of DNA damage 
in vivo, which would account for both, detoxification before 
the compound or its reactive metabolite reaches the DNA, 
and for DNA repair. If no increase in steady-state levels of 
“background” DNA damage or no increase in endogenously 
induced levels of the respective DNA lesions is observed, no 
increase in mutations and thus no elevated risk for malignant 
transformation would be expected at this exposure level. In 
practice, however, one has to consider the statistical power 
of the respective measurements to quantify remaining risks. 
If human exposure is well (in practice often orders of mag-
nitude) below the levels at which, for example, an appreci-
able increase in the background frequency of the respective 
DNA lesions can be statistically excluded, genotoxicity at 
this exposure level may be judged irrelevant and, thus, of 
low priority for further consideration of carcinogenicity. 
Moreover, in the case of very reactive chemicals such as 
acetaldehyde or formaldehyde (chapters "Acetaldehyde and 
Ethanol" and "Formaldehyde"), one needs to consider that 
not only the background levels of the compounds in blood 
but also their local levels at the site of entry, for example, 
nasal tissue in case of inhalation or levels reached in the gas-
trointestinal tract in case of oral exposure, might be relevant.
In contrast to DNA lesions, which may be repaired, muta-
tions are irreversible changes in the nucleotide sequence 
and thus in genetic information, which, depending on the 
affected position or gene, might be of considerable relevance 
for the carcinogenicity process. Therefore, it would be highly 
desirable to measure mutations instead of DNA damage. 
Nevertheless, this would require very sensitive in vivo muta-
genicity test systems, which are currently not available. One 
promising approach could be the newly established PIG-A 
test, which could even be implemented in repeated-dose 
toxicity studies, since only sampling of a small amount of 
blood is required for this test (for a recent review see Olsen 
et al. 2017).
Genotoxic compounds leading to DNA lesions may be 
clustered together with respect to the type of DNA damage 
they induce. Provided basal levels of the respective lesions 
in human tissues/cells are known, the additional DNA modi-
fications caused by the exposure to a given xenobiotic com-
pound can be used to evaluate the incremental increase of 
risk (relative additional risk) associated with this exposure. 
A key prerequisite for such a risk assessment approach is to 
know the type and frequency of biological effects, especially 
mutations and malignant cell transformation processes, 
possibly occurring after the respective DNA lesions have 
been induced. The kinetics of induction and disappearance 
of DNA lesions, e.g. by damage repair, need specific con-
sideration with regard to mutation fixation. In addition, the 
increase in induced mutations may follow quite different 
dose–response relationships. At higher concentrations (part 
A "Fundamental considerations", Fig. 1, range B), additional 
important effects need to be taken into account, especially 
proliferative responses and enhanced cell division within 
target cells/tissues.
In addition to the dosimetry of DNA lesions, monitoring 
of blood protein adducts provides complementary infor-
mation. This relates especially to the internal exposure 
towards electrophilic compounds resulting from a defined 
exogenous exposure, e.g. at specific working places. Tech-
niques to assess the internal exposure via quantification of 
protein adducts are well established for haemoglobin (Hb) 
and serum albumin (SA) as preferred targets (dosimetry) 
(see part A "Fundamental considerations"; chapter "Toxi-
cogenomics for hazard identification and risk assessment"). 
It has to be kept in mind, however, that protein adducts are 
to be considered markers of exposure, since, in contrast 
to DNA lesions, they are not repaired and, thus, indicate 
elevated exposure, usually without relevance for the carci-
nogenic process as such. To monitor short term exposures 
that may not cause measurable changes of adduct levels in 
blood proteins, the dosimetry of mercapturic acids (MA) 
or other metabolites in urine appears the method of choice 
(see part B "Selected examples", chapter "Acrylamide"). 
Such biomonitoring results can be assessed using reference 
parameters, e.g. the BAR value (Biological Reference Value) 
of the German DFG MAK Commission. The BAR value is 
based on the respective biomarkers reflecting background 
exposure of an occupationally unexposed reference popula-
tion at working age. In perspective, protein adducts and/or 
urinary/body fluid biomarkers (e.g. MA) may complement 
or even replace the determination of external exposure to 
dietary and environmental genotoxins.
More comprehensive mechanistic information can be 
provided by toxicogenomics approaches. Appropriate 
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toxicogenomics data have to be linked, also in terms of 
dose–response behaviour, to toxicologically relevant tradi-
tional apical endpoints. If properly used, such studies can 
provide information to improve our mechanistic understand-
ing of low dose relationships and, in consequence, of “bio-
logical thresholds”. However, it has to be kept in mind that 
the onset of transcriptional responses may require a certain 
level of DNA damage, which may be converted into muta-
tions even at lower concentrations (see part B "Selected 
examples", chapter "Benzo[a]pyrene"), which can restrict 
the sensitivity of such approaches. In addition, it becomes 
apparent that wherever available, patterns or signatures of 
biomolecules should be used to elucidate modes of action 
and to identify key events of relevance for adverse outcome 
pathways (see part A "Fundamental considerations", chap-
ter "Background DNA lesions in rodent and human tissues/
body fluids").
In combination with physiologically based kinetics 
(PBK) unique possibilities are provided to build up models 
reflecting the human situation, and even to take into account 
inter-individual differences. Furthermore, responses under 
realistic low dose regimens can be predicted. This may 
inform about the dose–response relationship of DNA reac-
tive metabolites supposedly operative at dose levels that are 
experimentally not accessible (see part B "Selected exam-
ples", chapter "Allylalkoxybenzenes").
Structure Activity Relationship (SAR) involves in silico 
methods designed to find relationships between the chemi-
cal structure and the biological activity of compounds. Such 
novel in silico approaches may support a read-across from 
compounds for which in vivo studies are available to those 
with limited or completely absent toxicity data.
The mechanistic profile resulting from the above informa-
tion is expected to comprehensively inform about adverse 
outcome pathways relevant for improved risk assessment.
Distinction of carcinogens based on MoA and quantitative 
risk assessment
Based on such an assessment of the key events leading to the 
apical outcome, i.e. the malignant cell transformation, strate-
gies may become applicable in the near future that allows 
to further characterize the mode of action of genotoxic car-
cinogens and to specify virtually safe doses at least in some 
cases. An example of this type of strategy is outlined in 
Fig. 20 and described below.
The first step in the strategy outlined in Fig. 20, therefore, 
is the mode-of-action based mechanistic characterization of 
Fig. 20  A Strategy for the assessment of the carcinogenic risk associated with an exposure to examples of genotoxic compounds. For details see 
text
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genotoxic compounds. At the doses at which an increased 
cancer incidence is observed they may act primarily by DNA 
damage induction (1), they may additionally exert promot-
ing activity (2) or they may (possibly additionally) affect the 
processing of DNA modifications (3). For the discrimination 
of the three groups in vitro data provide valuable hints on the 
mode of action, including dose–response relationships with 
regard to DNA damage induction and mutagenicity. For sub-
stances with genotoxic and additional promotional activity 
(Group 2), risk assessment would largely profit from the reli-
able quantification of cancer risk at concentrations below the 
onset of promotional activity, i.e. the border between range 
A and range B in Fig. 1 (Part "Fundamental considerations", 
“Introduction”). However, in most cases tumour incidences 
in this range will be too low to be assessed experimentally or 
from epidemiological data. In these cases, the onset of pro-
motional effects may be assessed and quantified by suitable 
biochemical parameters (including suitable toxicogenom-
ics data, see part A "Fundamental considerations", chapter 
“Background DNA lesions in rodent and human tissues/body 
fluids”). Regarding Group 3, i.e. compounds that increase 
DNA damage and mutagenicity via indirect mechanisms, 
for example by inactivation of DNA repair processes, in 
principle NOAELs (i.e. thresholds) exist in the absence of 
additional direct genotoxic activity, since the effects are 
due to interactions with proteins and/or induction of ROS. 
Nevertheless, this mode of action deserves special attention 
since unlike many other promoting effects the relevant inter-
actions may occur at particularly low concentrations. This 
could provoke repair-deficient conditions which also lead 
to an accumulation of endogenous DNA damage as well as 
DNA lesions induced by exogenous sources and, thus, may 
considerably increase the mutation frequencies per cell divi-
sion. This is the case of many metal compounds, as detailed 
in part B "Selected examples" for cadmium and arsenic (see 
chapter Sec. "Carcinogenic metal compounds: Examples 
cadmium and arsenic"). Since DNA repair inhibition would 
result in increased mutagenicity and clastogenicity, the 
absence of elevated levels of DNA damage, mutations and/
or chromosomal damage in vivo under steady-state condi-
tions may serve to quantify the no-effect concentrations as a 
basis for a limit value setting. Another example would be the 
induction of genome mutations following the disturbance of 
the spindle function (aneugenic effects).
Below the concentration at which additional promotional 
events occur, i.e. in the low dose Range A (Fig. 1), genotox-
icity needs to be evaluated quantitatively for all groups in a 
similar manner. In most cases, since the tumour incidence 
within range A is too low to be determined experimentally, 
only an upper limit for the additional tumour risk can be esti-
mated from the data (population and animal studies). How-
ever, the ability to exactly measure DNA lesions in tissues 
and body fluids has remarkably increased in recent years (see 
part A Fundamental considerations, chapter "Background 
DNA lesions in rodent and human tissues/body fluids"). In 
the case of a continuous exposure to a given genotoxic agent 
(steady-state conditions) in vivo a linear correlation between 
the induced DNA damage and the additional cancer inci-
dence can be anticipated for range A in Fig. 1 (part A "Fun-
damental considerations"), in which additional promotional 
effects of the genotoxic agent are absent by definition. There-
fore, the quantification of DNA lesions in target or surrogate 
cells in vivo is the next step in the suggested strategy shown 
in Fig. 20. Quantification of surrogate endpoints such as pro-
tein adducts might provide additional information (see part 
A "Fundamental considerations", chapter “Protein adducts 
as human biomarkers”). Subsequently, two cases (types of 
genotoxic agents) should be distinguished. If background 
levels of the same or very similar DNA lesions which can be 
ascribed to an unavoidable exposure to the same or similar 
compound, e.g. from endogenous sources, are detectable in 
the organism/tissue, the (extrapolated) level of DNA damage 
generated at a certain low level of exposure to the xenobi-
otic agent can be judged as irrelevant by comparison with 
the background levels: The relative increase in the cancer 
incidence can be estimated to be irrelevant, even if the actual 
absolute risk emanating from this type of DNA lesion is not 
known. A prerequisite for such a relative risk assessment is 
the reliable knowledge of the background level of relevant 
DNA lesions in target/reference populations. Examples for 
this type of genotoxic agents are ethanol, acetaldehyde and 
ethylene oxide, among others (see below).
For compounds without comparable background lesions 
such as benzo[a]pyrene or aflatoxin B1, the next task would 
be to evaluate the carcinogenic risk at concentrations within 
range A. If this risk were quantifiable, cancer risk in the 
low dose range could be assessed according to the slope 
in the range A in Fig. 1. However, in most cases this will 
not be possible experimentally; and a worst-case scenario 
(maximum slope calculated for the cancer incidence in range 
A, estimated from the onset of range B), might be applied. 
Furthermore, in many cases data on induced mutations in 
the low dose range in vivo are not (yet) available and/or 
not readily assessable, in part due to the lack of sensitive 
in vivo mutagenicity tests. In such cases, DNA lesions may 
be quantified in vivo (preferably in the target tissue), thereby 
providing quantitative data on the onset of measurable DNA 
damage in vivo. The quantification of steady-state levels of 
specific DNA lesions, determined after repeated exposure, 
provides an integrated measure of genotoxicity, which also 
accounts for the influence of detoxification and DNA repair.
In cases in which the carcinogenic risk associated with a 
specific lesion is known, these data could be used for quan-
titative risk estimation. To this end, for example, experi-
ments with animals deficient in the specific repair mecha-
nism of the respective DNA lesion may provide important 
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further information. Such a defect can result in a several-
fold increase of the respective lesion without confound-
ing promotional effects. If an increase of cancer incidence 
becomes observable in the animals under these conditions, 
the correlation between the DNA lesion levels and the can-
cer incidence—and thus the carcinogenic potential of the 
lesions—can be experimentally established. In this case, a 
reliable risk estimation based on the determination of DNA 
lesions appears possible.
Application of the proposed strategy to selected 
examples
In the following paragraphs, the present situation regarding 
the outlined strategy is exemplified for several genotoxic 
agents described in part B "Selected examples"
DNA lesions for which an endogenous background has 
been described comprise those emanating from the expo-
sure to acetaldehyde/ethanol, ethylene oxide, formaldehyde 
and further endogenous alkylating agents, such as acryla-
mide (see part B "Selected examples", chapter "Presence of 
endogenous background levels of the same or similar DNA 
lesions").
For example, for ethanol and acetaldehyde, which 
are endogenous substances mainly originating from the 
intermediate metabolism, a dose-dependent increase in 
DNA adduct levels induced by acetaldehyde in vitro and 
in vivo was observed in several studies. There is substantial 
inter-individual variability with regard to the endogenous 
background of these adducts in humans, reported to range 
from about 13–150 adducts/108 nucleotides. The biologi-
cal significance of the identified adducts with respect to the 
mutagenicity and carcinogenicity of ethanol and acetalde-
hyde remains unclear. However, an additional intake from 
exogenous sources that remains within the range of varia-
tion of the endogenous body burden will only contribute to 
a limited extent to cancer risk. Of note, the comparison to 
background levels requires to consider all tissues and body 
compartments of relevance, especially including the sites 
of first contact, such as the respiratory tract upon inhala-
tion or the upper gastrointestinal tract upon oral exposure. 
In addition to the induction of DNA damage, acetaldehyde 
is very reactive, giving rise to irritation and, thus, leading 
to an additional promotional activity, which may need spe-
cial consideration (see part B "Selected examples", chapter 
"Acetaldehyde and Ethanol").
Formaldehyde has been classified as carcinogenic, 
inducing nasal tumours with a sublinear dose–response rela-
tionship upon inhalation. While IARC assigned it to group 
1 (human carcinogen), the German MAK Commission 
established a MAK value which protects from formalde-
hyde carcinogenicity (carcinogen category 4). The induction 
of different types of DNA damage as well as an increased 
cell proliferation are considered key events. On the systemic 
level, DNA damage equivalent to the extent exerted by the 
endogenous formaldehyde burden is not induced until an 
inhalative exposure of about 100 ppm is reached. Since 
the critical effect of formaldehyde is the induction of nasal 
tumours, the crucial question is at which concentrations 
formaldehyde reaches the basal cells (target cells for nasal 
tumours). In addition to DNA damage, the promotional 
effect of cell proliferation appears required to convert DNA 
damage into mutations. Since formaldehyde is a very reac-
tive irritant, irritation is most critical, becoming evident far 
below exposure levels that increase the systemic formalde-
hyde background levels. With the currently available data 
it can be assumed that there is no additional risk of nasal 
tumours at low dose levels (≤ 0.3 ppm) (see part B "Selected 
examples", chapter Sec. “Formaldehyde”).
In the case of acrylamide, the key event resulting in 
genotoxicity has long been considered to be the formation 
of glycidamide (GA) and its interaction with DNA. How-
ever, GA, preferentially inducing N7-GA-guanine adducts, 
has been found to be a mutagen of rather low potency. This 
may be reconciled, at least in part, with the fact that it pref-
erentially alkylates DNA at N7-guanine, an adduct of very 
low mutagenic potential. Compared to the background range 
of a spectrum of human tissue DNA adducts determined 
by advanced HPLC–ESI–MS/MS methodology, N7-GA-
guanine levels measured in rats at single dosages up to at 
least 100 μg/kg bw were found to occur sporadically, not 
dose dependently and close to the low bound of human 
background levels of similar N7-guanine adducts. Toxi-
cogenomic response profiles in rodent target tissues, appear 
to indicate a non-genotoxic MOA rather than a genotoxic 
MOA. Taken together, the current weight of evidence sup-
ports a non-genotoxic MOA, and genotoxicity may only 
occur at unrealistically high dosage. If this conclusion is 
further confirmed, it may allow to establish a non-observed 
adverse effect level as a POD for risk assessment.
In the case of alkylating agents (MMS, EMS, MNU 
and ENU), which induce genotoxic effects via direct cova-
lent binding to DNA, the quantification of mutagenicity 
endpoints in vitro and in vivo (lacZ, pig-a, micronuclei) in 
parallel with that of haemoglobin adducts in vivo support 
the notion that significant mutagenicity is only observable 
under conditions at which the relevant DNA repair mecha-
nisms (in these cases mediated by MGMT) are saturated 
(see part B "Selected examples", chapter Sec. “Alkylating 
agents”). This may be true even for cases in which the dose-
dependence appears linear in the concentration range tested, 
because non-saturating concentrations were not applied (as 
for ENU in the lacZ and micronucleus tests, in contrast to 
the results in the pig-a test, in which lower, non-saturating 
concentrations were also tested). In other words, the avail-
able data allow to define the onset of the range B in Fig. 1, 
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which in this case is characterized by a saturation of repair 
mechanisms. The remaining question is whether an upper 
limit for the mutagenicity (and in the next step cancer risk) 
in the range below this threshold concentration (i.e. in range 
A) can be estimated, making use of the known sensitivi-
ties of the mutagenicity assays applied and considering that 
the endogenous background levels of N7-alkyl-guanine 
adducts have been reported to be in the range of about 29–44 
adducts/108 nucleotides. As suggested in the general strategy 
outlined above (Fig. 20), such a calculation appears more 
appropriate than either the assumption of a zero risk below 
this threshold concentration or the linear extrapolation of 
the range B data (which would clearly result in a high over-
estimation of the risk).
Ethylene oxide is endogenously formed due to CYP-
dependent ethylene oxidation, mainly driven by CYP2E1. 
Ethylene is an endogenous metabolite in part generated 
by the gut microbiome and is also taken up from external 
sources, such as food. However, a quantitative risk esti-
mation based on the DNA adduct levels appears not to be 
suited, since the levels of the different adducts formed vary 
in different organs, and their formation is not solely based 
on ethylene oxide. Therefore, the endogenous formation rate 
may better be extrapolated from the haemoglobin adduct 
frequency in unexposed human individuals by linear regres-
sion (see part B "Selected examples", chapter Sec. “Eth-
ylene oxide”). An increment of approximately 5 nmoles 
hydroxyethyl valine per gram haemoglobin corresponds to 
an average additional inhalative workplace exposure (40 h 
per week) of 1 ppm in the air. Compared to the average 
background of 20 pmol hydroxyethyl valine per gram hae-
moglobin in non-exposed healthy non-smokers, this increase 
by almost three orders of magnitudes per ppm qualifies this 
lesion as a particularly sensitive marker of exposure. This 
background value suggests the ethylene oxide exposure from 
endogenous sources to be at best in a range equivalent to a 
workplace exposure of 0.004 ppm and should represent a 
lifetime tumour risk increase of far less than 1 in 100,000.
Several compounds have been discussed in part B 
"Selected examples" which show a linear relationship 
between the dose and the level of DNA adducts. For exam-
ple, there is a linear relationship between the administered 
Aflatoxin B1 (AFB1) dose and the extent of AFB1-DNA 
binding (i.e. amount of AFB1-DNA adducts formed) in 
rats and rainbow trout, and no threshold for the formation 
of hepatic DNA adducts appears to exist. This means that 
tumour promoting effects are either absent or present at 
all concentrations to an extent that is proportional to the 
aflatoxin concentration and DNA adduct formation. In 
both cases, risk estimation based on the linear extrapola-
tion of adduct levels appears possible. The linearity of the 
data allows to calculate that in rats only 53 aflatoxin-DNA 
adducts per  108 nucleotides are required to induce a 50% 
tumour incidence, thereby indicating that this is a very 
potent DNA lesion with respect to mutagenicity and carci-
nogenicity (Otteneder and Lutz 1999). Of note, the AFB1-
DNA adduct in humans is often causing an inactivating point 
mutation in codon 249 of the p53 tumour suppressor gene 
according to sequencing data from population studies. Since 
an analogous p53 inactivation is not observed in rats, the 
finding is an indication that the potency of a given type of 
point mutation to cause tumours is species-dependent (see 
part B "Selected examples", chapter Sec. “Aflatoxin B1”). 
For carcinogenicity in humans, it is to be noticed however 
that an obvious and marked influence of promotional effects 
is exerted by HBV infection.
There is also a linear relationship through the origin 
between the dose of an allylalkoxybenzene and its level 
of bioactivation to the DNA reactive metabolite as well as 
the level of DNA adduct formation (see part B "Selected 
examples", chapter Sec. “Allylalkoxybenzenes”). This lin-
earity holds true from dose levels as high as the  BMD10 
(benchmark dose that leads to a 10% extra cancer incidence) 
down to dose levels as low as dietary human intake. Physi-
ologically based kinetic (PBK) modelling provides insight 
into the form of the dose–response curve for the formation of 
unstable DNA reactive metabolites even at dose levels that 
are experimentally not accessible. With respect to tumour 
formation, a role for additional toxicity as a promotional 
event in addition to the DNA adduct formation may be rel-
evant as well, given that for alkenylbenzenes dose levels 
causing carcinogenicity are close to or even overlap with 
those causing increased toxicity. This hampers a quantitative 
risk assessment for a low-dose range.
Benzo[a]pyrene induces various types of DNA dam-
age. In cell culture systems, stable adducts of its reactive 
metabolite, benzo[a]pyrene diolepoxide (BPDE) at the 
N-2 position of guanine are detectable at a concentration 
of ≥ 10 nM. Repair occurs via nucleotide excision repair; 
however, even in the low dose range, it was observed to be 
not complete. A linear dose–response relationship between 
DNA adducts induced by the reactive metabolite BPDE 
and mutations in the same cell line was reported even down 
to very low concentrations. In contrast, the transcriptional 
response to DNA damage was restricted to higher concentra-
tions. In consequence, no difference within the relationship 
between concentrations inducing DNA adducts and muta-
tions was observed, and a linear dose–response relationship 
with respect to carcinogenicity in the low dose range should 
be anticipated (see part B "Selected examples", chapter Sec. 
"Benzo[a]pyrene").
There is a linear correlation between the administered 
2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx) 
doses and the extent of MeIQx-DNA binding (i.e. amount 
of MeIQx-DNA adducts formed) in the liver of rats exposed 
to MeIQx, even in the low dose range (see part B "Selected 
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examples", chapter Sec. “2-Amino-3,8-dimethylimidazo[4,5-
f]quinoxaline (MeIQx)”). Thus, the steady-state adduct level 
of 113 ± 10 attogram/µg DNA was observed at a daily dose 
of 0.1 µg/kg (Frantz et al. 1995). This dose is only slightly 
higher than the daily uptake of 0.003–0.043 µg/kg bw/day 
calculated for humans (Murai et al. 2008). Indications for 
carcinogenic effects in the rat liver (formation of preneo-
plastic foci) were obtained at an exposure level of 10 ppm 
MeIQx in the diet (approx. 400 µg/kg bw/day). Data sup-
port the notion that the promoting activity of the compound 
is very low, but nevertheless involved in the cancer induc-
tion observed (which is associated with a high toxicity). 
The compound, therefore, seems suitable for a quantitative 
low-dose cancer risk assessment according to the scheme 
in Fig. 20. However, a putative threshold for the promoting 
effects of MeIQx (liver cell proliferation) and an upper limit 
for the cancer incidence directly below this concentration 
remain to be established.
As described in detail in part B "Selected examples", 
Pyrrolizidine alkaloids (PAs) differ largely not only with 
respect to their carcinogenic potential but also to the types 
of DNA adducts formed (e.g. monoadducts and DNA-DNA 
cross-links). Only limited information on dose–response 
relationships, especially in the low-dose range is available 
(see part B "Selected examples", chapter Sec. “Pyrrolizidine 
alkaloids”). In the case of riddelliine, the levels of DNA 
adducts were found to correlate closely with the tumorigenic 
potencies in rats in a dose-dependent manner. Moreover, a 
linear correlation was observed between the administered 
riddelliine doses and mutation frequencies in liver cII genes 
of Big Blue transgenic rats. However, no clear linear correla-
tion was observed between the induction of hepatic neoplas-
tic lesions (liver haemangiosarcomas) and the administered 
riddelliine or lasiocarpine doses, especially in the low-dose 
range. The potent hepatotoxicity of the compounds makes 
it difficult to separate genotoxic from tumour promoting 
effects. This hampers a quantitative risk assessment for the 
low-dose range.
Another important effect consists in the potential interfer-
ence of specific agents with the cellular response to DNA 
damage, thereby decreasing genomic stability. This applies, 
for example, to cadmium and arsenic, which are known 
human carcinogens, but also to other carcinogenic metal 
compounds like those of nickel, cobalt and antimony. Both 
cadmium and arsenic interact with DNA repair processes, 
cell cycle control and tumour suppressor functions, thus 
increasing the mutation frequency due to repair inhibition 
of endogenously generated DNA lesions as well as in com-
bination with other DNA-damaging agents (part B "Selected 
examples", chapter Sec. “Carcinogenic metal compounds: 
Examples cadmium and arsenic”). Furthermore, cadmium 
induces oxidative stress by inactivation of anti-oxidative 
defense systems, additionally affecting genomic stability. 
Also, both metals provoke epigenetic alterations. Of note, 
in the case of cadmium a potential limit value may be based 
on the interactions with the DNA damage response system. 
However, the concentration at which cadmium interferes 
with this system still needs to be elucidated and should be 
compared to exposure levels causing kidney toxicity (see 
detailed discussion in part B "Selected examples"). In the 
case of arsenic, an increased tumour risk is already evident at 
environmental exposure conditions even in Europe, and thus 
respective interactions are expected to be relevant already at 
very low exposure levels. In agreement with this assumption, 
interactions with DNA repair systems such as poly(ADP-
ribosyl)ation have been observed at extremely low concen-
trations in vitro. This allows the conclusion that meaningful 
health-based limit values would need to be below current 
environmental exposure. (for a detailed discussion see part B 
"Selected examples"). At present, therefore, the best option 
is to minimize exposure.
Gaps in knowledge and research needs
The Senate Commissions MAK and SKLM recommend 
the advancement of science-based limit values for tolerable 
exposure to (genotoxic) carcinogens. Therefore, the explora-
tion of key events relevant to the mode of action of genotoxic 
carcinogens, with specific consideration of DNA damage 
induction, dose–response relationships, DNA repair and 
mutagenic potential is proposed. To that end the following 
research needs have been consented:
• Exploration and validation of dependable (surrogate) bio-
markers to monitor endogenous and exogenous exposure 
to genotoxic agents in populations living under different 
nutritional, lifestyle, socioeconomic and working condi-
tions.
• Determination of human background DNA damage in 
these populations and establishment of an open-access 
comprehensive database on DNA background damage.
• Establishment of standard reference methodology for (in 
vivo) mutagenicity assays and exploration of the correla-
tion between in vivo DNA damage and in vivo mutation 
induction, case by case for individual genotoxic agents 
and for various types of DNA damage in different tissues.
• Systematic grouping of DNA lesions into classes accord-
ing to chemical structure and mutagenic potency to allow 
for read-across estimates within similarity classes.
• Development of lifetime cancer risk estimates associ-
ated with the various types of DNA damage and induced 
mutations in different tissues.
• Mechanistic understanding of (additional) promotional 
and indirect mechanisms of genotoxicity and establish-
ment of thresholds for these activities.
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• Evaluation of the merit of novel methodology (target tis-
sue to single-cell toxicogenomics, advanced PBK and in 
silico methods) to comprehensively inform about biomo-
lecular key events driving adverse outcome pathways.
Definitions/Glossary
DNA damage: chemical modification of DNA without physi-
ological function
Mutation: heritable change of the genome of a cell
Mutagenicity: capability to increase the number of muta-
tions per cell division
Genotoxicity: capability to cause cellular DNA damage 
and/or increase the number of mutations per cell division
Indirect genotoxicity: capability to increase the number of 
mutations per cell division without direct DNA interaction
Promoting activity: capability to increase the tumour fre-
quency without genotoxicity
Carcinogenicity: capability to increase the tumour 
frequency
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